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Abstract
All nine members of the LZT subfamily have similarities to members of the ZIP 
superfamily, especially in the region associated with their ability to transport zinc 
intracellular. Computer analysis of the nine sequences suggests that they are all members of 
this subfamily, however, in phylogenetic tree some members group separately, suggesting 
differences in function. The LZT-Hs7, LZT-Hs8 and LZT-Hs9 were cloned into a vector 
suitable for expression of recombinant proteins in mammalian cells. For the first time, this 
demonstration showed, a plasma membrane location for LZT-Hs7 and LZT-Hs8 which 
similar finding to LIV-1, and an intracellular location for LZT-Hs9, similar to that observed 
previously for LZT-Hsl. In addition, zinc transport capability was investigated. Affymetrix 
U133A analysis of LZT-Hsl, LIV-1, LZT-Hs4, LZT-Hs5 and pS2 confirmed that LZT-Hsl, 
LIV-1 and LZT-Hs4 were regulated by estradiol. This study was extended to investigate the 
expression of all nine family members in breast cancer cells treated with oestradiol, anti- 
oestrogens and additionally in tamoxifen and faslodex resistant cells, using semi-quantitative 
PCR. Differential expression of these family members was seen with some members 
constitutively expressed whilst others either elevated or reduced in the different conditions. 
This analysis demonstrated that LZT-Hsl was considerably elevated in tamoxifen resistance. 
In an effort to investigate a possible role for LZT-Hsl in tamoxifen resistant cells, it was 
reduced by siRNA. Interestingly, in the presence of siRNA for LZT-Hsl, it was not possible 
to demonstrate the activation of EGFR or Src as previously observered in the tamoxifen 
resistant phenotype using Western blotting analysis. This is an exciting result, which suggests 
a role for LZT-Hsl in driving the growth of tamoxifen resistant breast cancer cells.
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Chapter 1 
Introduction
1.1 Breast cancer
Breast cancer is a commonly encountered cancer in the United Kingdom (UK) and it is now 
the third most associated cause of cancer deaths after cancers of the lung and large bowel. 
The observed incidence of breast cancer in 2000 was 40,710 new cases in the UK. It is 
predominantly a disease associated with women, with only 1% of breast cancers occurring in 
men. A report by the cancer statistics division of the constitutive countries of the UK showed 
that a lifetime risk of women developing breast cancer is one in nine. Importantly, the 
survival rate for breast cancer patients has shown recent improvements, where the relative 
five-year survival rate for women diagnosed in England and Wales has increased to 77% 
during the period 1996 to 1999 compared to only 52% in 1971 to 1975. This has lead to an 
obvious reduction in mortality caused by breast cancer in the UK with for example breast 
cancer deaths falling from 15,625 in 1989 to 12,838 in 2002. It is thought that breast cancer 
mortality has declined because of several reasons, including the successful initiation of te 
breast screening program, the increased specialisation of care for patients and finally, the 
wide spread adoption of tamoxifen as an adjuvant therapy in the treatment of primary breast 
cancer and the above information was obtained from the CancerStats Monograph 2004 
publication.
1.2 Oestrogens and breast cancer
Although a relative contribution of multiple risk factors to the development of breast cancer 
may explain its high incidence and our failure to fully eradicate the disease, reproductive 
history and hormone exposure are believed to play a pivotal role in the origins and growth of 
the disease (Booth et al. 1989; Gwinn et al. 1990; Jordan et al. 2003). One of the most 
pertinent observations relevant to the treatment and understanding of breast cancer aetiology 
was the demonstration by Beatson in 1895 that ovariectomy performed on premenopausal 
patients with advanced breast cancer was able to cause a significant regression of their 
disease (Love and Philips 2002). This empirical observation has laid the foundation for the 
discovery of ovarian oestrogens as an important driving force for the growth of 
premenopausal breast cancer (Aebi et al. 2000; Kristensen and Borresen-Dale 2000; Miller et 
al. 1985), and also, the realisation that following the menopause oestrogens could be derived 
from non-ovarian sources, most notably adrenal androgens by peripheral aromatization 
(Burger 1996; Hutton et al. 1979; Lucisano et al. 1984; Nyholm et al. 1993). Importantly, 
since it was later discovered that some breast tumours possess the aromatase enzyme, it is 
now thought that a proportion of breast cancers assume a degree of autonomous growth 
control (Dowsett et al. 1996a; Macaulay et al. 1994; Reed and Purohit 1996; Sasano and 
Ozaki 1997).
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1.2.1 Mechanism of action of oestrogens
Evidence accumulated over several decades has provided a significant level of understanding 
of the cellular actions of steroid hormones in their target tissues (Liao 1975; McDonnell et al. 
1993; Sluyser and Kassenaar 1975). Early experiments using radio-labelled oestrogens 
showed that while these lipophic molecules penetrated all cells, they were retained only in 
classical oestrogen responsive tissues (Larionov et al. 2002; Marsigliante et al. 1992). This 
capacity to retain oestrogens was subsequently shown to be due to the presence of receptor 
proteins in target tissues, termed oestrogen receptors (Braunsberg 1977; McClelland et al. 
1998; Poortman et al. 1983). Such receptors were initially found in the rat uterus (Bergink 
1980; Leake 1997; Sutherland et al. 1980) and vagina (Miller and Sharpe 1998; Prat et al. 
2007) and some experimental and clinical breast cancers (Michalides et al. 1996; Patterson et 
al. 1982).
Using the titration method (Girdler et al. 2001; Wilson et al. 1984), and a sub-cellular 
fractionation technique (Marsigliante et al. 1995; Smith and Schwartz 1979; Wilkinson et al. 
1983), experiments showed that the oestrogen receptor proteins were cytoplasmic and 
nuclear in origin and that they bound oestrogens with high affinity (Attardi et al. 1980; Lazier 
and Haggarty 1979; Smith and Schwartz 1979). Upon oestrogen binding to the receptor 
protein, the resulting steroid-receptor complex undergoes a conformational change and 
dimerises with another oestrogen receptor subunit. As a result of this activation, the 
oestrogen receptor binds to chromosomal DNA at oestrogen response elements (EREs) in the
20
promoter regions of oestrogen responsive genes (Parker 1990; Sabbah et al. 1996). Such 
promoters are normally localised upstream of the translated regions of oestrogen responsive 
genes.
To stimulate DNA transcription, a transcription unit is formed which is composed of 
coactivator (CoA) molecules and oestrogen receptor complexes, which subsequently engage 
with the transcription apparatus (e.g. RNA polymerases). Separately, corepressor (CoR) 
molecules, which normally prevent transcription are loss from the ERE sites (Hagen et al. 
2004; Shibata et al. 1997). It is a combination o f these events which allows nuclear RNAs 
derived from oestrogen responsive genes to be specifically transcribed (Westley and May 
1988). Ultimately, the nuclear RNA is processed to produce messenger RNA (mRNA) 
species which are transported to the cytoplasm for subsequent translation by ribosomes into 
new protein products (Keir 1980; Knecht and Luck 1977).
The oestrogen receptor possesses two transcriptional activator functions, AF-1, which is 
present in the A/B domain of the receptor and is regulated in a ligand independent manner 
through growth factor promoted phosphorylation (Kato et al. 2000), and AF-2, which is 
present in the E domain of the receptor and is ligand dependent (Flototto et al. 2001). 
Frequently, in order that the receptor is maximally active, both AF-1 and AF-2 are required 
to be synergistically involved (Parker 1998).
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The diagram below is showing a representation of estrogen receptor (ER) and the structural 
domains of ER (A-F) with their amino acid numbers below the figure corresponding to the 
domain boundaries. Under the structural figure indicates the functional domain of the 
estrogen receptor and the far left describes the functions.
A B C D E F
1 38 180 263 302 553 595
Transactivation 4  » 4  »
AF-1 AF-2a AF-2
Dimerization 
DNA binding
Ligand binding _ _ _ _ _ _ — ^
D-box
<«-►
P-box ^
AE
Adapt from Anne M. Bowcock, et al. 1999. The Breast Cancer, Molecular Genetics, 
Pathogenesis, and Therapeutics. Humana Press, Totowa, New Jersey.
Genetically, there are two subtypes of oestrogen receptors, a and p, which are able to form 
homo- and heterodimers in cells (Marsigliante et al. 1996; Schwabe et al. 1993). It is 
believed that the a a and p p subtypes, and the a  p subtype, are able to promote different 
responses within target cells, although it is believed that the a subtype predominates in the 
classical oestrogen target tissues such as the breast (Chappell et al. 2000; Keeling et al. 2000; 
Scobie et al. 2002). Interestingly, various oestrogenic molecules bind to the ER subtypes with 
different affinities (Katzenellenbogen et al. 2000). Thus while 17p oestradiol, the most potent 
oestrogen produced in women, binds to both a and P receptors with high affinity, oestrone, a
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less potent oestrogen, binds predominantly to the a subtype, while oestriol, a weak oestrogen, 
binds primarily to the p subtype (Benassayag et al. 1999; Koga et al. 1990; Kuiper et al. 
1997; Platet et al. 2004).
The diagram below shows the mechanism of action of the estrogen where the estrogen 
receptor (ER) bound to the estrogen (E) and then act to bind to an estrogen responsive 
element (ERE). Subsequently, the transcription is activated by direct interaction with the 
components such as the RNA polymerase II transcription complex, and basal transcription 
factors (RNA Pol II/ Basal Txn Factors), sequence specific transcription factors (Txn 
Factors), and/or additional co-activator protein (CoA).
ER CoA
RNA Pol I I I Basa 
Txn Factors
Txn
actors
ERE
Adapt from Anne M. Bowcock, et al. 1999. The Breast Cancer, Molecular Genetics,
Pathogenesis, and Therapeutics. Humana Press, Totowa, New Jersey.
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In addition to the direct actions of oestrogen receptors on EREs, they have also been shown 
to modulate the transcription of genes that do not contain an ERE. This is facilitated by direct 
protein interactions between the oestrogen receptor and other nuclear transcription factors 
(Beato antf Klug 2000; Koohi et al. 2005; Salmi et al. 1998; Song et al. 1998). These include 
Activator Protein-1 (AP-1) (Cerillo et al. 1998; Gee et al. 2000; Kushner et al. 2000) and Sp- 
1 (Marino et al. 2006; Tanaka et al. 2000).
1.2.2 Membrane actions of the oestrogen receptor
In addition to the nuclear actions of oestrogens, it has recently been demonstrated that some 
oestrogen receptors may also be present in the cell membrane, and interact with caveolin-1 
(Kiss et al. 2006; Spies et al. 2006), additionally, G coupled proteins (Boonyaratanakomkit 
and Edwards 2004; Hart et al. 2005), several tyrosine kinase receptors, including the 
epidermal growth factor receptor (EGFR) (Godden et al. 1992; Sainsbury et al. 1985), and 
Insulin-like growth factor receptor-1 (IGF-1R) (Happerfield et al. 1997; Nardon et al. 2003), 
and a non-receptor tyrosine kinase, c-src (Hart et al. 2005; Kiss et al. 2006).
Through the G coupled proteins and tyrosine kinases, oestrogens are able to directly activate 
signals to the nucleus via phosphorylation cascades involving mitogen activated protein 
kinase (MAPK) (Luttrell et al. 1996) and phosphoinositide 3-kinase (PI 3K/AKT) (Muller 
and Frick 1999). Since signalling through these molecules is able to target and activate 
nuclear transcription factors, including ER and AP-1 (Gee et al. 2000; Rochefort 1995), the 
activation of membrane ER by oestrogens represents another way of effecting gene 
transcription (Sormunen et al. 1999).
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1.2.3 Oestrogen receptors and breast cancer
Multiple studies have shown that oestrogen receptors (ERa) are expressed in approximately 
70 to 80% of breast cancers (Girdler et al. 2001). Their presence has been linked to several 
good'prognostic features (Leygue et al. 1999), including low histological grade (Chappell et 
al. 2000; Umekita et al. 1992), low mitotic activity, tubular diffentiation (Knowlden et al. 
2000), and response to endocrine measures which will be discussed further in the thesis 
finding.
It is now standard practice to measure ERa in all primary breast cancers in the UK, where 
they are used to select patients for adjuvant endocrine therapy (Friedlander and Thewes 
2003; Howell et al. 1998; Jarzabek et al. 2005). According to a number of meta-analyses, 
oestrogen receptor positivity predicts for a disease free and survival benefit to anti-hormone 
therapy (principally, tamoxifen, see below), with patients with oestrogen receptor positive 
disease receiving tamoxifen enjoying a 25% 10-year survival advantage over those who do 
not receive the drug (Krulik 1994; Y. Nio 1999). In advanced disease, oestrogen receptor 
measurements, similarly predict for endocrine responsive disease, although it is evident that 
about 40% of oestrogen receptor positive tumours now fail endocrine treatments (Dowsett 
1996; Nicholson et al. 1989). Significantly, in advanced disease it is also clear that 
therapeutic benefit to endocrine measures is of a finite duration, with median response times 
being measured in months rather than years (Andersen 1992; Dowsett et al. 1996a; McGuire 
et al. 1975). Clearly, the majority of breast cancer are ultimately able to escape the beneficial
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actions of anti-hormonal therapy and gain a de novo or acquired resistant phenotype 
(Dowsett et al. 1996b; lino et al. 1997).
ERp has also been measured in breast cancer specimens (Jirstrom et al. 2005; Knowlden et 
al. 2000). Although there is much debate as to their clinical significance (Piquer et al. 1991), 
in one study their expression in ERa positive disease has been linked to endocrine response 
(Murphy and Watson 2006; Skliris et al. 2006).
1.3 Endocrine therapies
In light of the importance of oestrogens in breast cancer growth, several classes of drugs have 
been synthesised that are in clinical practice or development. These include antioestrogens 
(e.g. tamoxifen and fulvestrant) (Elkak and Mokbel 2001; Howell et al. 1996), aromatase 
inhibitors (Harris et al. 1983; Macaskill and Dixon 2007)and LH-RH agonists (Schally et al. 
1984; Tan and Wolff 2007; Zidan et al. 2002).
1.3.1 Tamoxifen, a Selective Estrogen Receptor Modulator (SERM)
The antioestrogenic drug tamoxifen is the most commonly used anti-cancer agent in breast 
cancer (Legha and Blumenschein 1982; Pritchard and Sutherland 1989). It was first 
developed in the mid 1960’s and entered clinical trials in the early 1970’s. Like previous 
ablative and additive endocrine measures, tamoxifen promotes tumour remissions in 
approximately one-third of unselected women with advanced disease and in about 60% of 
patients with oestrogen receptor (a) positive tumours (Davis and Carbone 1978; Kimmick 
and Muss 1995; Pritchard and Sutherland 1989). Because of its relatively low incidence of
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side effects, tamoxifen usage was quickly extended to earlier stages of breast cancer where it 
has been shown to extend 10 year survival rates of primary breast cancer patients by 
approximately 25% (Espie 1998).
ji
Significantly, the mode of action of tamoxifen involves its binding to oestrogen receptors 
where it produces a complex that can possess both oestrogen agonistic and antagonistic 
activity (Favoni and De Cupis 1998; Rochefort and Borgna 1981). The diagram below shows 
the model for the mechanism of action of anti-estrogens where the non-steroidal anti­
estrogen Tamoxifen binds to estrogen receptor (ER) results in an altered conformation which 
subsequently interferes with the ER’s interaction with the transcription factors.
CoAER
KNA Pol II / Basal 
Txn Factors
Txn
actors
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Adapt from Anne M. Bowcock, et al. 1999. The Breast Cancer, Molecular Genetics,
Pathogenesis, and Therapeutics. Humana Press, Totowa, New Jersey.
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It is thought that in breast cancer cells, its antagonistic activity prevails and thus oestrogen 
responsive events are reduced leading to an inhibition of tumour growth (Howell 2006). This 
may however, be a time dependent event since tamoxifen has been shown to induce an initial 
tumour flare that precedes the growth inhibition. In molecular terms, while tamoxifen is 
believed to be a full antagonist of the AF-2 activity of the oestrogen receptor, it often 
possesses some AF-1 activity (Mahfoudi et al. 1995). It is thought that its ability to maintain 
AF-1 responses associates with its agonistic properties (Mclnemey and Katzenellenbogen 
1996).
Although the majority of effects promoted by tamoxifen are clearly beneficial to the patient, 
tumour model systems suggest that it is a poor inducer of apoptosis (cell death) and surviving 
tumour cells invariably develop resistance (Johnston 1997). This phenomenon is also seen in 
the clinic with tumour remissions in patients with advanced disease on average only lasting 6 
to 18 months before disease progression is evident (Michlmayr et al. 1981). Increases in 
tumour EGFR activity have been reported in some tumour models as a mechanism to 
promote tamoxifen resistant growth and in MCF-7 human breast cancer cells (the model 
system used in the present thesis), it has been shown that membrane associated EGFR is 
raised as much as 40-fold on the acquisition of tamoxifen resistance (Knowlden et al. 2003; 
Miller 1987; Nicholson et al. 1994). In such cells, there is also evidence for the up-regulation 
of HER2, an EGFR family member, increased heterodimerisation of EGFR and HER2 and 
increased activity of several of their downstream signal transduction pathways, including 
MAPK and PI3K/AKT (Hutcheson et al. 2003; Leary and Dowsett 2006).
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Indeed, in such resistant cells it has been suggested that some of the EGFR/HER2 induced 
kinases are able to phosphorylate and activate oestrogen receptors, adding to their AF-1 
activity (Britton et al. 2006). Significantly, in human breast cancers increased EGFR and 
H£R2 have been linked to poor patient outlook (Eccles 2001) and failure to respond to 
various endocrine measures, including tamoxifen (Knoop et al. 2001). Interestingly, 
increased AP-1 activity has also been linked to tamoxifen resistance and increased growth 
factor signaling, where the oestrogen receptor may bind directly to AP-1 to promote 
transcription of genes involved in growth regulation (Cui et al. 2006).
1.3.2 Faslodex, a Selective Estrogen Receptor Down-regulator (SERD)
The anti-oestrogenic drug faslodex is termed a pure anti-oestrogen in that it possesses no 
obvious oestrogenic activity (Addo et al. 2002; Hermenegildo and Cano 2000; Home et al. 
1988; Howell 2006; Sainsbury et al. 1987). In model systems this property produces a more 
complete inhibition of tumour growth than is achieved with tamoxifen (Dowsett et al. 2005; 
Long et al. 1998). Clinically, faslodex has been shown to produce tumour remissions in 
advanced breast cancer patients with a response rate that is slightly superior to tamoxifen 
(Howell et al. 2004; McKeage et al. 2004). Despite its favourable clinical profile, faslodex is 
at present most commonly used as a second or third line endocrine therapy after tamoxifen or 
aromatase inhibitors (Mauriac et al. 2003).
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In molecular terms, although faslodex, like tamoxifen, binds to the oestrogen receptor, it is 
biologically inert and destabilises the oestrogen receptor protein leading to rapid ER 
degradation (Osborne et al. 2004).
The diagram below shows the mechanisms of action of anti-estrogens where the steroidal 
anti-estrogens Faslodex may act by increasing the turnover rate of estrogen receptor (ER) or 
by decreasing the stability o f the estrogen receptor (ER). They may also interfere with DNA 
binding or interactions of the estrogen receptor (ER) with components of the RNA PolII/ 
Basal Txn Factor complex.
CoAER
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Adapt from Anne M. Bowcock, et al. 1999. The Breast Cancer, Molecular Genetics,
Pathogenesis, and Therapeutics. Humana Press, Totowa, New Jersey.
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Indeed, within hours of exposing breast cancer cells to faslodex in vitro oestrogen receptor 
levels dramatically fall. Such activity has also been recorded in clinical breast cancer 
specimens removed 3 weeks after the initiation of faslodex treatment (Robertson et al. 2007). 
Despite this interesting property, resistance develops in all advanced breast cancer patients 
treated with the drug and is present de novo in approximately 50% of women (Dowsett et al. 
2005). In experimental models of faslodex resistance, increased EGFR has once again been 
linked to the development of this state, although less is known about the downstream 
consequences of altered EGFR signaling (McClelland et al. 2001).
1.3.3 Oestrogen deprivation using aromatase inhibitors
Alternative strategies to directly targeting breast cancer oestrogen receptors with anti- 
oestrogenic drugs in post-menopausal women primarily involve the use of aromatase 
inhibitors (Combs 1995; Harris et al. 1983). These inhibitors prevent the aromatisation of 
androgens to oestrogens and may be divided into two types based on their mechanism of 
action. Steroidal aromatase inhibitors bind to the substrate pocket of the aromatase enzyme 
causing an irreversible inhibition, while non-steroidal inhibitors competitively and reversibly 
inhibit the P450 domain of the aromatase protein (Bossche et al. 1994).
The current, so called, third generation of aromatase inhibitors (among are exemestane,
anastrozole and letrozole) show a high degree of selectivity for the aromatase enzyme and
inhibit whole body aromatisation by 97 to 99% (Dowsett 1998). They have been shown to be
effective in both advanced (Santen et al. 1982) and primary (Evans 1994) breast cancer and
the latter instance to be superior to tamoxifen. Despite this, however, they are not spared the
31
phenomenon of de novo and acquired resistance, where model systems suggest that tumour 
cells, in some instances, may become hyper-sensitive to very low levels of oestrogens (Chen 
et al. 200,6). Although the precise mechanisms involved in resistance to oestrogen deprivation 
are still under investigation, several studies have once again suggested a role for increased 
growth factor signalling involving both membrane (Miller et al. 2005) and nuclear (Shin et 
al. 2006) oestrogen receptors.
1.4 Endocrine resistance and tumour progression
In general terms, two characteristics of tumour cells dictate long-term patient prognosis, their 
growth rate and their invasiveness, where rapid growth and high invasive potential are 
invariably associated with poor outlook (Nicholson et al. 1993; Parr et al. 2004). 
Significantly, recent studies from the Tenovus Centre for Cancer Research laboratories have 
suggested that the development of acquired resistance to tamoxifen, faslodex and the EGFR 
inhibitor gefitinib is associated with these characteristics (Hiscox et al. 2004) and has 
accelerated research to identify the signalling molecules involved.
Several pathways have to date been linked to the increased invasiveness of anti-hormone
resistant cells, including increased levels and activity of c-src, a non-receptor tyrosine kinase
able to effect cellxell and cellimatrix interactions (Knowlden et al. 2005) and c-met, a
receptor tyrosine kinase, previously strongly implicated in tumour metastasis (Sonobe et al.
1998). Interestingly, a recent link between breast cancer cell’s growth and invasion and the
activation of such tyrosine kinases has been forged by the observations that firstly, zinc can
activate several tyrosine kinases, including the EGFR (Samet et al. 2003), IGF-1R
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(Knowlden et al. 2005) and c-Src (Wu et al. 2002). Secondly, zinc levels are increased in 
some anti-hormone resistant cells and finally, the cellular levels of zinc are regulated, in part, 
by the LIVI family of zinc transporters, where LIVI levels in clinical breast cancer 
specimens has been associated to tumour cell spread to the regional lymph nodes (Manning 
et al. 1994).
1.5 LIV-1 and LZT subfamily of zinc transporters
Zinc transporter families
Zinc is an essential ion in cells, without it, cells die. Zinc is a co-factor for more than 300 
enzymes and is involved in protein, nucleic acid, carbohydrate and lipid metabolism, as well 
a in the control of gene transcription (Wu et al. 1977), differentiation (Krishna Murthy et al.
1973), development and growth (Nakamura 1965). Zinc deficiency can be detrimental, 
causing stunted growth (Bierich et al. 1982) and serious metabolic disorders (Pfeiffer et al.
1974), while excess zinc can be toxic to cells (Suh et al. 2000). It is therefore important that 
levels of zinc within cells be constantly controlled. In stress cells, zinc does not pass through 
cellular membranes and relies on two families of zinc transporters for its transport.
The ZnT family, which is previously termed CDF for cation diffusion facilitators, of zinc 
transporters (Paulsen and Saier Jr 1997), transport zinc out of cells or into intracellular 
compartments from the cytoplasm (now termed SLC30A). Whereas the ZIP family (for Zrt-, 
Irt-like Proteins, SLC39A) of zinc transporters (Eide 2004), transport zinc into the cell 
cytoplasm from either outside the cell or from intracellular compartments. The ZnT family
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contains 9 human sequences and the ZIP family contains 14 human sequences (Liuzzi and 
Cousins 2004).
The ZIP family of zinc transporters is reported to have approximately 86 members, which 
can be further divided into four separate subfamilies. The first subfamily is the fungal and 
plant sequences (subfamily I), second is the mammalian, nematode and insect genes 
(subfamily II), thirdly, the gufA gene of Myxococcus xanthus with unknown function (gufA 
subfamily) and finally, the LIV-1 subfamily related to the oestrogen-regulated gene, LIV-1 
(Taylor and Nicholson 2003). The role of each of these subgroups is suggested to be 
transport of metal ions especially zinc across cellular membranes and into the cytoplasm 
(Gaither and Eide 2001; Guerinot 2000).
The LZT subfamily members and the ZIP superfamily have eight conserved transmembrane 
domains. The LZT subfamily has a long and variable extracellular N-terminus region whilst 
the C-terminus is very short, as also found in the ZIP superfamily. Additionally, there are 
special motifs such as the HEXPHE motif found in transmembrane domain V and an HNF 
motif in transmembrane domain IV. This motif is placed within the pore formed in the 
transmembrane domains that it is able to form a metal binding site for the ZIP transporters. 
Furthermore the sequences contain histidine-rich repeat motifs throughout the LZT subfamily 
sequences, on the N-terminus and extracellular loop between transmembrane domains II and 
III, which are also suggested to enable zinc transport. Another region between
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transmembrane III and IV is an area with mixed charge and a number of polarity residues 
which may also play a role in zinc transport (Taylor and Nicholson 2003).
The 14 human members of the SLC39A family fall into four groups: subfamily I (ZIP 9), 
subfamily II (ZIP 1, 2 and 3), gufA subfamily (ZIP 11) and the LZT subfamily (LZT-Hsl to 
LZT-Hs9). The LZT subfamily represents the LIV-1 family of Zinc Transporters as LIV-1 
was the first member to be discovered (Manning et al. 1994) and for the 9 members of the 
LZT subfamily, in this thesis they will be referred as ‘LZT-Hs()’, where the bracket contains 
the number assigned to each of the LZT members and Hs refers to homo sapiens. However, 
in this thesis, the original LIV-1 gene nomenclature remains.
Some of the family members have been studied and do have a role in progressing diseases 
and additionally, LIV-1 gene that has been linked to oestrogen regulation and breast cancer 
metastasis (Manning et al. 1994). A defect in the LZT-Hs5 gene produces the zinc deficiency 
disease, acrodermatitis enteropathica caused by a defective uptake of zinc in the intestine 
(Nakano et al. 2003). One member of the LZT subfamily called the LZT-Hs6 or BigM103 
has been suggested to inhibit cancer cell growth and is induced by Beg and retinoic acid 
(Begum et al. 2002) and LZT-Hs4 increases intracellular zinc and it is regulated by IL-6 
(Liuzzi et al. 2005). It is known that HKE4 increases intracellular zinc whilst present in 
endoplasmic reticulum (Taylor et al. 2004) or the Golgi body (Huang et al. 2005). The 
functional significance of the various members of the LZT family of zinc transporters is so 
far largely undetermined. Although data is slowly emerging on the role of the individual
family members in individual tissues, the expression of all 9 members of the LZT family has 
not been attempted yet in any tissues. Furthermore, the functional significance of individual 
members in a disease state such as breast cancer has not been examined.
The hypothesis of this study is to observe whether any members of the LZT subfamily 
besides LIV-1 show significant level of expression in breast cancer disease.
Thesis aims:
1. To compare and examine the structures of the LIVI family members whether they 
have similarities/dissimilarities, and finally observe their potential functional motifs.
2. To clone the LZT-Hs7, LZT-Hs8 and LZT-Hs9 genes subsequently, investigate their 
protein sub-cellular distribution, and capacity to transport zinc.
3. To assess the oestrogen/anti-oestrogen regulation of the nine LI VI family members in 
MCF-7 human breast cancer cells and make comparison this to a computer prediction 
of the presence of EREs within the oestrogen receptor a  promoter.
4. To determine the expression of the nine LIVI family members in endocrine 
responsive and resistant MCF-7 breast cancer cells to assess their likely contribution 
to the increased tumour cell growth and invasiveness seen in resistant cells.
5. To reduce the expression of a LIV1 family member using siRNA technology, 
subsequently assess its impact on EGFR signalling because it is a major effecter of 
endocrine resistance.
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Chapter 2 
Materials and Methods
2.1 Materials
2.1.1 Plasticware
The plasticware used in this study were: 50ml Falcon tubes were purchased from Becton 
Dickinson Ltd, Cowley, Oxfordshire, UK; 10cm bacteria plates were obtained from Fisher 
Scientific UK Ltd, Loughborough, Leicestershire, UK; 250ml polypropylene centrifuge 
bottles used in the large scale preparation of DNA were bought from Kendro Laboratory 
Products Ltd, Bishops Stortford, Herfordshire, UK; microcentrifuge tubes were supplied 
from Elkay Laboratory Products (UK) Ltd, Basingstoke, Hampshire UK; Disposable pipette 
tips were bought from Greiner Labortechnik Ltd, Stonehouse, Gloucestershire, UK. The 
plasticware used were T25 and T75 tissue culture flasks, 35mm, 60mm and 150mm tissue 
culture dishes, 12- and 24- well tissue culture plates and Cryovials manufactured by Nunc, 
Roskilde, Denmark and supplied by Fisher Scientific UK Ltd, Loughborough, Leicestershire, 
UK. The filtered 12.5 cm tissue culture flasks were manufactured by Faison Plastics obtained 
from BD Biosciences Clontech UK, Cowley, Oxford, UK.
2.1.2 Enzymes and inhibitors
The molecular biology enzymes which were used in the PCR and RT-PCR study were:
TMRNAsin RNase Inhibitor were purchased from Promega UK, Southampton, UK; MMLV 
Reverse Transcriptase and Vent® Proofreading Taq polymerase enzymes were purchased
37
from Invitrogen, Paisley, UK; Biotaq™ DNA polymerase enzyme is bought from Bioline 
Ltd, London, UK.
2.1.3 Chemical, media and buffers
All molecular biology grade chemicals and media was purchased from Sigma-Aldrich 
Company Ltd, Poole, Dorset, UK; general laboratory grade chemicals and solvents were 
obtained from Fisher Scientific UK Ltd, Loughborough.
2.1.4 Molecular weight markers
DNA molecular weight markers used to estimate size of the nucleic, namely the lkb DNA 
ladder was bought from Promega UK, Southampton, UK; the HyperLadderlV was supplied 
from Bioline Ltd, Humber Road, London, UK., as listed in Appendix C.
2.1.5 Antibiotic
The antibiotic ampicillin was purchased from Sigma-Aldrich Company Ltd, Poole, Dorset, 
UK. To prepare the ampicillin stock solution of 1000X concentration, lOOmg of ampicillin 
was diluted in 1ml of sterile nuclease free water and then sterilized by filtration through a 
0.2pM filter which was purchased from Millipore Inc., Harrow Middlesex, UK and aliquots 
were stored in -20°C.
2.1.6 Oligonucleotides
Primers for all PCR procedures were synthesized by MWG-Biotech AG, Anzinger Str. 7, D- 
85560 Ebersberg, and Germany.
38
2.1.7 Equipment
The UV transilluminator, namely Fotodyne Inc. 3-3002 UV transilluminator used to visualize 
all ethidium bromide stained gels was bought from Flowgen Instruments Ltd, Maidstone, 
Kent, UK. The UV spectrophotometer, namely the Cecil CE2041 2000 series UV spec, used 
to determine the concentrations of both nucleic acid and proteins in solution, was purchased 
from Cecil Instruments Ltd, Cambridge, UK. Gel electrophoresis equipment was purchased 
from Invitrogen, Paisley, UK. The power supply was using the Bio-Rad Power Pac p i000 
which was purchased from Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK. 
Two systems used to photograph the EtBr gels, namely the Polaroid® Hand Held DS-34 
Camera and secondly, AlphaDigiDoc Imaging System with Olympus C-5060 Wide zoom 
camera. The former system was purchased from the Polaroid® Corporation, Cambridge UK, 
and the Hypercassettes™ used autoradiography was bought from Amersham Biosciences UK 
Ltd, Little Chalfont, Buckinghamshire, UK. The latter system was purchased from Alpha 
Innotech Corporation, San Leandro, California, attached with a Canon-Pixma iP400 printer. 
The micro centrifugation steps were carried out using refrigerated microcentrifuge, namely 
IEC Micromax RF 3593, which was purchased from Thermo Life Sciences, Basingstoke, 
Hampshire, UK. The Sorval RS6000 centrifuge model RC5B with the SLA600TC and 
SLA 1500 rotors were bought from Kendro Laboratory Products Ltd, Bishops Stortford, 
Hertfordshire, UK. The Beckman TL-100 and L-80 ultracentrifuges were bought from 
Beckman Coulter UK Ltd, High Wycombe, Buckinghamshire, UK.
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2.1.8 Computer searches
The computer software packages were used to access information of the LZT subfamily 
members to determine their similarities and dissimilarities of their sequences/genes and 
secondary structure proteins and to investigate their potential functional motifs. The 
computer software packages were used to verify the positive LZT-Hs7, LZT-Hs8 and LZT- 
Hs9 recombinants (Table 2-1).
2.1.9 Protein biochemistry
For the purpose of SDS PAGE procedure, the resolving and stacking gel buffers were 
purchased from Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK. Other 
chemicals used were 40% acrylamide/bis-acrylamide solution, Trizma® base, glycine, KC1, 
HEPES, sodium azide, Tween 20, TEMED, DTT the reducing agent and finally, for the 
protease inhibitors were leupeptin, bacitracin, PMSF, pepstatin A and aprotinin; all were 
purchased from Sigma-Aldrich Company Ltd, Poole, Dorset, UK. As for the general 
laboratory reagents used including glycerol, formaldehyde, NaCl, NaH2P04 and Na2HP04 
all were bought from Fisher Scientific Ltd, Loughborough, Leicestershire, UK. The recipes 
for the buffers are in Appendix B.
For the blotting materials, nitrocellulose transfer membranes with pore size of 0.45pm were 
purchased from Sigma-Aldrich Company Ltd, Poole, Dorset, UK. The Whatman No3 filter 
paper was obtained from Whatman International Ltd, Maidstone, Kent, UK.
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The chemiluminescent substrates used for the detection of immunostained Western blotted 
membranes (Supersignal® West Dura Extended Duration Chemiluminescent Substrate, the 
Supersignal® West Femto Maximum Sensitivity Substrate and the Supersignal® West Pico 
Substrate) were bought from Pierce and Warriner Ltd., Cheshire, UK. The Alexa Fluor 488- 
conjugated antimouse and Alexa Fluor 594-conjugated antirabbit antibodies and Texas Red 
Phalloidin were bought from Molecular Probes, Europe BV, Leiden, The Netherlands. The 
Rainbow™ coloured protein molecular weight marker for protein size estimation on SDA- 
PAGE gels was purchased from Amersham Biosciences UK Ltd, Little Chalfont, 
Buckinghamshire, UK. For the purpose of SDS-PAGE and Western Blotting procedures, the 
Bio-Rad Mini-Trans Blot™ and Power Pac 300 were purchased from Bio-Rad Laboratories 
Ltd, Hemel Hempstead, Hertfordshire, UK; while the Leica RPE automatic microscope used 
for fluorescence microscopy was purchased from Leica Microsystems Ltd, Milton Keynes, 
UK.
2.2 Cloning
2.2.1 Vector choice
To facilitate the cloning of LZT-Hs7, LZT-Hs8 and LZT-Hs9 the plasmid vector, 
pcDNA5/FRT/V5-His-TOPO® TA (Invitrogen) was used throughout. This vector has a CMV 
promoter upstream of multiple cloning sites, which enable its expression in mammalian cells. 
The downstream region includes a V5 epitope that enables its detection. The vector also 
contains an ampicillin resistance gene for positive recombinant selection.
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2.2.2 TA cloning
To facilitate the cloning the plasmid vector, pcDNA5/FRT/V5-His-TOPO® TA, possess a 
single 3’ thymidine (T) overhangs for the TA Cloning technique and by adding 3’ adenines 
(A) overhangs are used to clone the blunt-ended fragments of PCR products. Cloning by 
DNA amplification by Vent® Proofreading Taq polymerase produces blunt-ended products 
following the 3’ to 5’ exonuclease activity.
Additionally, the vector has Topoismerase covalently bound to the vector. This bond between 
the vector and the Topoisomerase enzyme is the phosphor-tyrosyl (Try-274) bond 
subsequently attacked by the 5’ hydroxyl of the PCR product hence releasing the enzyme and 
efficiently cloning the PCR products.
2.2.3 Design of oligonucleotides
For genes of interest, the forward primers were designed to include the Kozak translation 
initiation sequence (G/A) NN ATG, which allow a proper initiation of translation, followed 
by the ATG start codon. The reverse primer of LZT-Hs9 comprised a region that matched the 
3’ side of the specified target regions of the genes of interest followed by the V5 epitope 
sequence and ending with a stop codon, TAA. The V5 epitope enables the detection of the 
recombinant protein by the anti-V5 antibody (Table 2-2).
2.2.4 Amplification conditions for cloning
The 25pl of PCR mixture consisted of 0.5pl of the DNA template i.e 0.5pl of LZT-Hs7, 
LZT-Hs8 and LZT-Hs9 plasmids, 24pl of the PCR master mix which contains of 0.25mM of
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dNTP’s, 0.5pM of 3’ and 5’ primers, 0.1 Weiss units/pl of Vent® Proofreading Taq 
polymerase, IX PCR buffer (lOmM Tris-HCl pH 8.3, 50mM KC1, 1.5mM MgCb, 0.001 w/v 
gelatine) and 0.5pl nuclease free water. In the thermal cycler, to separate the double stranded 
DNA, the plasmid was heated to 94°C for a minute. Following this, the Vent® Proofreading 
Taq polymerase synthesizes new double-stranded DNA molecules by catalyzing the 
template. The polymerase operates at a temperature called the annealing temperature, which 
is 57°C and this was performed for 1 minute. To allow the successful synthesis of the new 
DNA strands, a further incubation was carried out at 72°C for 1 minute. This procedure was 
repeated for 26 cycles which enables the DNA to replicates exponentially in the automated 
thermal cycler. Additionally, further 10 minutes incubation period was added enable the 
cycle to complete.
To facilitate the cloning of the PCR products after amplification with Vent® Proofreading 
Taq polymerase, the vial containing these products was place on ice and 1 pi or unit of 
Bioline Taq polymerase was added per tube. After mixing, tubes were incubated at 72°C for 
10 minutes and then quickly placed on ice back to the cloning procedure.
2.2.4.1 Cloning reaction
(fi)The TOPO Cloning solution was prepared by adding together 4 pi of fresh PCR product, 1 
pi of Salt Solution, 1 pi of TOPO® vector and 1 pi of sterile water which were supplied by 
the manufacturer. The mixture was mixed gently and incubated for 30 minutes at room 
temperature.
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The cloning procedure was completed by adding 6 pi of the TOPO® Cloning mixture to a 
vial of One Shot® TOP 10 Chemically Competent E. coli followed by gentle mixing. 
Subsequently, the mixture was placed on ice was for 30 minutes, followed by 30 seconds 
period of heat-shock at 42°C before being once again transferred on ice. 250 pi of SOC 
medium at room temperature was added into the transformation mixture and the tube capped 
tightly before being rotated horizontally at 200 rpm at 37°C for 1 hour. This transformation 
mixture was spread on a prewarmed antibiotic ampicillin selective plate and incubated 
overnight at 37°C before the colonies were picked and tested for positivity using PCR.
PCR cocktail was prepared without the DNA addition in a final reaction volume of 25 pi. A 
colony was subsequently picked and part of it was resuspended in the PCR cocktail. The 
remaining part of the colony was preserved on another ampicillin selective agar plate for 
further analysis. This procedure was repeated for multiple colonies if required.
2.2.4.2 Testing of colonies
A PCR procedure was used to analyze positive recombinants. In the study we chose to test 
for the positive colonies using an orientation analysis only which confirms that the bacteria 
have the construct inserted in the correct orientation. Two sets of primers pair were used in 
the PCR cocktail. Firstly, forward primer (T7) for the vector that was included in the kit and 
a reverse primer that hybridizes within the inserted gene. Secondly, a reverse primer (BGH) 
which was included in the kit and a forward primer that hybridizes within the inserted gene. 
The primers used in the PCR to confirm positive recombinants for LZT-Hs7, LZT-Hs8 and 
LZT-Hs9 (Table 2-3).
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Positive transformed bacteria cultures were stored at -70C in a solution containing 15 -  20% 
glycerol. In each instance, the suspension of bacteria for storage was taken from 
logarithmically growing cultures in ampicillin selective Luria Bertani broth (0.85ml) and 
added to 0.15ml of autoclaved sterile glycerol solution.
2.2.4.3 Agarose gel electrophoresis
Agarose gel electrophoresis is a procedure for analyzing the PCR products by size 
fractionation. For the purpose of preparing 3v/v agarose gel multipurpose agarose (Bioline 
Ltd, London, UK) was dissolved in IX TAE buffer by heating until boiling in a microwave 
oven. The solution was then cooled to room temperature and lpl of lOmg/ml stock solution 
of EtBr was added to 50ml and the solution was poured into a casting tray and positioned the 
well comb at one end of the gel. Following this, the gel was left to set for about 40 minutes 
on a level surface and then submerged in an electrophoresis tank containing IX TAE buffer.
The DNA molecular weight marker and the PCR products were loaded into the formed wells 
using Gilson pipette. For the PCR product mixture, each mixture contained 1 volume of the 
DNA loading buffer to 5 volumes of the PCR products. The DNA molecular weight marker 
solution was made up of equal volumes of DNA loading buffer and the DNA molecular 
weight marker. A constant voltage of 95 volts was applied across the gel until the leading dye 
front had migrated to the desired distance from the positive electrode. The DNA molecular 
weight marker to determine the DNA size is in Appendix C.
45
The DNA was visualized using an ultraviolet transilluminator and photographed using either 
a DS34 direct screen instant Polaroid® camera with Polaroid® type 667 black and white film 
or a AlphaDigiDoc Imaging System attached to Olympus C-5060 Wide Zoom camera. In the 
latter instance, a print out of the gel was made using a Canon-Pixma iP400 printer.
2.2.4.4 Verification of sequences
Sequencing of the plasmid was carried in the Molecular Biology Support Unit within School 
of Biosciences, Cardiff University, using an ABI377 Automated DNA Sequencer. The DNA 
sequences generated from the cycle sequencing of the positive recombinant clones were 
analysed using a BLAST computer software package (Table 2-1). In all instances, this 
confirmed that the recombinants clones examined were fully homologous to their relevant 
cDNAs and had not mutated during the PCR procedure.
2.2.5 Plasmid purification
The molecular biology kits used for harvesting the plasmids were the QLAprep Spin 
Miniprep kit and the EndoFree Plasmid Maxi kit, which were bought from Qiagen Ltd, 
Crawley, West Sussex, UK.
2.2.5.1 Mini preparations of the plasmids
Plasmid purification was carried out using a commercially available QLAprep Spin Miniprep
kit, which uses the anion exchange resin method. This method which allows about 1 0 - 3 0
pg of plasmid to be prepared. Firstly, a 2ml aliquot of L-broth containing 50pg/ml
concentration of ampicillin in a capped Falcon 2059 polypropylene tube, was inoculated with
a single colony of transformed bacteria and incubated overnight at room temperature in a
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shaking incubator. Following this, 1.5ml of the culture was transferred into a sterile 
microcentrifuge tube and centrifugated at room temperature at 3,000 rpm for 5 minutes to 
produce a bacteria pellet. The plasmid was isolated from the bacteria pellet according to 
manufacturer instructions while using the QIAprep Spin Miniprep kit. The plasmid integrity 
was checked by loading a 1 fig aliquot of the isolated plasmid DNA on an agarose gel 
followed by its electrophores. The plasmid stocks were aliquoted for sequencing verification 
of the sequences and stored at -20°C.
2.2.5.2 Maxi preparations of plasmids
Large scale preparation of highly purified plasmid DNA generates material suitable for the 
transfection of mammalian cells. This was achieved by EndoFree Plasmid Maxi kit. Firstly, 
glycerol stocks were inoculated with a positive recombinant clones using an inoculating loop, 
which were then streaked on selective Luria Bertani agar plates containing 50pg/ml of 
ampicillin. The plates were subsequently incubated overnight at 37°C and single bacteria 
colonies were obtained and used to re-inoculate 2 -  5 ml of selective Luria Bertani broth. 
These bacterial starter cultures were incubated at 37°C with continuous agitation for 12 hours 
at 37°C until the cultures entered the late logarithmic phase of growth.
A 250 ml aliquot of sterile Luria Bertani broth in a 1 L conical flask supplemented with 50 
pg/ml of ampicillin was inoculated with 2.5 ml of the overnight starter culture and the 
mixture was incubated at 37°C for 1 hour. The culture was transferred into a 250 ml 
polypropylene centrifugation bottle and placed into a SLA 1500 rotor that was spun at 4°C for 
10 minutes at 5,000 rpm in a Sorvall RS6000 centrifuge. After discarding the supernatant, the
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cell pellets were resuspended in a cell resuspension buffer appropriate to the method 
instructed by the EndoFree Plasmid Maxi kit supplied protocol.
The plasmid integrity was check by loading a 1 pg aliquot of the isolated plasmid DNA on 
the agarose gel followed by electrophoresis. The plasmid stocks were aliquoted for 
sequencing verification of the sequences, cell transfection and stored at -20°C.
2.3 Cell culture
All cell lines, including CHO cells, were routinely maintained in their respective propagation 
media and the media was replenished twice during 7 day of culture periods. All monolayer 
cell lines were routinely cultured in a monitored flow CO2 gassed incubator. The ambient 
temperature of the incubator was 37°C and it had a humidified atmosphere of 5% CO2 .
2.3.1 Cell passage
On reaching confluence, cells were passaged. This involved a washing step at room 
temperature PBS buffer then incubation with 2ml of trypsin/EDTA solution (0.05%/0.025% 
w/v) at 37°C for 5 minutes, followed by the trypsin/EDTA inactivation by the addition of 
10ml of their respective propagation media. Using a fixed angle rotor in a Jouan C312 
centrifuge, the cells were pelleted at 1,000 rpm for 5 minutes. The media was then aspirated 
and the cell pellet resuspended in 10ml of propagation media. Finally, the cells were 
aliquoted into tissue culture flasks containing their propagation media using a dilution factor 
suitable to the cell lines.
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2.3.2 CHO cells
Chinese Hamster Ovary (CHO) cells were used for transient transfection of the LZT-Hs7, 
LZT-Hs8 and LZT-Hs9 recombinants for subsequent protein and immunofluorescence 
studies. Throughout the investigations, the experiments used cells cultured in 35 mm and 15 
cm dishes.
CHO cells were routinely cultured and passaged in complete Minimal Essential (a-MEM). 
The complete formula contains 10% FCS, 4mM L-glutamine, lOpg/ml 
penicillin/streptomycin and 2.5pg/ml of fungizone-Amphotericin B. To propagate the CHO 
cells, the cells were plated out at a 30-fold dilution into 15cm tissue culture flasks.
For recombinant protein analysis, which requires relatively large numbers of CHO cells, 17- 
hour or 24-hour transfected cells were grown in incubator until 80% confluent before 
harvesting the cells. Transfected cells for immunofluorescence for protein localization study, 
CHO cells were grown on 0.17mm thick coverslips placed in 35mm dishes and then post­
harvest the cells after 17-hour incubation. Transfected cells for protein molecular weight 
study, the cells were grown on 35 mm dishes and then post-harvest the cells after 24-hour 
incubation. In all instances, cells were incubated at 37°C in 5% CO2 .
2.3.3 LZT-Hs7, LZT-Hs8 and LZT-Hs9 transient transfections
Prior to commencing the transfection, two types of medium were prepared; firstly, a 
transfection medium containing the lipid and DNA mixture in a-MEM with 2% glutamine, 
and secondly, a replenishing medium containing 2% glutamine and 10% serum in a-MEM.
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The latter was used to wash the confluent cells before the transfection. In each instance the 
above medium were produced asceptically.
Once the appropriate solutions were prepared, the cells normal growth medium was removed 
and the cells were washed for three times with PBS buffer at room temperature. Following 
this, 1.5 ml of the replenishing media was added into the dish.
The lipid and DNA complex mixture was produced according to (Taylor et al. 2003) using 
4.4pg of DNA to 13.8pl of Lipofectamine2000™. This was sufficient for a transfection in 
either a well of six-well plate or one 35mm tissue culture dish. The lipid mixture was made 
by adding 13.8pl of Lipofectamine2000™ into 250pl of serum free medium in a marked 
microcentrifuge tube. The DNA mixture was made by adding 4.4pg of Qiagen® Maxi-Prep 
purified recombinant DNA to 250pl of the serum free medium in a second marked 
microcentrifuge tube. These steps are termed as the diluting procedure. Subsequently, the 
diluted Lipofectamine2000™ and DNA were added together and this was performed within 5 
minutes of the dilution step. The resulting transfection mixture was then gently mixed and 
incubated at room temperature for 20 minutes. Once the incubation was completed, the lipid 
and DNA mixture was gently overlayed onto the earlier replenished cell dishes. The dishes 
were again placed into the humidified atmosphere incubator at 370C in 5% C02. The 
transfection mixture was not removed, until the cells were harvested accordingly.
50
2.3.4 MCF-7 cells and its sub-lines
A variety of MCF-7 sub-lines were used to assess the expression of the LZT family of genes 
using mRNA analysis. In the Tissue Culture Laboratory, at Tenovus Centre for Cancer 
Research, their MCF-7 cells which are the ER human positive breast cancer cell line which 
has been exposed to variety hormonal and anti-hormonal agents. This has lead to the 
development of several sub-lines which have become resistant to anti-oestrogen and 
oestrogen withdrawal. Parental MCF-7 cells were originally obtained from Aztra-Zeneca 
Pharmaceuticals Division, Macclesfield, UK.
The MCF-7 cell line was routinely cultured and passage in complete RPMI 1640 medium, 
whilst the anti-hormonal resistant cells were grown in in complete RPMI 1640 supplemented 
with a maintenance concentration of the specified agent. The concentrations of hormones and 
anti-hormones routinely used were 10'9M 17-P oestradiol and 10*7M tamoxifen or faslodex. 
The complete RPMI 1640 media was supplemented with 4mM L-glutamine, 5% charcoal 
stripped Foetal Calf Serum (FCS), lOpg/ml of penicillin/streptomycin and 2.5pg/ml 
fungizone-Amphotericin B. The culture medium was changed twice a week.
All stock solutions of 17-p estradiol, tamoxifen and faslodex are prepared in ethanol and 
stored at -20°C. The 17-P estradiol and tamoxifen were purchased from the Sigma-Aldrich 
Company Ltd, Dorset, UK, while the faslodex is supplied by Astra-Zeneca, Pharmaceuticals 
Division, Macclesfield, UK.
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In total seven MCF-7 sub-lines were used to isolate mRNA and these were :
1) Parental MCF-7 cells:
2) MCF-7 cells treated with 10'9M oestradiol for 10 days
3) MCF-7 cells treated with 10'7M tamoxifen for 10 days
4) MCF-7 cells treated with 10'7M faslodex for 10 days
5) MCF-7 cells grown in heat inactivated charcoal stripped serum for 10 days (X-medium).
6) Tamoxifen resistant MCF-7 cells grown semi-confluence
7) Early faslodex resistant MCF-7 cells grown semi-confluence Early resistance involved
growing the cells for 70 passages. Late faslodex resistant MCF-7 cells grown semi­
confluence Late resistance involved growing the cells for 140 passages
8) MCF-7 cells resistant to X medium grown to semi-confluence (X-cells)
Cells for the above were seeded in six-well plates or or 35 mm tissue culture dishes for the 
RNA and protein studies respectively. In each instance 3 x 10s cells were seeded and they 
were incubated at 37°C in a humidified atmosphere containing 5% CO2 incubator until they 
are 80% confluent.
2.3.4.1 Preparation of RNA for PCR
All the RNA samples described in this study were isolated using the TRI® reagent (Sigma- 
Aldrich, Dorset, UK) RNA kit.
2.3.4.2 Preparation of mRNA
In order to prepare a small amount of mRNA (30 - 50 pg) for the following RT-PCR study, 
approximately 1.5 X 106 cells of sub-confluent adherent cultured cells were harvested from a
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60mm tissue culture dish. The media was discarded by aspiration and after that tissue culture 
dishes were washed with room temperature PBS buffer for three times. In order to lyse the 
cells, 1 ml of the TRI reagent was added directly on a culture dish. The dish was swirled 
around to enable the lysate to form and the mixture appeared viscous. The resulting lysate 
was scraped of the dish using a cell scraper. Prior to this the cell scraper was washed with 
ethanol and PBS buffer to aovid contamination. The cell lysate was subjected to repeated 
suction and reversed using pipette to make them homogeneous. The lysate was transferred 
into a microcentrifuge tube and placed on ice.
To separate RNA from DNA and protein, 0.2ml of chloroform was added into the lysate. The 
microcentrifuge tube was capped and was shaken vigorously using a vortex and following 
this, the lysate was set at room temperature for five minutes to allow the formation of three 
layers of solution in the lysate. The TRI reagent dissolves the RNA into the aqueous phase 
layer. The aqueous layer containing the RNA was aspirated and aliquoted to a new 
microcentrifuge tube. In an attempt to isolate the total RNA, 0.5ml of isopropanol was added 
into the RNA in the aqueous layer. The microcentrifuge tube was capped and the solution 
was mixed gently. Following this, the solution was set at room temperature for 10 minutes. 
The microcentrifuge tube was cemtrifuged at 13,000X rpm for 10 minutes and the RNA 
pellet was obtained at the bottom of the microcentrifuge tube. By avoiding the debris pellet, 
the solution was aspirated and leaving the pellet behind. 1 ml 75% ethanol was added into the 
microcentrifuge tube to wash the RNA pellet. The capped microcentrifuge tube was shaken 
vigorously but briefly, using vortex. Once the RNA pellet was floated in the ethanol, the
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microcentrifiige tube was centrifuged at 13,000X rpm for 5 minutes period was carried out. 
By avoiding the RNA pellet, the ethanol solution was aspirated as much as possible and the 
pellet was left to set at the bottom of the microcentrifuge tube.
For the purpose of air-drying the RNA pellet, as little as possible, ethanol solution was left 
with the pellet. To recover the pellet, the microcentrifiige tube was uncapped and about ten 
minutes period at room temperature would allow the ethanol solution to dry completely. 
Finally, the RNA pellet was dissolved in 10 to 50ul nuclease-free water (Invitrogen, UK,) 
and stored at -80°C refrigerator for avoiding degradation of the RNA. The quality of the 
RNA was evaluated by Cecil CE 2041UV Spectrophotometer and electrophoresis in 3% 
agarose and by PCR-based technique, or RT-PCR. The RNA concentration was estimated 
using the Cecil CF2041 UV spectrophotometer. This was performed by reading the optical 
density of 4 pi of RNA diluted to a final volume of 1 ml in sterile nuclease free water and 
was read at 260nm. The RNA concentration was calculated from a RNA calibration curve. 
The RNA purity was determined by calculation of the ratio of absorbance at 260nm to 
absorbance at 280nm and the pure RNA has a ratio of 1.8-2.2.
2.3.4.3 RT-PCR
RT-PCR is a PCR technique which used the reverse transcriptase enzyme to transcribe 
mRNA sequences into a double stranded cDNA template. This method was to synthesize and 
extend the first strand of DNA using random hexamer oligonucleotides (Knowlden et al. 
1997).
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20pl of RT-PCR solution was used, containing lpg total cellular RNA, lOpM random 
hexamer oligonucleotide mixture, 0.156mM dNTP mixture, 0.01M dithiothreitol and IX 
concentrated PCR buffer.
To denature the secondary structure of the RNA, the resulting solution was denatured at 95°C 
for five minutes on the thermal cycler (PTC-100™ Programmable Thermal Controller, MJ 
Research, Inc). Once the denaturing process was completed, the microcentrifuge tube was 
removed from the thermal cycler and quickly placed on ice for five minutes. After this 
period, the mixture was spun in a centrifuge for 1 minute. For the purpose of obtaining good 
quality PCR products, 0.5pl of RNase inhibitor (equivalent to 25 Weiss units) and 1 pi of 
MMLV-Reverse Transcriptase were added into the resulting RT-PCR solution on ice. These 
molecules were added into the solution to prevent any RNA degradation and prime DNA 
synthesis from the RNA templates, respectively. Following this addition, the microcentrifuge 
tube was capped to prevent dehydration during the reverse transcription process process. In 
the thermal cycler the reversed transcription program incubation uses 40 minutes at 42°C. 
The temperature was then raised to 95°C for five minutes to allow denaturing of the cDNA 
and RNA complexes and the inactivation of the MMLV-Reverse Transcriptase molecules in 
the samples.
The resulting cDNA mixtures from the reverse transcriptase reaction were used in at standard 
Polymerase Chain Reaction, which used gene-specific primers to the various LZT family 
members. Experiments involving the RNA profiling of the LZT family of genes used the
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primers listed in Table 2-4. Along side the LZT family of genes, the expression of pS2, p- 
actin and a-actin was also examined. The primer sets for these genes are listed in Table 2-5. 
The assigned annealing temperature, the number of cycles used for the amplification and the 
expected band size for the LZT family of genes, together with the control genes (pS2, a- and 
p- actin) are also shown in Table 2-4 and Table 2-5, respectively.
2.3.5 siRNA to LZT-Hsl transient transfection
Small interfering RNA, siRNA, molecules were synthetically developed to knockdown 
mRNA of genes of interest. In order to characterize LZT-Hsl gene functions in the 
tamoxifen resistant cell line, transient transfection was performed using a commercially 
available siRNA to LZT-Hsl. The siRNA to LZT-Hsl kit that was bought from Dharmacon, 
Thermo Fisher Scientific Inc, UK.
The procedure involved the addition of 0.2 nmol of the siRNA molecule is diluted in 250pl 
of serum free medium to 4pl of Lipofectamine2000™ reagent is diluted to 250 pi in serum 
free medium. These solutions must be mixed together within 5 minutes of making and must 
be incubated with the cells within 60 minutes. As such, the mixture was spread over the 
tamoxifen resistant cells in a 35mm tissue culture dish for either 24 or 48 hours incubation at 
37°C in 5% CO2 . The controls for the siRNA study were tamoxifen resistant cells without 
siRNA treatment, tamoxifen resistant cells with Lipofectamine2000™ only and tamoxifen 
resistant cells with siC scrambled control treatment. Following the siRNA and control 
treatments, preparations were made for two studies; in mRNA study, cells were harvested 24
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hours after the transient transfection and in the second study, the cells were harvested at 48 
hours.
Table 2-4 and Table 2-5 are showing the details of the primers and parameters for PCR 
programme for analysis in the RNA expression study.
2.3.6 Detection of proteins by Western blots
2.3.6.1 Lysis solution
In order to avoid protein degradation, the cell harvesting procedure was always carried out on 
ice. The lysis buffer, Triton-X-100, contained 50mM Tris of pH 7.5, 5mM EGTA, 150mM 
NaCl, 1% Triton X-100, 2nM sodium orthovanadate, 50mM sodium fluoride, lOmM sodium 
molybdate, 20pM phenylarsine oxide, ImM phenyl-methylsulfonyl fluoride, lOpg/ml 
leupeptin and lOpg/ml aprotinin.
After washing the cells in room temperature PBS, 30pl of the lysis solution was added to 
each dish. Then using a scraper the protein lysates were collected into labeled 
microcentrifiige tubes. The cell debris was pelleted by centrifugation at 13,000 rpm for 20 
minutes at 4°C and the supernatant, which contained the protein of interest, was aliquoted 
into new microcentrifiige tubes and stored at -70°C until used.
2.3.6.2 Protein concentration determination
To determine the concentration of protein in the whole cell lysate, a small sample was 
removed and used in a colorimetric protein assay kit (Bio-Rad DC Protein Assay Kit). The
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method is based on the folin phenol method of Lowry and colleagues which allows rapid 
determination of protein concentrations following their solubilisation by a detergent. All the 
samples were read for their absorbance at 750nm measurement in a Cecil CE2041 
spectrophotometer relative to a standard protein curve generated from a series of known 
concentration of BSA.
2.3.6.3 Protein preparation
A small sample containing 40-80pg of protein was aliquoted into an equivalent volume of 
2X concentrated Laemmli sample buffer and the resultant mixtures was denatured at 100°C 
for ten minutes in dry heating block (Techne DB-2A Dri-Block). After a brief pulse spin on 
the microcentrifuge, the denatured protein samples were used for SDS-Page and Western 
blotting.
2.4 SDS-Page and Western Blot
The discontinuous polyacrylamide gel electrophoresis method for protein separation was 
used here. The protein marker scale to determine the protein molecular weight is in Appendix 
C.
2.4.1 SDS-Page
For the purpose of separation, two types of gels were used, the stacking gel and a resolving 
gel. In the former gel of the concentration of acrylamide was 4%, whereas the resolving gel 
was 7.5%. All western blots were carried out using the Bio-Rad Blot™ apparatus. The 
resolving gel buffer used was 1.5M Tris-HCl pH 8.8 (Bio-Rad) and the stacking gel buffer
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was 0.5M Tris-HCl pH 6.8 (Bio-Rad). The stock acrylamide solution comprised of 30% 
Acrylamide and 0.8% N,N’-methylene-bis-acrylamide.
Using the resolving gel mixture, appropriate Bio-Rad gel formers with 1mm spacers and 
10cm back plates were set-up. Immediately, after pouring the resolving gel, a thin layer of 
water was discharged on top of the gel. The resolving gel was then left to solidify for about 
30 minutes. Once the gel was solidified, the water was removed using a piece of Whatmann 
3MM filter paper. Following this, the stacking gel solution was poured onto the resolving gel 
and appropriate gel combs put in place. The gel combs used were 10mm and each of the 
formed wells has a capacity to hold a total of 50pi protein sample. Finally, after the stacking 
gel solidified, the wells were rinsed out and flooded with electrophoresis (0.05M Tris, 
0.384M glycine, 0.1% SDS). As routine, one track of the gel was loaded with 10 pi of 
standard Rainbow Markers™ (Amersham BioSciences) while the other tracks were used to 
load the protein samples. The gels were subject toelectrophoresis at 150V for about an hour, 
which allowed the dye front to migrate the desired distance down the gel.
2.4.2 Western Blot
The term western blotting is commonly used to describe both the transfer of protein from an 
acrylamide gel to a nitrocellulose membrane and then the subsequent immunoblotting 
procedure using specific antibodies. Using specific antibody probing it is possible to identify 
a protein of interest from other protein of similar.
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Following the gel electrophoresis, the polyacrylamide gels were transferred to an 
immobilised membrane using a Bio-Rad Blot™ electrophoresis cell. In the assembly of one 
unit of the transfer apparatus, two 10cm X 8cm sheets of nitrocellulose membrane 
(nitrocellulose membrane pore size 0.45 pM, Sigma-Aldrich) were cut for each gel. Prior to 
the transferring procedure, a transfer buffer was prepared (25mM Trizma® base , 191mM 
glycine, 20% v/v methanol and 0.1% SDS). The buffer was then filled into a tray, 
temporarily, and in the electrophoresis transfer tank. Using the buffer in the tray, the filter 
paper, the fiber pads supplied with the transfer apparatus and the nitrocellulose membrane 
were pre-soaked. In addition, the gels were removed from the glass backing plates and 
immersed in the tray. In the electrophoresis transfer tank, the blotting insert, a small magnetic 
stirrer and an ice pack were placed in the tank.
The procedure of western blotting, there are several sources of error have been identified and 
trapped air bubbles in the blotting cassette must be avoided. The assembly of the blotting 
cassette therefore is always done whilst everything else is submerged in the transfer buffer in 
the tray. To set up the western blot, the blotting cassette was opened and the black side 
placed down in the tray. A single fiber pad was then placed in the black side of the cassette 
followed by a single sheet of filter paper that was placed next to the gel. Following this, the 
nitrocellulose membrane was placed on the gel and a single sheet of filter paper was 
positioned on top of it and lastly followed by another single fiber pad. The blotting cassette 
was then carefully closed and pressed gently under the transfer buffer to expel any trapped 
air bubbles. Once the cassette is ready, it was then positioned in the blotting insert with the
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membrane nearest the positive electrode of the electrophoresis unit. An ice block was 
inserted in the transfer tank before the lid was placed on the transfer tank. The buffer was 
gently stirred while the current was applied at 150V across the electrodes for an hour at room 
temperature.
2.4.3 Immunoblotting
Immunoblotting allows characterization of protein of interest using monoclonal or polyclonal 
antibodies. The membrane was first incubated with 5% w/v substitute of 2.5g Marvel milk 
reconstituted in 50ml of TBS Tween. The blocking was done in a 50ml Falcon tube whilst it 
was on a rotatory mixer at room temperature for 1 hour. The blocking solution was then 
decanted into a waste container and the blots incubated with a primary antibody in 1% w/v of 
the blocking solution. The antibody incubation step was also performed on a rotatory mixer 
at room temperature for 1 hour. Prior to the secondary antibody incubation, the membranes 
were washed 3 times for a total of 15 minutes with a TBS Tween solution. Following this, 
the secondary antibody was applied to the membrane and once again incubated for 1 hour on 
a rotatory mixer at room temperaturefollowed by 9 washes in a total of 45 minutes. The 
membranes was then placed in a fresh plastic sleeve.
2.4.4 Protein detection
On completion of the immunoblotting process, the membranes were incubated with 1 ml of a 
chemiluminescent detection mixture at room temperature for five minutes and then 
transferred to another fresh plastic sleeve. This was then exposed to an X-ray film 
(Hyperfilm-ECL) in a closed cassette. The first film was normally exposed for 30 to 60 
seconds in order to judge the correct subsequent exposure time.
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2.4.5 Antibodies
The anti-V5 antibody that detects the 14 amino acid epitope at the C-terminal fusion proteins 
expressed using pcDNA5/FRT/V5-His-TOPO® TA vector was bought from Invitrogen, 
Paisley, UK and used at a dilution of 1:1000. The Y1068, phosphorylated EGFR and Y1178 
phosphorylated EGFR antibodies were purchase from Cell Signalling, Technology, 
Hertfordshire, UK, whilst phosphor c-Src 418 antibody was purchased from Biosource 
International, Nivelles, Belgium and in each instance they were used at a dilution of 1:2000. 
Rabbit-antimouse antibodies were obtained from Dako, High Wycombe, Buckinghamshire, 
UK, and the donkey-antirabbit antibodies were purchased from Amersham Biosciences UK 
Ltd., Little Chalfont, Buckinghamshire, UK), and used at a dilution of 1:2000. The p-actin 
mouse monoclonal antibody which recognizes an N-terminal epitope of the p-isoform of 
actin was bought from Sigma-Aldrich Company Ltd, Poole, Dorset, UK, and was used at a 
dilution of 1:10,000. The LZT-Hsl polyclonal antibody was ‘in-house’ generated antibody 
and the serum was used at dilution of 1:750.
2.5 Fluorescent microscopy
2.5.1 Coverslip procedure
2.2 X 105 CHO cells were grown on a 0.17 mm thick coverslips prior to transfection for 24 
hours. Following this, the cells were fixed with 4% v/v formaldehyde for 15 minutes then 
incubated either with permeabilising or non-permeabilising buffer. Permeabilising buffer was 
prepare from 0.4% w/v Saponin and 1% w/v bovine serum albumin in PBS buffer, whilst the 
non permeabilising buffer lacks Saponin. Subsequently, the cells were incubated in 10% v/v 
normal goat serum, and followed by an 1 hour incubation at room temperature with anti-V5
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antibody. After washing Alexa Fluor 488-conjugated anti-mouse antibody was added 
followed by 1 hour incubation at room temperature. F-actin was stained using Texas Red®-X 
for 15 minutes. After the incubations the coverslips were assembled on to slides using 
Vectorshield containing 1.5 fig/ml of DAPI to counterstain the cell nuclei. All the coverslips 
are visualized using the imaging system.
2.5.2 Detection of zinc using Newport Green™ diacetate
Tamoxifen resistant cells were grown on coverslips for 24 hours following the transient 
transfection procedure and then were rinsed with warm PBS. 50pM of Newport Green dye 
was then discharged directly onto the coverslips and incubated in the dark for 30 minutes at 
37°C.
2.5.3 Imaging system
2.5.3.1 AlphaDigiDoc Innotech Imaging
The AlphaDigiDoc Innotech Imaging system was used to scan all gel electrophoresis and X- 
ray images and was linked to Olympus C-5060 Wide zoom camera. An ultra violet light box 
and a white light box were used for the gel electrophoresis and X-ray images, respectively. 
The images densities and statistics data were generated by using Spot Density Measurement 
function and an Excel Microsoft, statistical package respectively.
2.5.3.2 Fluorescent microscope
The fluorescent microscope used was an inverted LEICA DM IRE2 microscope with an oil
immersion 63X objective and a Hammamatsu camera. The images were taken using a
mercury-lamp-base system, which was supported by Openlab Modular computer software
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package. Fluorescent superimposed images were acquired using multiple band-pass filters 
that were set for DAPI, fluorescein and Texas Red Phalloidin.
It is important to note, for stringent analysis, all experiments done in triplicates and repeated 
at least three times. This applies to the recombinant study (Chapter 3), the RNA expression 
study (Chapter 5), also in the procedures involved in the computer searches (Chapter 3 and 
Chapter 5). The only exception to this is in the LZT-Hsl small interfering RNA study where 
the RNA expression experiments were done in triplicates and repeated three times while the 
protein analysis was done once and pooled the triplicates protein samples used for a Western 
blotting procedure. The MCF-7 cells treated with Tamoxifen for the small interfering RNA 
study were prepared immediately upon request, by the Tissue Culture Laboratory, in Tenovus 
Centre for Cancer Research, while the RNA collections were prepared prior to storage in the 
-80°C refrigerator until the respective study started.
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Table 2-1: Computer softwares packages used for LZT subfamily to gather information
Databases WWW-Address Description
DRAGON
ERE
FINDER
http://research.i2r.a-
star.edu.sg/DRAGON/E
RE-V2/
System for Identification and Interactive Analyses 
of Estrogen Response Elements in DNA Sequences
EMBL Http ://www.ebi .ac.uk/em
W
European Molecular Biology Laboratory 
nucleotide sequence database at EBI, Hinxton, UK
GenBank Http://www.ncbi.nlm.nih 
. eov/Genbank/GenbankO 
verview.html
DNA Genome Sequence Database at National 
Center for Biotechnology information, NCBI, 
Bethesda, MD, USA
SWISS-
PROT/TrEM
BL
Http://www.expasv.ch/ PIR-Intemational Protein Sequence Database, 
annotated protein database by PIR, MIPS and 
JIPID at NBRF, Georgetown University, USA
Fasta3 Htto ://www.ebi .ac.uk/fas 
ta3/
Sequence similarity and homology searching 
against nucleotide and protein database using 
Fasta3 (Global Alignment)
BLAST2 Http://www.ebi.ac.uk/bla
stall/
NCBI blast2 (blastall) program (Local Alignment)
TMPRED http ://www.ch .embnet.or 
g/ software/TMPREDfor 
m.html
Tool to prediction of transmembrane regions and 
protein orientation
Tree View http ://taxonomy.zoology. Tool to build phylogenetic analysis of protein and
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gla.ac.uk/rod/rod.html DNA sequences
ELM http://elm.eu.org/ Tool to search of functional sites in proteins
NetNGlyc http://www.cbs.dtu.dk/se
rvices/NetNGlyc/
Tool to predict N-glycosylation sites in human 
proteins
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Table 2-2: Forward and reverse primers of LZT-Hs7, LZT-Hs8 and LZT-Hs9 for 
cloning
LZT subfamily gene 
and the sequence 
accession number
Forward primer Reverse primer Nucleotide size 
(Base pairs)
LZT-Hs7 
NM_173596
5’- CCC ATC ACC 
ATG GGG TCC
5 -  TTC TCA GCC 
CTC AGT GGT C-3’
1686
CCA GTG -3’
LZT-Hs8 
NM_152725
5’- CCC ATC ACC 
ATG TGC TTC
5 - TAT TTT AAT ATT 
TTG CTC -3’
1962
CGG ACA AAG -3’
LZT-Hs9 
NM_152264
5’- CCC ATC ACC 
ATG TCC CTG
5 -  TAA CGT AGA 
ATC GAG ACC GAG
1094
CCC TGG -3’ GAG AGG GTT AGG
GAT AGG CTT ACC 
GTT ACT CGG GAG -
3’
Underlined nucleotides in the forward primer are located on the 5’end of the sequence whilst 
in the reverse primer the underlined nucleotides are complementary to the 3’ end of the 
sequence. The red is the complementary sequence o f V5 tag.
Table 2-3: Forward and reverse primers for LZT-Hs7, LZT-Hs8, and LZT-Hs9 for 
orientation analysis by PCR
LZT family of 
gene
Forward primer Orientation analysis 
using BGH primer
Nucleotide size 
(Base pairs)
LZT-Hs7 5’- CCC ATC ACC ATG 
GGG TCC CCA GTG -3’
5’ - CCC ATC ACC 
ATG GGG TCC CCA 
GTG- 3 ’
1827
LZT-Hs8 5’- CCC ATC ACC ATG 
TGC TTC CGG ACA 
AAG -3’
5’ - CCC ATC ACC 
ATG GGG TCC CCA 
GTG- 3 ’
2103
LZT-Hs9 5’- CCC ATC ACC ATG 
TCC CTG CCC TGG -3’
5’ - CCC ATC ACC 
ATG GGG TCC CCA 
GTG- 3 ’
1295
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Table 2-4: Primers set, annealing temperature, cycle number and expected band size
for the LZT subfamily of genes in RNA profiling study
LZT
subfamily
Forward primer Reverse primer Annealing
°c
Cycle Expected 
size 
(Base pairs)
LZT-Hsl 5’- ATC GCT 
CTC TAC TTC 
AGA TC -3’
5’- CTC TTC 
TGA ACC 
CCT CTT G - 
3’
57°C 392
LZT-Hs2 5’- TTG GCA 
GTT CAA 
GAG GGA 
AAG -3’
5’- CGA TTA 
TGC TCA 
TAC TGT -3’
55°C 31 451
LIV-1 5’- GTC TAA 
CAG CTC 
TAG GAG GC 
-3’
5’- CAC CAA 
TTG CTA 
GGC CAT CG 
-3’
55UC 35 576
LZT-Hs4 5’- TGC TTG 
GCT TAT 
GGA GAA CC 
-3’
5’-GAG ATG 
ACG GTC 
ACA CAG 
AGG -3’
55°C 29 425
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LZT-Hs5 5’- CCC ATC 
ACC ATG 
GCG TCC 
CTG G -3’
5’-GGT GCC 
CTC GGG 
GTT GCT 
GAG G -3’
55UC 29 330
LZT-Hs6 5’- CCC ATC 
ACC ATG 
GCC CCG 
GGT CGC 
GCG -3’
5’- CCC ATC 
ACC ATG 
GCC CCG 
GGT CGC 
GCG -3’
55UC 29 335
LZT-Hs7 5’- GGG TGA 
CCT GGA 
AGA GTC AA 
-3’
5’- CAG CAA 
GGG CCG 
TAG TAG AC
-3’
57UC 33 388
LZT-Hs8 5’- AAA CTT 
GCC TTC 
CCC AGA CT 
-3’
5’- TGA GTG 
AGA GGC 
CCT TCT GT -
3’
57UC 31 297
LZT-Hs9 5’- CCC ATC 
ACC ATG 
GCG GGC 
CCA AG -3’
5’-GGG AAT 
GAC AAG 
CAA CGG 
GAA-3’
59UC 29 242
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Table 2-5: Primers set, annealing temperature, cycle number and expected band size
for the control genes for mRNA profiling study
Control
genes
Forward primer Reverse primer Annealing
°c
Cycle Predicted 
size(Base pairs)
a-actin 5’- CTA CGT 
CGC CCT GGA 
CTT CGA GC - 
3’
5’- GAT GGA 
GCC GCC GAT 
CCA CAC GG -3’
55UC 29 204
p-actin 5’- GGA GCA 
ATG ATC TTG 
ATC TT -3’
5’- CCT TCC 
TGG GCA TGG 
GGT CCT -3’
55°C 29 336
pS2 5’- CAT GGA 
GAA CAA GGT 
GAT CTG -3
5’- CAG AAG 
CGT GTC TGA 
GGT GTC -3’
55°C 29 336
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Chapter 3 
Computer Search
This chapter describes the scientific classification of the LIV-1 family of genes used in this 
thesis in comparison to other literatures. The study of the family protein secondary-structure 
is important to show the similarities and differences among the LZT family members 
themselves and between the LZT subfamily and the ZIP superfamily. The secondary motifs 
study also predicts the protein functional sites that arise because of particular requirements 
on the secondary-structure of specific region or more than one. This region or regions may be 
important for their binding properties or importantly, their enzymatic activity. Subsequently, 
as an introductory study, the post-translation modification such as the phosphorylation sites 
in the LIV-1 family of proteins were investigated that possibly contributes to regulation of 
enzyme for example in the MAPK pathways for carcinogenesis. The aim of the work 
presented in this chapter was to establish whether there were recogniseable motifs, which 
were relevant to the function of LIV-1 subfamily.
3.1 Gene nomenclature
ZIP transporters consist of a superfamily of zinc transporters that are divided into 4
subfamilies. One subfamily (LIV-1 subfamily) consists of genes that share similarities to the
LIV-1 gene, which is an oestrogen-regulated gene and it has been implicated in metastatic
breast cancer disease (Manning et al. 1994), This superfamily is also known as the SLC39A
family of metal transporters, which play a role in zinc homeostasis. The ZIP superfamily
acronym stands for Zrt-, Irt-like proteins and the LIV-1 subfamily has been termed LZT,
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which stands for LIV-1 family of ZIP Transporters. Table 3-1 shows the gene nomenclature 
across the 9 members of the LZT subfamily and in this thesis they will be referred as ‘LZT- 
Hs ( ) ’, where the bracket contains the number assigned to each of the LZT members and Hs 
refers to homo sapiens. However, in this thesis, the original LIV-1 gene nomenclature 
remains.
3.2 Protein secondary-structure prediction
ClustalW (Eddy 1995) computer software package allows the sequences of all 9 members of 
the LZT subfamily to be aligned in order to observe any differences in secondary-structure 
protein among the LZT subfamily. As we know, the ZIP superfamily play a role in zinc 
homeostasis, and alignment of the full distribution of the LZT subfamily by ClustalW will 
help prediction of any interesting structural properties within the LZT subfamily. The 
BOXSHADE3.2 computer software package was used to shade the residues. Identical 
residues shown by black color and complementary residues were identified in grey, using a 
cut-off value of 50% homology as shown in Figure 3-1. There are four main areas within the 
LZT subfamily that show a large proportion of identical residues, among there are the 
CPALLY region, transmembrane domains (TM), ZIP consensus sequence and H E X P H E 
motif.
This alignment of the LZT subfamily using ClustalW could be represented as a phylogenetic
tree shown in Figure 3-2. As can be seen, LZT-Hs4 and LZT-Hs6 are clustered together,
LZT-Hsl clustered with LZT-Hs9, and finally, LZT-Hs2 clustered with the LIV-1 gene.
These patterns shown in the phylogenetic/dendogram representation, suggests the possibility
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of these clustered genes sharing similar properties of either secondary-structure and/or 
protein functionality.
3.3 Uniqueness of LZT subfamily members
Within the LZT subfamily, the individual family members probably share properties 
predicted to be involved in zinc transport and this section discuss the similarities among the 
LZT subfamily, which are not found in the ZIP superfamily.
3.3.1 N- terminus
The N-terminus is the sequence immediately after the translation start site, and predicted to 
reside extracellularly in those family members that reside on the plasma membrane. There 
are 133 residues in the N- terminus of LZT-Hsl gene and 405 residues in the LZT-Hs2 gene. 
317 residues in the LIV-1 gene, 152 residues in the LZT-Hs4 gene, 325 residues in the LZT- 
Hs5 gene, 127 residues in the LZT-Hs6 gene, 212 residues in the LZT-Hs7 gene, 365 
residues in the LZT-Hs8 gene and 66 residues in the LZT-Hs9 gene (Figure 3-1).
3.3.2 C- terminus
C- terminus of the LZT subfamily is very short and is situated immediately after
transmembrane domains 8. It was observed, 6 residues in the C- terminus of LZT-Hs2 gene,
6 residues in the LIV-1 gene, 3 residues in the LZT-Hs4 gene, 2 residues in the LZT-Hs5
gene, 3 residues in the LZT-Hs6 gene, 7 residues in the LZT-Hs7 gene and 2 residues in the
LZT-Hs8 gene. Neither LZT-Hsl nor LZT-Hs9 has any residues beyond transmembrane
domain 8 (Figure 3-1). Since LZT-Hsl is known to reside in the endoplasmic reticulum may
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suggests a similar location for LZT-Hs9 (Taylor et al. 2004). This trait of very short and 
extracellular C- terminus predictions are similar to the attributes of the ZIP superfamily zinc 
transporters (Guerinot 2000).
3.3.3 HNF motif unique to LZT subfamily
As seen in Figure 3-3, another interesting feature in transmembrane domain IV is that it holds 
a conserved motif H N F ,  where H is histidine, N for asparagine and F is for phenylalanine 
residues. The ZIP superfamily of zinc transporters have conserved residues in a similar 
region however they have H S residues (S, serine), instead of the H N F in LZT subfamily, 
however both of the conserved regions are predicted to be part of an intramembrane heavy 
metal binding site despite having differences in the motif between these two families.
3.3.4 CP ALLY motif unique to LZT subfamily
There is a motif in 7 out of 9 LZT subfamily members that contains 3 conserved cysteine and 
1 proline residue. This has been termed the CPALLY motif (Figure 3-4). Cysteine residues 
are known to have a role in protein tertiary structure and this motif may thus have an 
important role in the control of zinc transport. Interestingly LZT Hsl and LZT Hs9 do not 
contain the CPALLY motif. LZT-Hsl resides on intracellular membranes (Huang et al. 2005; 
Taylor et al. 2004) and this may suggest a role for the CPALLY motif in regulating zinc 
influx into the cell. Furthermore, neither LZT-Hsl nor LZT-Hs9 contains the cysteine residue 
preceding the HEXXH motif in transmembrane domain V. This may suggest that 1 of the 3 
cysteine in the CPALLY motif binds to the cysteine in transmembrane V to control the zinc 
influx.
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3.3.5 HEXPHE motif unique to LZT subfamily
As seen in Figure 3-.5, a conserved motif in the LZT subfamily located in transmembrane 
domain V is the H E X P H E motif, where H is for Histidine, E is Glutamic acid, P is Proline 
and ‘X’ is any amino acid. In contrast, the ZIP superfamily have a motif H X X X E instead 
of H E X P H E which it was predicted to form a pore region providing a transport 
mechanism for zinc ions. Interestingly, within the LZT subfamily members, LZT-Hs4 and 
LZT-Hs6 genes have lost their initial H, histidine residue of the HEXPHE motif sequence 
and replaced by glutamic acid (E) residue. Changes in this amino acid of these sequences 
suggest that these genes may prefer to transport metal ions other than zinc (Liuzzi et al. 
2005).
3.3.6 PEST motif unique to LZT subfamily
Strong PEST motifs consists of amino acid proline (P), glutamic acid (E), serine (S) and 
threonine (T) and when present, PEST motifs are able to reduce the half-lives of proteins 
dramatically as they target proteins for proteolytic degradation allowing the protein to exert 
various different cellular functions (Rechsteiner and Rogers 1996). The PEST site analysis 
achieved using the PESTfmd software package is shown in Figure 3-5, indicated by red 
arrows. There are only 2 genes of the LZT subfamily identified with a PEST motif and they 
are: LZT-Hs2, in the sequence at position 206 with RGEPSNEPSTETN residues and at 
position 575 with RLNETELTGLEQQESPP, whilst the second gene is LIV-1, PEST site at 
position 209 with KDVSSSTPPSVTS residues.
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3.4 The compilation of information from the various computer searches describing each 
of members of the LZT subfamily.
3.4.1 LZT-Hsl
LZT-Hsl sequence contains 469 residues (Figure 3-5), and it has a close relationship with 
LZT-Hs9 sequence with both sequences sharing a high similarity of residues (Figure 3-2). 
The LZT-Hsl gene has one predicted N-linked glycosylation site that is located 
intracellularly (Table 3-6). Interestingly, LZT-Hsl does not contain the CPALLY motif and 
it resides on the ER membrane. This may suggest an important role of the motif for control of 
zinc influx at the plasma membrane or intracellular organelles. The LZT-Hsl gene has 9 
histidine residues in between transmembrane III and IV which may play a role in zinc 
transport (Figure 3-5). The protein resides in the endoplasmic reticulum, Golgi body and 
membrane fractions (Table 3-5).
3.4.2 LZT-Hs2
The total amino acids in LZT-Hs2 sequence is 831 residues (Figure 3-5) and it has the 
greatest homology with LIV-1 of all the family members (Figure 3-2). There are five 
predicted N-linked glycosylation sites, which are located extracellularly suggesting that the 
protein resides on the plasma membrane and the protein could potentially be glycosylated 
(Table 3-6). There are two strong potential PEST sites, one of which is situated 
extracellularly in the N-terminus and the other is located intracellularly (Figure 3-5). The 
PEST regions suggest that LZT-Hs2 may be post-translationally modified by proteolytic 
cleavage. Recently, work in the Tenovus Centre for Cancer Researh laboratories has shown,
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LIV-1 has been observed to be cleaved in the endoplasmic reticulum region before relocation 
to the plasma membrane (Taylor, personal communication) and the presence of the PEST 
sites may suggest proteolytic processing of LZT-Hs2 (Figure 3-5). The protein is suggested 
to be found on the plasma membrane (Table 3-5).
3.4.3 LIV-1
The LIV-1 sequence is 749 residues (Figure 3-5), and it shares similarities with the LZT-Hs2 
and LZT-Hs7 sequences based on homology of residues (Figure 3-2). Four predicted N- 
linked glycosylation sites are located extracellularly, suggesting that the protein resides on 
the plasma membrane and the protein is potentially glycosylated (Table 3-6). One strong 
potential PEST site is located extracellularly in the N-terminus suggesting proteolytic 
processing using a similar mechanism to LZT-Hs2 sequence. Finally, the LIV-1 protein has 
been located on the plasma membrane and in lamellipodiae (Table 3-5), suggestive of 
involvement in proliferation process by the latter (Table 3-5).
3.4.4 LZT-Hs4
The LZT-Hs4 sequence contains 492 residues (Figure 3-5), and it has a close relationship 
with the LZT-Hs6 sequence because both sequences share a high similarity (Figure 3-2). The 
LZT-Hs4 gene has three predicted N-linked glycosylation sites that are located 
extracellularly suggesting that the protein resides on the plasma membrane (Table 3-6) and 
that LZT-Hs4 protein is likely to be glycosylated. Interestingly, the first histidine residue of 
the HEXPHE motif is replaced by a glutamic acid residue suggesting that this gene may 
preferentially transport metal ions other than zinc.
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3.4.5 LZT-Hs5
The total amino acids in the LZT-Hs5 sequence is 647 residues (Figure 3-5) and it shares 
residues homologous with LZT-Hsl, LZT-Hs2, LIV-1, LZT-Hs7 and LZT-Hs9 (Figure 3-2). 
There is one predicted N-linked glycosylation site, which is located intracellularly (Table 3- 
6). There is no strong potential PEST site and the LZT-Hs5 protein is suggested to be located 
on the plasma membrane (Table 3-6).
3.4.6 LZT-Hs6
LZT-Hs6 sequence contains 460 residues (Figure 3-5) and it has a close relationship with 
LZT-Hs4 (Figure 3-2). The LZT-Hs6 protein has two predicted N-linked glycosylation sites 
(Table 3-6), which are located extracellularly suggesting that the protein may be glycosylated 
and reside on the plasma membrane (Table 3-5). Interestingly, the first histidine residue of 
the H E X P H E conserved motif in the LZT-Hs6 protein in replaced with a glutamic acid 
residue suggesting that the LZT-Hs6 gene may transport other metal ions to zinc. The LZT- 
Hs6 protein is suggested to be located in vesicles (Table 3-5).
3.4.7 LZT-Hs7
The total amino acids of the LZT-Hs7 sequence is 540 residues (Figure 3-5) and it has a high 
homology of residues with the LZT-Hs2 and LIV-1 sequences as shown in the phylogenetic 
tree (Figure 3-2). Three predicted N-linked glycosylation sites are located extracellularly 
suggesting that the protein resides on the plasma membrane of cells and the protein is 
potentially glycosylated.
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3.4.8 LZT-Hs8
The total amino acids in the LZT-Hs8 sequence is 654 residues (Figure 3-5) and it is present 
on a separate arm of the phylogenetic tree suggesting no close homology to other family 
member (Figure 3-2). Interestingly, there is no histidine residue identified in between 
transmembrane domains III and IV (Figure 3-5). Results from the study have found that the 
LZT-Hs8 protein resides on the plasma membrane (Table 3-5).
3.4.9 LZT-Hs9
The LZT-Hs9 sequence contains 364 residues (Figure 3-5) and it shows a close relationship 
with the LZT-Hsl sequence (Figure 3-2). The LZT-Hs9 protein does not contain any 
glycosylation site suggesting that it may be located intracellularly. Interestingly, like LZT- 
Hsl protein, the CPALLY motif is absent in LZT-Hs9 protein suggesting a similar function 
of subcellular location or function (Figure 3-5). Results from the study have found that the 
LZT-Hs9 protein resides intracellularly suggestive of the endoplasmic reticulum (Table 3-5).
3.5 Characterization of LZT subfamily and ZIP superfamily
The aim of the following discussion is to understand the role of the LZT subfamily by 
comparing the similarities and differences between the LZT subfamily and ZIP superfamily.
3.5.1 Similarity of transmembrane domains LZT subfamily to ZIP superfamily
One of the features of ZIP superfamily proteins includes sharing a similar membrane 
topology in which case the amino- and carboxy-terminal ends of the protein are located on
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the outside surface of the plasma membrane and the superfamily are predicted to have 8 
transmembrane domains (Guerinot 2000).
There are many transmembrane prediction methods available however only 2 computer 
packages were used for the transmembrane domains. These were TMpred and DAS software 
packages (Table 2-1), that were based on a hidden Markov model, which is a similar method 
to that used in ClustalW. A study has revealed that in transmembrane topology predictions, 
the accuracies of prediction were lower among eukaryotic sequences as compared to those 
obtained for prokaryote counterparts (Ikeda et al. 2002).
It appears that LZT-Hsl possessed 8 transmembrane domains instead of 7 as predicted in 
Table 3-2. This may be because there is a proline residue located in transmembrane domain 
V of the protein sequence, which has a less hydrophobic feature, and may bias the TMpred 
software package prediction (Hofmann and Stoffel 1993). Nevertheless, the LZT-Hsl has 
been characterized with 8 transmembrane domains due to its close homology with other 
family members (Figure 3-1).
Table 3-2 shows results for TMpred computer packages search indicating LZT-Hs8 and 
LZT-Hs9 N- terminus ends are located outside the transmembrane domains. This is 
unexpected as the other family members have an internal N-terminus, that includes a 
transmembrane domain and after cleavage in the cell, this would render the N-terminus end 
of the protein to be located extracellularly. A possible explanation for the discrepancy of
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LZT-Hs8 and LZT-Hs9 could be that the apparent but weak detection of a shorter 
transmembrane domain within the N-terminus (Table 3-2).
Table 3-3 shows the results of a SignalP search for cleavage sites for all the members of LZT 
subfamily, and they each contain a single signal peptide cleavage site predicted to be located 
at the N-terminus (Emanuelsson et al. 2007). The cleavage process will remove this initial 
transmembrane domain and allow the remaining N-terminal sequence to be located outside 
the cell. This process is also observed within the ZIP superfamily sequences and this explains 
why the usual prediction of transmembrane domains is nine.
In general, this shows that the LZT subfamily members have 8 transmembrane domains as 
observed in the ZIP superfamily of zinc transporters with an additional signal peptide 
transmembrane domain. Figure 3-1 shows an alignment of the LZT subfamily encompassing 
eight transmembrane domains indicated with red color lines and roman numerals written 
underneath for each transmembrane domain (TM).
3.5.2 Similarity between LZT subfamily and ZIP superfamily
The protein secondary structure analysis of LZT subfamily members has provided sufficient 
proof that it belongs to ZIP superfamily zinc transporters. Firstly, the ZIP superfamily is 
predicted to contain eight transmembrane domains, an extracellular N- and C- termini region 
and containing a long variable region in the cytoplasmic loop between transmembrane
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domains III and IV, and the discussion above has proved that the LZT subfamily sequences 
share the same attributes.
Additionally, one main character of the ZIP superfamily is the ability to transport zinc that is 
also shared by the LZT subfamily members. Previously, it has been shown that LIV-1 
(Taylor et al. 2003) and HKE4 (Taylor et al. 2004) genes transport zinc ion despite the fact 
that the latter has the first histidine, H, residue of the H E X P H E motif replaced by 
glutamic acid, E, hence suggesting the gene might able to transport other ions. Among other 
family members that transport zinc or other metal ions are LZT-Hs4(Tominaga et al. 2005), 
LZT-Hs5 (Dufher-Beattie et al. 2003), LZT-Hs6 (Dalton et al. 2005) and LZT- Hs7 (Dufner- 
Beattie et al. 2004; Huang et al. 2005; Wang et al. 2004).
3.5.3 Differences of histidine rich region between LZT subfamily and ZIP superfamily
The ZIP superfamily contain a histidine rich region of H X H X H where H is for histidine 
residue and X refers to any substitute residue, which is present on the loop between 
transmembrane domain III and IV. This region is thought to be important for zinc transport. 
In other words, this cytoplasmic histidine region is predicted to be a metal binding domain 
for the ZIP superfamily of zinc transporters (Guerinot 2000).
Interestingly, in the LZT subfamily, the histidine repeats occur throughout the sequence,
mainly in the extracellular N terminus, between transmembrane II and III, and between
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transmembrane IV and V (Figure 3-5). It is observed that the LZT-Hs2 and the LIV-1 
proteins contain the highest number of histidine repeats within the LZT subfamily, in contrast 
to LZT-Hs9, which contains only 1 histidine residue.
The total number of histidine residues in the variable loop between transmembrane III and IV 
for LZT-Hsl protein is 9 histidine residues. LZT-Hs2 contains 20 histidine, LIV-1 contains 
21 histidine, LZT-Hs4 contains 7 histidine, LZT-Hs5 contains 6 histidine, LZT-Hs6 contains 
5 histidine, LZT-Hs7 contains 6 histidine, LZT-Hs8 has none, and finally, LZT-Hs9 contains 
only 1 histidine residue in this region. Obviously, all members except LZT-Hs8 (none), a 
high number of histidine residues and this raised the question if LZT-Hs8 gene functions 
differently to others or for example, it may not preferentially transport zinc but other metal 
ions.
Another important feature of the region between transmembrane domains III and IV it 
contains a mixed charge region. In the ZIP superfamily, it is predicted that the zinc ion is 
taken up as a divalent cation that has a strong tendency to form tetrahedral complexes to 
exert its function (Guerinot 2000). Importantly, the LZT subfamily possess a mixed charge 
region in the same place as the ZIP superfamily variable region is, which the latter is 
predicted as a binding region for metal ion, for example, zinc ion.
The mixed charge region prediction for the LIV-1 family was achieved by using the SOSUI
(Hirokawa et al. 1998) software package revealing the location and presence of charged
residues in the variable loop between transmembrane domains III and IV (Table 3-4). The
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mixed charge region is a region of unbalanced quantity of charge in the variable loop and 
may play a role in binding and transport divalent cations such as zinc. Among the negative 
charged amino acids are D, aspartic acid residue and E, glutamic acid residue, in contrast, the 
positive charged amino acids are K, lysine residue and R, arginine residue. Molecules that 
add polarity to the region are the N, asparagine residue, Q, glutamine, S, serine and Y, 
tyrosine residues. Importantly, this region possesses a mixed charge region and also contain 
many high polarity molecules suggesting that the region may be important for metal ion 
transport for the LZT subfamily.
All the LZT subfamily members have less residues with negative charges compared to the 
number of residues with positive charges (Table 3-4), however, even with weak negative 
surface potential such as this, divalent cations could still be attracted through the membrane. 
There were equal number of positive and negative charges for LZT-Hsl, and in contrast, 
LZT-Hs2 has only 2 residues with negative charges and 7 residues with positive charges. 
LIV-1 has 4 residues with negative charges but 10 residues of positive charges. Interestingly, 
LZT-Hs4 has an equal number of positive and negative residues in this mixed charged 
region, and LZT-Hs5 has 9 residues with negative charges and only 4 residues with positive 
charges. Overall, LZT-Hs6, LZT-Hs7, LZT-Hs8 and LZT-Hs9 hold only 3, 1, 4 and 1 
negative residues, respectively, as compared to 5, 4, 5 and 1 positive residues.
The polarity of the protein may be important for helping the divalent zinc ions pass through 
the transmembrane domains. In Table 3-4 it is shown that in total LZT-Hsl have 6 residues
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with polarity, LZT-Hs2 has 9, LIV-1 has 11 residues, LZT-Hs4 has 12 residues and LZT-Hs5 
has only 4 residues that could add polarity to the mixed charged region. LZT-Hs6, LZT-Hs7, 
LZT-Hs8 and LZT-Hs9 has 6, 5, 7 and 3 residues with polarity, respectively.
3.5.4 Differences between LZT subfamily and ZIP superfamily
There are four differences between the LZT subfamily and the ZIP superfamily zinc 
transporters; firstly, there are sevenfold more histidine rich repeats in the LZT subfamily than 
in the ZIP superfamily of zinc transporters. Secondly, the conserved region of H E X P H E 
X in the LZT subfamily is a unique motif with a potential metalloprotease ability that is not 
found in the ZIP superfamily of zinc transporters. Thirdly, the LZT subfamily members have 
a long N-termini compare to the ZIP superfamily of zinc transporters and finally, the 
possibility of a pore structure formation between transmembrane III and IV, which includes 
with transmembrane II, and the conserved mixed charge region may suggest a mechanism of 
zinc transport.
3.6 Predicted functional site in members of LZT subfamily
The Eukaryotic Linear Motif (ELM) software packages predict small functional sites of 
proteins from the sequences. The computer software package also predicts the protein-protein 
interaction, regulation of the protein by phosphorylation, acetylation or other post- 
translational modification or the proteins’ cell compartment targeting (Puntervoll et al. 2003).
Table 3-7 shows the summary of the predicted functional sites for the LZT subfamily.
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3.6.1 Proline-Directed Kinase phosphorylation site: ([S/T])P motif
One motif that is shared by all 9 of the LZT subfamily members is the proline-directed kinase 
site with the sequence formula of ([ S / T ]) P , where S is serine, T is threonine and P is 
proline residue. This motif consists of a serine/threonine residue preceding a proline residue 
that is required to activate the kinase enzymatic function such as phosphorylation process.
3.6.2 MAPK interacting molecule
A large family of MAP and CDK-like kinases recognize this motif. The MAPK kinase and 
the extracellular-signal-regulated kinases (ERK) are responsible for sending proliferation and 
mitogenic signals. Generally, the mechanism involves sending signals from the cellular 
surface to the nucleus by activation of transcription factors. This motif is observed on 
proteins present in the nucleus and cytosol of the cell suggesting the proteins may be 
involved in cell proliferation. As can be seen in Table 3-7, within the LZT subfamily, most of 
the respective members are found to possess one of these motifs.
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Table 3-1: LZT subfamily gene nomenclature
LIV-1 family gene Protein name Human gene name Sequence Accession number
LZT-Hsl HKE4 SLC39A7 NM 006979
LZT-Hs2 ZIP10 SLC39A10 NM_020342
LIV-1 LIV-1 SLC39A6 NM012319
LZT-Hs4 ZIP 14 SLC39A14 NM_015359
LZT-Hs5 ZIP4 SLC39A4 NM_173596
LZT-Hs6 BIGM103 SLC39A8 NM 022154
LZT-Hs7 ZIP5 SLC39A5 NM_173596
LZT-Hs8 ZIP 12 SLC39A12 NM_152725
LZT-Hs9 ZIP 13 SLC39A13 NM_152264
The information gathered from text-based search using National Center for Biotechnology 
Information (NCBI) for the nucleotide and protein sequences information.
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Figure 3-1: Alignment of 9 members of LZT-family
Alignment of 9 sequences using ClustalW. Residues colored black and grey correspond to 
50% identical or complementary residues, respectively. CPALLY, transmembranes 
domains with roman numeral designation (TM), ZIP consensus and HEXPHE motif 
indicated.
Figure 3-2: Phylogenetic tree representing LZT subfamily
LZT-Hs8
LZT-Hs4
LZT-Hs6
LZT-HS5
LZT-Hsl
LZT-HS9
LZT-HS7
LZT-Hs2
LIV-1
Alignment of the multiple sequences of the LZT subfamily genes analysis result converted 
into the phylogenetic tree presentation by using Tree View software. The tree shows three 
main clusters within the LIV-1 family indicating the relationship within the LZT subfamily.
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Table 3-2: Prediction of LZT subfamily transmembrane (TM) domains topology
LZT-Hs4 protein has the N- 
terminus inside and 9 strong 
transmembrane helices.
LZT-Hs5 protein has the N- 
terminus inside and 9 strong 
transmembrane helices.
LZT-Hs6 protein has the N- 
terminus inside and 9 strong 
transmembrane helices.
LZT-Hsl protein has N- 
terminus inside and 7 strong 
transmembrane helices.
LZT-Hs2 protein has the N- 
terminus inside and 8 strong 
transmembrane helices.
LIV-1 protein has the N- 
terminus inside and 9 strong 
transmembrane helices.
LZT-Hs7 has the N-terminus 
inside and 9 strong 
transmembrane helices.
LZT-Hs8 protein has the N- 
terminus outside and 10 
strong transmembrane
helices.
LZT-Hs9 protein has the N- 
terminus outside and 8 strong 
transmembrane helices.
The information o f transmembrane domains topology gathered from TMpred software 
packages. The red line is the basal score for the weight-matrices values of the protein and the 
plot above the score is the prediction topology o f the protein.
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Table 3-3: Predicted cleavage sites for LZT subfamily
LZT
subfamily
SignalP search for cleavage site prediction
LZT-Hsl Cleavage site between position 25 and 26 with the amino acid sequence 
LVA-GH
LZT-Hs2 Cleavage site between position 25 and 26 with the amino acid sequence 
NHC-HE
LIV-1 Cleavage site between position 20 and 21 with the amino acid sequence 
TNP-LH
LZT-Hs4 Cleavage site between position 30 and 31 with the amino acid sequence 
AHA-SS
LZT-Hs5 Cleavage site between position 22 and 23 with the amino acid sequence 
ATA-SP
LZT-Hs6 Cleavage site between position 22 and 23 with the amino acid sequence 
GVA-EG
LZT-Hs7 Cleavage site between position 24 and 25 with the amino acid sequence 
VGG-SV
LZT-Hs8 Cleavage site between position 23 and 24 with the amino acid sequence 
VFS-TE
LZT-Hs9 Cleavage site between position 32 and 33 with the amino acid sequence 
AGG-SQ
The location of signal peptide cleavage sites in amino acid sequences obtained from SignalP
3.0 software packages.
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Table 3-4: Predicted polarity and charge residues between transmembrane III and IV
LZT
subfamily
members
D E K R N Q S Y
LZT-Hsl 2 3 3 2 1 l 4 -
LZT-Hs2 1 1 6 1 - 4 4 1
LIV-1 2 2 8 2 2 4 3 2
LZT-Hs4 2 1 3 1 1 4 5 2
LZT-Hs5 3 6 - 4 1 - 3 -
LZT-Hs6 1 2 5 - - 1 4 1
LZT-Hs7 - 1 1 3 1 2 2 -
LZT-Hs8 2 2 4 1 2 1 4 -
LZT-Hs9 - 1 - 1 1 1 1 -
The site of charge residues were obtained from SOSUI software package, (+) indicates the 
positive charges and, (-) for negative charges. The residues involved are D for aspartic acid, 
E for glutamic acid, K for lysine, R for arginine, N for asparagine, Q for glutamine, S for 
serine, and Y for tyrosine. Residues D and E represents the negative charges, whilst K and R 
are the positive charges, and N, Q, S, Y are residues of polarity.
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Figure 3-3: Two conserved motif of HNF and HEXPHE in transmembrane IV and V
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The HNF motif and HEXPHE conserve motif observed in the nine members of LZT 
subfamily. In the transmembrane domain IV, the histidine, H, residue in LZT-Hs9 gene lost 
the conserved motif and replaced by aspartic acid, D, residue. In the transmembrane domain 
V, LZT-Hs4 and LZT-Hs6 genes were observed to possess the glutamic acid, E, residue 
instead of histidine residue in the conserved m otif sequence in contrast to other family 
members.
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Figure 3-4: CPALLY motif in the LZT subfamily
Hs2 315
LIV-1 250
Hs4 90
Hs5 248
Hs6 73
Hs7 156
Hs8 288
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The information extracted from the Boxshade3.2 analysis result and with 50% homology, the 
black shaded letters are identical residues while the grey letters are complementary residues 
found within the LZT subfamily. It is obvious that in LZT-Hsl and LZT-Hs9 their CPALLY 
motif replaced by other amino acid suggestive of these genes function differently without this 
motif (not shown).
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Figure 3-5: Schematic diagram of LZT subfamily member’s tertiary structure
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The schematic diagram is a compilation of information from the computer search for each 
member of the LZT subfamily.
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Table 3-5: Summary of LZT subfamily predicted function and localization
LZT Chromoso
me
location
Location in cells Known Function Distribution in tissues
LZT-Hsl 6p21.3 Endoplasmic 
reticulum H 
Golgi body A 
Membrane 
fraction0
Transport zinc 
and manganese 
ions
mammary gland, esophagus, lymph 
node, breast tumor tissue, placenta8
LZT-Hs2 2q33.1 Plasma membrane Influx zinc ion Testis8
LIV-1 18ql2.1 Plasma membrane 
and lamellipodiaeD
Influx zinc ion Breast cancer, pituitary tumor, 
breast, embryonic stem8
LZT-Hs4 8p21.2 Plasma membrane11 Influx zinc, 
uptake of iron; 
bind to non­
transferrin
Colon8
LZT-Hs5 8q24.3 Plasma membrane Uptake of zincF Small intestine, stomach, colon, 
cecum and kidney8
LZT-Hs6 4q22-q24 Vesicles Influx zinc and 
cadmium ions
Cervix8
LZT-Hs7 12ql3.13 Basolateral 
polarized cells, 
plasma 
membraneG/N
Remove zinc ion Kidney, stomach tumor tissue, 
bladder, small intestine, rectum8
LZT-Hs8 1 Op 12.33 IntracellularN Unknown corpus callasum, hippocampus, 
kidney, tumor tissue, retina, brain, 
Alzheimer cortex8
LZT-Hs9 Upll.12 Intracellular1" Unknown glioblastoma multiforme, 
liposarcoma, squamous cell 
carcinoma, bone, lung tumour, 
cervix tumour tissue8
A- (Huang et al. 2005) 
B- (Ando et al. 1996)
C- (Strausberg et al. 2002)
D- (Taylor et al. 2003)
E- (Taylor et al. 2005)
F- (Kury et al. 2002)
G- (Wang et al. 2004)
H- (Taylor et al. 2004)
N- Demonstrated in next chapter: Engineering LZT-Hs7, LZT-Hs8 and LZT-Hs9 recombinants
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Table 3-6: Summary of LZT subfamily glycosylation sites and molecular weight
LIV-1 family gene N-linked 
glycosylation located 
in N-terminal b
N-linked 
glycosylation located 
intracellular b
Predicted molecular 
weight of the protein 
(kDalton)0
LZT-Hsl nil 2 49.915
LZT-Hs2 5 5 94.131
LIV-1 4 2 84.282
LZT-Hs4 3 nil 54.059
LZT-Hs5 1 nil 68.421
LZT-Hs6 1 2 49.630
LZT-Hs7 2 1 56.361
LZT-Hs8 5 1 72.805
LZT-Hs9 nil 1 38.352
Based on the search using NetNglyc 1.0 Server 
Based on the search using Compute pI/Mw
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Table 3-7: Summary of LZT subfamily predicted functional sites
Function 
sites d
Importance of the functional 
site
LZT family 
matched to 
sequence
Nucleotide sites 
found at
([SAT])P— Proline-Directed Kinase 
phosphorylation site
LZT-Hs2 5 sites (199,245,350,550,588)
MAPK
interacting
molecules
Carry docking motif to 
regulate specific interaction 
MAPK cascade
LZT-Hsl
LIV-1
LZT-Hs6
LZT-Hs7
LZT-Hs8
LZT-Hs9
3 sites (164, 310,377) 
1 site (76)
1 site (147)
2 sites (239, 442)
2 sites (502,532, 533) 
2 sites (105, 212)
d This information was abstracted from the 3LM software packages search and below is a
schematic representation of the transmembrane domains depicting the MAPK predicted sites. 
(LZT-Hs4 and LZT-Hs5 predicted sites are not found)________________________________
<Hs2>
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3.7 Discussion
This chapter used several computer prediction softwares to investigate the similarities and 
differences in the protein sequence of the 9 members of the LZT subfamily. The alignment of 
the sequences using ClustalW confirmed that these family members have extremely 
conserved regions that coincide with the transmembrane domains. These proteins are 
predicted to be zinc influx transporters with a complex transmembrane structure that may 
provide a pore for zinc to be transported across. It is therefore not surprising that the 
transmembrane domains are conserved and these would represent the main functional regions 
of the molecules. The software prediction packages for transmembrane domains can 
sometimes be erroneous, as their alogorithms do not allow for the presence of any proline 
residues. There is a conserved proline in transmembrane (TM) IV, which prevents this 
domain from being recognised. However some packages do recognise this area as a 
transmembrane domain and in conjunction with the obvious alignment of the different 
members (Table 3-2), it is valid conclusion that they all have 8 transmembrane domains, and 
not counting the signal peptide transmembrane domain at the N-terminus end.
Additionally, this alignment of 9 sequences also demonstrates the long and variable N- 
terminus region. This suggests that this region contains motifs that may regulate the function 
of the individual family members. An example of this is the motif termed CPALLY, that is 
present upstream of transmembrane domain I. This motif consists of three highly conserved 
cysteine residues as well as a single proline residue. It is entirely possible that this motif folds 
over the pore of the zinc transporter and is able to control the opening and closing of the pore
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and hence regulate the transport of zinc across the membrane. Interestingly, there is a fourth 
cysteine positioned immediately preceding the HEXXH motif in transmembrane IV, which 
would reside in close proximity to the CP ALLY motif in the tertiary structure. Furthermore, 
there are two exceptions to this. LZT-Hsl and LZT-Hs9 not only have no CPALLY motif but 
they also have no cysteine preceding the HEXXH motif. Additionally, LZT-Hsl is known to 
reside intracellularly on endoplasmic reticulum membranes and perhaps this data suggests 
that the CPALLY motif is only important for molecules responsible for zinc influx into the 
cell.
Furthermore, the computer analysis predicts many N-linked carbohydrate side chains for 
these family members within the N-terminus region which would be located extracellularly if 
they were present on the plasma membrane. Again, LZT-Hsl and LZT-Hs9 are the exception 
and contain no such predicted side chains. LZT-Hsl resides in the endoplasmic reticulum and 
therefore it would not be glycosylated. These data also suggest that LZT-Hs9 would be 
predicted to also reside intracellularly.
The computer searches had identified 2 out of 9 members of the LZT subfamily to have the 
PEST sites in their sequences. These sites are suggestive that the proteins undergo post- 
translational proteolytic processing within the cell. Both LZT-Hs2 and LIV-1 have PEST 
sites. Recent results in the Tenovus Centre for Cancer laboratories, using 2 different 
antibodies to LIV-1 (one to the start and another to the end of the N-terminus) have 
demonstrated that LIV-1 is cleaved at the N-terminus before it relocates to the plasma
membrane. This conclusion was reached as the antibody that detected the epitope near the N- 
terminus did not recognise the plasma membrane located LIV-1, whereas the second 
antibody, positioned downstream of the PEST site recognised the LIV-1 positioned on the 
plasma membrane. As LZT-Hs2 is the other protein with the PEST sites it is predicted that it 
may also undergo post-translational processing before it would relocates itself to the plasma 
membrane to transport zinc ions. Interestingly, LZT-Hs2 also had the most homologous 
sequence to LIV-1 as shown in the phylogenetic tree (Figure 3-2), suggestive that it may be 
processed in the cell in the same way as LIV-1.
The alignment of the 9 members of the LZT subfamily has revealed a unique motif within the 
sequences with the sequence HEXPHE. This is in contrast to the ZIP superfamily of zinc 
transporters, which have a HXXXE motif in transmembrane domain V. In the LZT 
subfamily, the motif is located in transmembrane V and the pore formation is suggestive of 
transporting zinc ions across the cell’s membrane. Among the 9 members of the LZT 
subfamily, there are 2 proteins which have been identified that have the first residue, 
histidine, of the HEXPHE motif, replaced by another residue, glutamic acid, E. This change 
amino acid residue may be indicative of a preferences for transport of metal ions other than 
zinc (Liuzzi et al. 2006).
There is also a difference in the amount of histidine rich repeats between the LZT subfamily 
and to the ZIP superfamily of zinc transporters, that is the former contains seven fold more 
histidines (Taylor et al. 2003). The ZIP superfamily histidine repeats are only found in
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transmembrane III and IV whereas the LZT subfamily has histidine repeats throughtout its 
sequence (Figure 3-5). It was observed that LZT-Hs2 and LIV-1 genes have the highest 
number of histidine repeats whilst LZT-Hs9 contains only 1 histidine in the region between 
transmembrane domains III and IV. A high number of histidines is suggestive of zinc ion 
coordination in the structure and the presence of only 1 histidine in LZT-Hs9 may imply a 
role increasing the catalytic activity rather than binding zinc (Little 1977). In contrast, LZT- 
Hs8 does not contain any histidines residue in the region between transmembrane domains 
III and IV and this is suggestive of impaired zinc transport activity.
Finally, the mixed charge region, which is located between transmembrane domains III and 
IV, is possibly involved in the transport mechanism of the zinc ions. Zinc ions are divalent 
cations and areas of protein of mixed charge are thought to be more reactive and involved in 
binding of zinc ions. It has been shown that the concentrations of divalent ions are increased 
near the channel mouth by a weak negative surface potential (Adam 1980). Table 3-4 shows 
that almost all of the LZT subfamily members have a substantial mixed charged region on 
the loop between transmembrane domains III and IV, and this might provide the activity 
needed to bind zinc ions. It is suggested that the divalent zinc ions would act an opposite 
attraction to allow them to pass through transmembrane domains. Additionally, the residues 
with high polarity might encourage transport of zinc ions. Interestingly, the potential proline- 
directed kinase phosphorylation sites in the cytoplasmic region of LZT-Hs2 (2 sites found), 
and the predicted sites of MAPK cytoplasmic region of LZT-Hsl (3 sites), LZT-Hs7, LZT- 
Hs8 and LZT-Hs9 (each protein has 2 sites found in cytosol), were discovered in some
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members of the LZT subfamily. Together with the knowledge that MAP kinase pathway is 
involved in breast cancer progression may suggest an important role of these molecules in 
cell models.
The analysis of the sequences performed in this chapter has enabled us to confirm that LZT- 
Hs7, LZT-Hs8 and LZT-Hs9 are indeed members of the LZT subfamily of zinc transporters. 
At the start of this project, none of these molecules had previously been investigated in cells. 
It was therefore the intention to clone LZT-Hs7, LZT-Hs8 and LZT-Hs9 into a vector to 
allow expression in mammalian cells. This would enable these molecules to be characterized 
for cellular location and zinc transport ability.
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Chapter 4
Cloning LZT-Hs7, LZT-Hs8 and LZT-Hs9 recombinants
In this chapter, the sub-cellular distribution of the LZT-Hs7, LZT-Hs8 and LZT-Hs9 proteins 
was investigated. In addition, the capacity of these proteins to transport zinc ions was 
investigated. The approach adopted to express these proteins in naive cells was using the 
pcDNA/FRT/V5-His TOPO®TA vector. It was therefore necessary to clone LZT-Hs7, LZT- 
Hs8 and LZT-Hs9 recombinants.
4.1 Positive clones’ analysis
LZT-Hs7, LZT-Hs8 and LZT-Hs9 genes were exponentially amplified using the polymerase 
chain reaction (PCR), which was optimized for each of the genes, Figure 4-1 shows the PCR 
results for LZT-Hs7, LZT-Hs8, LZT-Hs9 and demonstrates band sizes of approximately 
1686, 1962 and 1094 basepairs respectively. These values are in accordance with their 
predicted sizes. The PCR procedure used two control genes to confirm the PCR technique, 
which are our ‘in-house’ LIV-1 gene, and a vector without any gene insertion. Of all the PCR 
products, only LZT-Hs9 appeared to have two bands instead of a single PCR product. Since 
it was unclear what the upper band represented, the LZT-Hs9 1094 band was isolated by low 
melt gel purification. Importantly, the figure also shows the strong signal intensities of all the 
PCR products which indicates an adequate quantity of DNA has been produced allowing to
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proceed to the next procedure, to clone them individually into the pcDNA5/FRT/V5-His- 
TOPO® TA vector.
This vector was selected to drive expression of the recombinant proteins in mammalian cells 
by the CMV promoter. The oligonucleotides had been designed to incorporate the relevant 
gene downstream of the CMV promoter. The 3’- oligonucleotide removed the stop codon 
from the sequence at the C-terminal end in order that the V5 tag was included on the C- 
terminal end of the recombinant protein (in the case of LZT-Hs9). This would enable 
detection of the recombinant protein by Western blot and by immunofluorescence. The other 
two genes (unlike LZT-Hs9) LZT-Hs7 and LZT-Hs8, had a C-terminal V5 tag that originated 
from the vector, instead of inserting the sequence in their 3’- oligonucleotide.
Having confirmed the correct genes for LZT-Hs7, LZT-Hs8 and LZT-Hs9, they were cloned 
into the mentioned vector and Escherichia coli was then transformed with the plasmids. The 
bacteria were then grown and the plasmid purified using an endotoxin free plasmid 
purification kit to enable expression in mammalian cells by transient transfection. Before the 
plasmid was purified it was important to check the colonies for the correct gene insertion. 
This was achieved by PCR using the 5’ oligonucleotide for each insert, and a 3’ 
oligonucleotide for BGH, 141 residues downstream of the multiple cloning sites.
4.1.1 LZT-Hs7
As may be seen in Figure 4-2, the PCR procedure confirmed the LZT-Hs7 gene was inserted 
into the pcDNA5/FRT/V5-His-TOPO® TA vector in the correct orientation and gave a band
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of approximately 1827 basepairs in all of the 9 lanes. Although in each instances, the PCR 
signal was good, indicating an approximately high concentration of product, lanes 2, 3 and 7 
show contaminations with double bands or a PCR product of an inappropriately large size. 
Only clones 1, 4, 5, 6, 8 and 9, therefore, are suitable for making large-scale plasmid 
preparations to enable the detection of the LZT-Hs7 recombinant protein.
4.1.2 LZT-Hs8
As may be seen in Figure 4-3, the PCR procedure confirmed the LZT-Hs8 gene was inserted 
into the pcDNA5/FRT/V5-His-TOPO® TA vector in the correct orientation and gave a band 
of approximately 2103 basepairs in only a lane. There were no bands in lanes 2, 3, 4, 5, 7, 8, 
9 and 10, however, lane 6 has a PCR product of an inappropriately large size. Only clone 1, 
therefore, is suitable for making large-scale plasmid preparations to enable the detection of 
the LZT-Hs8 recombinant protein.
4.1.3 LZT-Hs9
As may be seen in Figure 4-4, the PCR procedure confirmed the LZT-Hs9 gene was inserted 
into the pcDNA5/FRT/V5-His-TOPO® TA vector in the correct orientation and gave a band 
of approximately 1235 basepairs in lanes 14 and 15. Although in each instances, the PCR 
signal was good, indicating an approximately high concentration of product, lanes 3, 5, 7, 8, 
9, 10 and 11 show contaminations with double bands. There were no bands detected in lanes 
1, 2, 4, 6, 12 and 13. Only clones 14 and 15, therefore, are suitable for making large-scale 
plasmid preparations to enable the detection of the LZT-Hs9 recombinant protein.
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To summarize, the LZT-Hs7 has six positive recombinant clones, whilst LZT-Hs8 has only 
one positive recombinant clone and two positive recombinant clones were obtained for LZT- 
Hs9. Since, any contaminants in the PCR products must be avoided, only the positive 
recombinant clones were taken forward for large-scale plasmid preparation to enable 
transfection of mammalian cells and testing for expression of recombinant protein.
4.2 Western blot analysis
This technique allows the identification the recombinant proteins of LZT-Hs7, LZT-Hs8 and 
LZT-Hs9 by detection of their V5 epitope and Figure 4-5 shows their expression of the 3 
LZT family members in CHO cells, following their transfection with the pcDNA5/FRT/V5- 
His-TOPO® TA vector. Recombinant protein sizes of 63 kDalton, 73 kDalton and 43 kDalton 
were determined by automated Rf value analysis for LZT-Hs7, LZT-Hs8 and LZT-Hs9, 
respectively.
The chemiluminescent detection used SuperSignal®Femto Maximum Sensitivity Substrate 
for LZT-Hs7 and LZT-Hs9 recombinant proteins and SuperSignal®Dura Maximum 
Sensitivity Substrate for LZT-Hs8. Subsequently, the signals were imaged using 
AlphaDigiDoc Innotech Imaging system and the Rf value of the recombinant proteins 
automatically calculated using AlphaDigiDoc computer software for the 3 LZT family 
members’ recombinant proteins sizes.
108
Figure 4-1 : PCR products of LZT-Hs7, LZT-Hs8 and LZT-Hs9 genes
LIV-1 LZT-Hs7 LZT-Hs8 LZT-Hs9 Control gene
The gel shows PCR products for LIV-1, LZT-Hs7, LZT-Hs8, LZT-Hs9 and the control 
vector gene in duplicates samples. The band sizes of the LZT family members were 
approximately 2223 basepairs, 1686 basepairs, 1962 basepairs and 1094 basepairs, 
respectively. The far left lane is the DNA molecular weight marker ladder.
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Figure 4-2: PCR product of LZT-Hs7 transformed colonies for orientation analysis
1 2 3 4 5 6 7  8 9
The gel shows the PCR products of 9 LZT-Hs7 transformed colonies isolated for orientation 
analysis. The primers used were the forward primer of LZT-Hs7 and the reverse sequencing 
primer of the vector, BGH, a band size of 1827 basepairs was detected. The far left is the 
molecular weight marker ladder.
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Figure 4-3: PCR product of LZT-Hs8 transformed colonies for orientation analysis
1 2  3 4 5 6 7 8 9  10
< ■..■— . -  -  2103 bp
1.5kb H
1 kb --------------- P i
750 bp K j J
500 bp— — M
The gel shows PCR products of 10 LZT-Hs8 transformed colonies isolated for the orientation 
analysis. The primers used were the forward primer of LZT-Hs8 and the reverse sequencing 
primer of the vector, BGH, a band size of 2103 basepairs was detected only in lane 1. The far 
left is the molecular weight marker ladder.
Figure 4-4: PCR product of LZT-Hs9 transformed colonies for orientation analysis
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
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The gel is shows PCR products of 15 LZT-Hs9 transformed colonies isolated for orientation 
analysis. The primers used were the forward primer of LZT-Hs8 and the reverse sequencing 
primer of the vector, BGH, a band size of 1235 basepairs was detected. The far left is the 
molecular weight marker ladder.
1235bp
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Figure 4-5: Western blot analysis of the LZT-Hs7, LZT-Hs8 and LZT-Hs9 
recombinants to determine their recombinant protein sizes
LZT-Hs9 LZT-Hs8 LZT-Hs7
73 kD 
63 kD
43 kD
250 kD 
160 kD 
105 kD 
75 kD
50 kD
35 kD
The Western blot membrane shows the LZT-Hs7, LZT-Hs8 and LZT-Hs9 recombinant 
proteins expressed in CHO cells, following transient transfection. The cells were harvested 
24 hours post transfection and 40 pg of protein lysate used as protein sample. The proteins 
were separated using SDS-Page electrophoresis, transferred onto nitrocellulose membrane 
and probed with anti-V5 antibody. The LZT-Hs7 protein size is 63 kDalton, LZT-Hs8 
protein size is 73 kDalton and LZT-Hs9 protein size is 43 kDalton. The far right lane shows 
the position of the protein molecular weight markers.
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4.3 Immunofluorescence studies
An immunofluorescence technique was used to assess the subcellular distribution of the 
LZT-Hs7, LZT-Hs8 and LZT-Hs9 in the Chinese Hamster Ovary (CHO) transfected cells. 
The technique employs two sets of antibodies; firstly, a primary antibody which detects the 
V5 antibody embedded in the recombinant LZT-Hs7, LZT-Hs8 and LZT-Hs9 fusion proteins 
,and secondly, a dye-coupled antibody, Alexa Fluor 488-conjugated antimouse that 
fluoresces green. Only in one instance, as shown in Figure 9D that Alexa Fluor 594- 
conjugated antimouse fluoresces red was used for LZT-Hs9 positive recombinant detection. 
Texas Red Phalloidin and DAPI were used to detect F-actin structures and cell nuclei 
respectively. Result of this study are shown in Figures 4-6, 4-7 and 4-9, for LZT-Hs7, LZT- 
Hs8 and LZT-Hs9 recombinant proteins respectively
As may be seen in Figure 4-6A, the LZT-Hs7 recombinant protein is located on the plasma 
membrane and in the lamellipodiae of transfected CHO cells in non-permeabilised buffer 
conditions. As expected, the staining of F-actin structures showed red immunofluorescence 
in all CHO cells as shown in Figure 4-6B, contrasting with the low efficiency of transfection 
of the recombinant protein as shown in Figure 4-6A and 4-6C. Importantly, overlay of the 
red and green fluorescence, with DAPI staining shown in blue in Figure 4-6C, revealed that 
although the recombinant LZT-Hs7 protein was mostly contained within the F-actin filament 
structures, in some instances it extends beyond it, as shown in Figure 4-6C with a white 
arrow pointer. Finally, in Figure 4-6D shows more green fluorescence appeared due to LZT- 
Hs7 positive recombinant proteins, indicating its abundance.
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Figure 4-7 A shows the expression of the recombinant LZT-Hs8 protein in transfected CHO 
cells and clearly shows a different staining pattern from LZT-Hs7 in Figure 4-6A. 
Permeabilisation of the cells did not affect the distribution of LZT-Hs8 recombinant protein, 
which appears to be present at high levels suggested to be in the endoplasmic reticulum 
region. Figure 4-8A shows recombinant LZT-Hs8 protein apparently in endoplasmic 
reticulum in many transfected CHO cells indicating its abundance. Although, LZT-Hs8 
appears to be present at high levels in the endoplasmic reticulum of permeabilised cells, it is 
also present on the plasma membrane of transfected CHO cells of non-permeabilised cells as 
seen in Figure 4-8B.
Like LZT-Hs8, recombinant LZT-Hs9 protein appears to accumulate in the endoplasmic 
reticulum of transfected CHO cells in permeabilised conditions as seen in Figure 4-9A and 
Figure 4-9C, and remains within the outline of the F-actin structures shown in Figure 4-9B 
and Figure 4-9C. Unlike LZT-Hs8, LZT-Hs9 recombinant protein is not presents on the 
plasma membrane CHO cells in non-permeabilised conditions (not shown). In another 
experiment to locate the recombinant LZT-Hs9 protein, a dye-coupled antibody, Alexa Fluor 
594-conjugated antimouse that fluoresces red, shows clearly the presents of LZT-Hs9 
intracellularly and perinuclear region suggesting it to be in the endoplasmic reticulum region 
as seen in Figure 4-9D.
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Figure 4-6: Expression of LZT-Hs7 recombinant proteins in CHO cells treated in non-
permeabilised conditions
A) LZT-Hs7 recombinant protein probed with anti-V5 antibody and Alexa Fluor 488 with 
plasma membrane and lamellipodiae staining (white arrows). B) F-actin structures stained 
with Texas Red Phalloidin. C) Merged images of LZT-Hs7 positive cells located on 
lamellipodiae extending beyond F-actin. (white arrow). D) Abundance of positive LZT-Hs7 
cells with plasma membrane immunostaining.
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Figure 4-7: Expression of LZT-Hs8 recombinant proteins in CHO cells in
permeabilised conditions
A) LZT-Hs8 recombinant protein probed with anti-V5 antibody and Alexa Fluor 488 with 
suggestive of intracellular and perinuclear staining. B) F-actin structures stained with Texas 
Red Phalloidin in transfected cell (yellow arrow). C) Merged images showing LZT-Hs8 
positive cell (located intracellularly) and F-actin staining.
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Figure 4-8: Expression of LZT-Hs8 recombinant proteins in CHO cells in
permeabilised conditions (A) and non-permeabilised conditions (B)
A) Merged images showing LZT-Hs8 recombinant protein detection using Alexa Fluor 488 
(fluoresces green) located intracellularly and suggestive of the endoplasmic reticulum 
staining and appeared to be abundance in transfected cell expressing the LZT-Hs8 in the 
permeabilised conditions.
B) Merged images showing LZT-Hs8 recombinant protein probed using Alexa Fluor 488 
(fluoresces green) located on plasma membrane in non-permeabilised conditions. Not so 
many transfected cells are the expression LZT-Hs8. In both images, the F-actin structures 
stained with Texas Red Phalloidin and 1 (an example) LZT-Hs8 positive cell shown with 
white arrow.
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Figure 4-9: Expression of LZT-Hs9 recombinant proteins in CHO cells in non-
permeabilised conditions
A) LZT-Hs9 recombinant protein probed with anti-V5 antibody and Alexa Fluor 488 
showing intracellular staining (white arrow) suggestive of endoplasmic reticulum. B) F-actin 
structures (of same cell) stained with Texas Red Phalloidin. C) Merged images of LZT-Hs9 
positive cells and F-actin stains. D) LZT-Hs9 recombinant protein stained with Alexa Fluor 
594 (white arrow) suggestive of endoplasmic reticulum staining.
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4.4 Preliminary zinc analysis transfected tamoxifen resistant cells
Since LZT-Hs7, LZT-Hs8 and LZT-Hs9 are predicted to be zinc influx transporters; an 
attempt was made to determine whether tamoxifen resistant cells transfected with LZT-Hs7, 
LZT-Hs8 and LZT-Hs9 had increased intracellular zinc detected by using Newport Green 
DCF™ diacetate, a zinc sensitive dye. Newport Green DCF™ diacetate fluoresces green in 
cells on exposure to zinc, the intensity of which corresponds to the level of intracellular zinc. 
The LZT-Hs7, LZT-Hs8 and LZT-Hs9 recombinant proteins were conjugated with Alexa 
Fluor 594 antibody that fluoresces red. The cell nuclei were counter stained with DAPI 
(blue). These multicolour images are shown in Figure 4-10, Figure 4-11 and Figure 4-12 for 
LZT-Hs7, LZT-Hs8 and LZT-Hs9 recombinant proteins in tamoxifen resistant cells, 
respectively.
These preliminary experiments did not provide enough evidence for the uptake of zinc in the 
LZT-Hs7 as expected (Figure 4-10). However, from Figure 4-11, there is a suggestion that 
the LZT-Hs8 positive cell has decreased intracellular zinc, as evidenced by the decreased 
green level in that cell (white arrow) as compared to LZT-Hs8 negative cells. This result 
disagrees with LZT-Hs8 acting as zinc influz transporters because of the reverse effect of 
zinc exposure shown here. Nevertheless, from Figure 4-12, there is a suggestion that the 
LZT-Hs9 positive cell has increased intracellular zinc, as evidenced by the increased green 
level in that cell (white arrow) as compared to LZT-Hs9 negative cells. This result agrees 
with LZT-Hs9 acting as zinc influz transporters.
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Figure 4-10: Expression of LZT-Hs7 recombinant proteins in tamoxifen resistant cells
loaded with Newport Green™ diacetate
A) LZT-Hs7 positive cells were stained red with anti-V5 antibody and Alexa Fluor 594 with 
plasma membrane and lamellipodiae staining (white arrows). B) The same cells loaded with 
Newport Green™ diacetate. C) The green colour of tranfected (yellow arrow) and 
untransfected (red arrow) cells was similar.
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Figure 4-11: Expression of LZT-Hs8 recombinant proteins in tamoxifen resistant cells
loaded with Newport Green™ diacetate
c
A) LZT-Hs8 positive cells were stained red with anti-V5 antibody and Alexa Fluor 594 with 
plasma membrane staining (white arrow). B) The same cells loaded with Newport Green™ 
diacetate. C) The green color of tranfected cell (yellow arrow) shows less dense as compared 
to untransfected (red arrow).
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Figure 4-12: Expression of LZT-Hs9 recombinant proteins in tamoxifen resistant cells
loaded with Newport Green™ diacetate
A) LZT-Hs9 positive cells were stained red with anti-V5 antibody and Alexa Fluor 594 with 
suggestive of endoplasmic reticulum staining (white arrow). B) The same cells loaded with 
Newport Green™ diacetate. C) The green colour of tranfected cell (yellow arrow) denser as 
compared to untransfected (red arrow) and zinc dye accumulated in vesicles (red arrow).
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4.5 Discussion
LZT-Hs7, LZT-Hs8 and LZT-Hs9 were successfully cloned into pcDNA5/FRT/V5-His- 
Topo® TA vector and this was the first time that LZT-Hs8 and LZT-Hs9 have been cloned 
and expressed. The recombinant proteins are detected using anti-V5 antibody; nevertheless, 
the V5 epitope sequence could be inserted in the reverse primers design. However, LZT-Hs9 
has the V5 epitope sequence inserted into its reverse primer thus the LZT-Hs9 protein weight 
will be increased by an insignificant amount of the V5 epitope’s of 14 residues long. The 
LZT-Hs7 and LZT-Hs8 were designed with the V5 epitope from the vector, which adds an 
approximately 3.6 kDalton (manufacturer instruction) additional weight to the recombinant 
clones. The actual protein weight obtained for LZT-Hs7, LZT-Hs8 and LZT-Hs9 was 63 
kDalton, 73 kDalton and 43 kDalton, respectively.
Protein identification involved separating the mixture of proteins by electrophoresis and 
transfer to a nylon membrane so that an antibody together with the protein molecular weight 
markers could visualized the protein band. The ratio of the distance migrated of these 
proteins compared to the distance migrated by the solvent front, produced the Rf values. The 
protein molecular weight markers’ Rf values are used to make a standard curve and enabling 
the unknown bands to be checked against the standard curve for estimation of their respective 
protein weight, although throughout this study, our Rf values were automatically calculated 
by the AlphaDigiDoc Innotech computer software.
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A band of 63 kDalton was obtained for LZT-Hs7 while computer search has predicted the 
size is 56 kDalton. The LZT-Hs7 recombinant protein was expressed as a fusion protein, with 
an additional 3.6 kDalton added which incorporated the V5-tag was not inserted at the C- 
terminal end. The LZT-Hs7 does have two predicted N-linked glycosylation sites on the N- 
terminus therefore, it is expected that additional protein weight as much as 10 kDalton must 
be added onto the predicted size, as the N-terminus is located extracellularly. Nevertheless, in 
another study, LZT-Hs7 recombinant protein showed 2 bands with size of 80 and 70 kDalton 
(Wang et al. 2004), in contrast another published that LZT-Hs7 produced only 1 band of 61 
kDalton (Dufner-Beattie et al. 2003). The latter finding shows similar protein weight 
estimation as our current study however, there is a 3.4 kDalton weight more, probably due to 
margin of error for SDS-Page technique or there has been a small glycosylation occurred on 
the side chain.
A band of 73 kDa was obtained for LZT-Hs8 and computer search has predicted that LZT- 
Hs8 protein weight is 72.805 kDalton. As in LZT-Hs7, LZT-Hs8 recombinant proteins were 
expressed as a fusion protein with an additional 3.6 kDalton as the V5-tag at the C-terminal 
end. Although the computer search has predicted that LZT-Hs8 has 5 N-linked glycosylation 
sites on the N-terminus, it is not evidenced by the protein weight as LZT-Hs8 produced a 
band of 73 kDalton. The recombinant protein for LZT-Hs8 have been located on the plasma 
membrane and therefore it may be expected to be glycosylated as much as 5 to 10 kDalton 
providing a band approaching 85 kDalton. Although this was not clear, it may suggest
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cleavage of the N-terminus before location at the plasma membrane, as observed recently 
from the LIV-1 protein (Taylor, personal communication).
A band of 43 kDalton was obtained for LZT-Hs9 and the computer search has predicted that 
LZT-Hs9 protein weight is 38.352 kDalton. Unlike LZT-Hs7 and LZT-Hs8, LZT-Hs9 
recombinant protein had the V5-tag inserted at the C-terminal end within the oligonucleotide 
and not within the multiple cloning sites. This would have added a negligible amount to the 
recombinant protein, instead of the 3.6 kDalton added to LZT-Hs7 and LZT-Hs8. This gene 
has been predicted not to have any N-linked glycosylation sites and the LZT-Hs9 is located 
intracellularly where glycosylation will not occur. Therefore, our estimated LZT-Hs9 protein 
weight is acceptable due to margin of error for SDS-Page technique.
All three recombinant proteins were successfully expressed in CHO cells. In order to image 
their cellular location, immunoFluorescence experiments were performed on coverslips and 
the proteins were fluorescently labelled for detection. These experiments were conducted in 
both permeabilised and non-permeabilised conditions in order to discover whether they 
resided on the plasma membrane of the cells or on intracellular membranes. These results 
demonstrated an intracellular location for all the recombinant proteins and an additional 
plasma membrane location for LZT-Hs7 and LZT-Hs8 proteins. In the latter, the protein 
expression was very low level and indeed, it was very difficult to detect positively 
transfected cells during the experiment. This is a similar result to that observed for LIV-1 
protein (Taylor et al. 2003).
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The phylogenetic tree (Figure 3-2) showed that LZT-Hs7 clustered with LZT-Hs2 and LIV-1 
genes, in the way indicated that these genes probably share a similar subcellular location. 
LIV-1 is located on the plasma membrane of the cell (Taylor et al. 2003) therefore the other 
two genes are predicted to be on the plasma membrane. The current study showed LZT-Hs7 
is located on the plasma membrane, which is consistent with the prediction.
The phylogenetic tree (Figure 3-2) has linked LZT-Hs8 to LIV-1 gene, indicating both are 
highly homologous to each other. A recent experiment in the Tenovus laboratories has shown 
that LIV-1 is cleaved at the N-terminus and then it relocates itself to the plasma membrane. 
This conclusion was reached as a specific antibody detected an epitope near the N-terminus 
and did not recognise plasma membrane located LIV-1, however, another antibody detecting 
an epitope at the end of the N-terminus did recognize LIV-1 on the plsma membrane (Taylor, 
personal communication). The relocation of LIV-1 protein to the plasma membrane may 
explain a similar mechanism for LZT-Hs8 recombinant protein and explain the low level 
present on the plasma membrane
LZT-Hs9 has been shown (Figure 3-2) to be highly homologous to LZT-Hsl gene, which is 
suggestive of them sharing similar feature. LZT-Hsl is located on intracellular membranes 
that includes the endoplasmic reticulum (Taylor et al. 2004) and from our finding, LZT-Hs9 
is also found intracellularly suggested to be located in endoplasmic reticulum region. Like 
LZT-Hsl, LZT-Hs9 does not have any glycosylation sites within its protein sequence and
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secondly, neither of them have a CPALLY motif within their protein sequences suggesting 
LZT-Hs9 is similar to LZT-Hsl.
These attributes are consistent with other LZT subfamily members for instance LZT-Hsl 
located in the endoplasmic reticulum (Taylor et al. 2004), LIV-1 located on the plasma 
membrane (Taylor et al. 2003) and LZT-Hs4 resides on the plasma membrane (Taylor et al. 
2005).
All together, the V5-epitope tag was used successfully to detect all the recombinant proteins 
in mammalian cells using fluorescent microscopy technique.
A preliminary study was conducted to detect the zinc transport capability in the LZT-Hs7, 
LZT-Hs8 and LZT-Hs9 recombinant proteins. Unfortunately, it was not possible to show 
zinc transport capability for LZT-Hs7 as evidenced by a similar level of green dye in 
transfected and untransfected cells. In contrast, the LZT-Hs7 has been shown by others to 
carry Zn(II) into the cell (Dufner-Beattie et al. 2003) thus it was expected to observe more 
green dye in the transfected CHO cells than in the untransfected.
Loading of cells expressing LZT-Hs8 and LZT-Hs9 with Newport Green™ diacetate 
suggested these two genes are capable of transporting zinc in opposing directions. There is 
no published work to compare these results to as no others have expressed these genes. The 
transfected tamoxifen resistant cells expressing LZT-Hs8 has decreased level of zinc as
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compared to untransfected cells, suggesting LZT-Hs8 transports zinc from the cytoplasm to 
outside the cell. Secondly, transfected tamoxifen resistant cells expressing LZT-Hs9 had an 
increased zinc dye level compared to untransfected cells, indicating the zinc ions were 
transported from outside the cell into the cytoplasm. Indeed, these controversies from only a 
preliminary study raised more questions and they now need repeating with a more elaborate 
experiment design. However, there is increasing evidence in the literature that human ZnT5 
variant B, which belongs to a SLC30 zinc transporter family may be able to transport zinc in 
both directions across membranes (Valentine et al. 2007).
An alternative explanation for the observed results lies in the basic theory that the variable 
region between transmembrane domains III and IV are involved in zinc ion transport 
(Guerinot 2000). The variable region has many factors influencing its variability including 
the mixed charges and high frequency of histidine residues. It was observed that LZT-Hs8 
has the smallest amount of mixed charges compared to the other 2 (Table 3-4), and no 
histidine residues in the variable region suggesting an explaination for inability to transport 
zinc. However, LZT-Hs7 has a higher frequency of mixed charges than LZT-Hs9 and the 
former contains 6 histidine residues while the latter has 1 histidine. This would suggest that 
LZT-Hs7 should be able to transport zinc and therefore needs to be confirmed with other 
methods and staining techniques.
The second scope of the study was to compare the zinc transport capacity in the cells, in the 
present of fluorescent dye, aiming at differentiating recombinants of LZT-Hs7, LZT-Hs8 and
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LZT-Hs9, to the non-recombinant transfected cells. Caution must be exercised, in the 
interpretation of these experiments, because it is unclear whether he fixation process altered 
the zinc levels in these cells. However, the fluorescent labels were Alexa Fluor 594 for 
labelling the recombinant transfected cells and Newport Green dye for labelling the zinc ion 
showed that fixed cells had a defined morphological structure and presented fluorescence. 
Both of the staining characteristics detected only in the dead cells due to the fixation 
procedure. Other fluorescent stains and methods may be better to consider as a tool to 
investigate cell’s zinc capacity and more importantly, the study must use live cells if the 
homeostasis of zinc is an active process.
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Chapter 5
RNA profiles of the LZT subfamily and siRNA LZT-Hsl studies
In this chapter, the study shows the expression of the nine LIV-1 family members across 
breast cancer lines. The study used the PCR technique and the RNA samples, from the wild 
type MCF-7, the endocrine responsive cells and the resistant derivatives of MCF-7 cells. 
Subsequently, a preliminary study continued on the LZT-Hsl gene expression using small 
interfering RNA technology to show the gene knockdown impact. Another preliminary study 
is to locate the presence of ERE (estrogen response element) upstream of the gene using 
Dragon ERE Finder version 2.1.
5.1 Affymetrix Data: LZT subfamily members mRNA expression in responsive and 
resistant MCF-7 cells
The affymetrix data was taken from a database of previous work held within the Tenovus
Centre for Cancer. Table 5-1, summarizes the Affymetrix data derived for the five members
of the LZT subfamily of genes represented on the U133A gene chip in response to oestradiol
and various anti-hormonal treatments in MCF-7 cells. LZT-Hsl, LZT-Hs4 and LZT-Hs5 had
single probes to their genes, while LIV-1 and LZT-Hs6 had 2 and 3 probes respectively. In
all but one instance (one of the 3 probe sets for LZT-Hs6), gene expression was deemed to be
present in the treated samples. ANOVAs significance testing, however, suggest only Hs6 was
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altered by the treatments (p<0.05), possibly showing some oestradiol suppression as shown 
in (Table 5-1). This was evident for the two probes sets called as present.
Table 5-2 summarizes the Affymetrix data derived from the five members of the LZT 
subfamily of genes in the resistance study. Once again, all genes, except for one probe for 
LZT-Hs6, were called as present. In contrast to the oestradiol and various anti-hormonal 
treatment set, Anova significance testing indicated substantial increases in the all of the 5 
members of the LZT subfamily in at least one form of resistance (p<0.05), with LZT-Hsl 
and possibly LZT-Hs4 being raised in all forms of resistance. Interestingly, the expression of 
the LIV-1 gene appeared to be suppressed in tamoxifen resistant cells.
Table 5-3 shows the Affymetrix probe sets derived for the Anova significant genes in the 
resistant study. The heat map represents each probe set and shows an elevation of the LZT 
subfamily gene expression in at least one form of resistance.
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Table 5-1 : Affymetrix data for five of the LZT subfamily in response to oestradiol and
anti-hormonal treatments
Gene Number of 
probes
Present and 
absent call
Anova
significance
p<0.05
Comment
LZT-Hsl 1 v X -
LIV-1 2 V X -
LZT-Hs4 1 V X -
LZT-Hs5 1 V X -
LZT-Hs6 3 %
(shown in Table 
5-3)
2/ s Possibly 
suppressed by 
oestradiol
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Table 5-2: Affymetrix data for 5 members of the LZT subfamily in various anti- 
hormonal resistant cells
Gene Number of 
probes
Present and 
absent call
Anova
significance
P<0.05
Comment
LZT-Hsl 1 V
. ^
Elevated in tamoxifen 
and faslodex 
resistance, and 
probably in X-cells
LIV-1 2 V 2/2
(shown in Table 
5-3)
Elevated in X-cells 
and possibly in 
faslodex resistance. 
Suppressed in 
tamoxifen resistance
LZT-Hs4 1 V V Elevated in all forms 
of resistance
LZT-Hs5 1 V V Elevated in X-cells
LZT-Hs6 3 2/ s 2/ s
(shown in Table 
5-3)
Elevated forms of 
resistance, except 
tamoxifen resistance
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Table 5-3: Anova significant probe sets
Gene Cells Probeset ID Heatmap
LZT-Hs6 Oestradiol and anti­
hormone treated
209267_s_at +E2 C Tam Fas X-m
LZT-Hs6 Oestradiol and anti­
hormone treated
219869_s_at +E2 C Tam Fas X-m
LZT-Hs6 Anti-hormone 209267_s_at C TamR FasR FasRLate X-m X-c
resistant cells
LZT-Hs6 Anti-hormone 219869_s_at C TamR FasR FasRLate X-m X-c
resistant cells
LIV-1 Anti-hormone 202088_at C TamR FasR FasRLate X-m X-c
resistant cells
LIV-1 Anti-hormone 202089_s_at C TamR FasR FasRLate X-m X-c
resistant cells
Legend:
TamR:tamoxifen resistant cells, FasRrfaslodex resistant cells, FasRLate:faslodex late 
resistance, X-m: MCF-7 grown in heat inactivated charcoal stripe serum, X-cells:MCF-7 
resistant to X medium grown semi-confluence, Tamitamoxifen, Fasifaslodex, C:control 
MCF-7 cells, E2:oestradiol
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5.2 PCR Data: LZT subfamily members mRNA expression in responsive and resistant 
MCF-7 cells
In light of the above results demonstrating the differential regulation of a number of LZT 
subfamily during response and resistance, the study was extended to monitor all of the 
members of the LZT subfamily in MCF-7 responsive and resistant cells using a semi- 
quantitative PCR procedure. The 3 PCR sets for each of the LZT family members were 
converted into histograms and are represented in Figures 5-1 to 5-18. An ANOVA test was 
performed on each data set to evaluate its significance (p<0.05) and these are shown in Table 
5-4, pS2, a known oestrogen regulated gene which is down regulated in resistance was 
examined in the RNA preparations and the data is shown in Figures 5-1 and 5-2. Table 5-5 
shows the summary of the LZT family members across all the treatments and in resistance.
5.2.1 pS2
The data presented in Figure 5-1 clearly shows pS2 to be an oestrogen regulated gene with 
oestradiol promoting the elevation of pS2 mRNA expression versus the untreated oestrogen 
deprived MCF-7 control cells (p<0.05). Of the antihormone treatments employed, only 
faslodex showed any reduction in pS2 mRNA versus the untreated control. This, however, 
did not reach statistical significance. Figure 5-2, shows the expressions of pS2 in the various 
forms of antihormone resistance, with significantly lower levels (versus wild-type cells) 
being recorded in early and late stage faslodex resistances.
5.2.2 LZT-Hsl
Figure 5-3 shows LZT-Hsl to be an oestrogen-regulated gene with oestradiol treatment
promoting an increase in mRNA expression versus the untreated oestrogen deprived MCF-7
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control cells. These data contrast with a lack of an effect of the antihormones. Importantly, 
LZT-Hsl mRNA expression was significantly highly increased in all forms of anti-oestrogen 
resistance (p<0.05) and in the cells resistant to oestrogen deprivation (p<0.003) (Figure 5-4).
5.2.3 LZT-Hs2
Figure 5-5 shows LZT-Hs2 largely expression is unaltered in MCF-7 cells by the oestradiol 
and antihormonal treatments and is only slightly suppressed in tamoxifen resistance (Figure 
5-6).
5.2.4 LIV-1
Figure 5-7 shows only marginal increases in the expression of LIV-1 gene in oestradiol 
treated cells (not significant), with some decreases in expression in the presence of faslodex. 
In comparison to the wild-type cells, only X-cells showed any evidence of increased LIV-1 
expression in resistance (Figure 5-8).
5.2.5 LZT-Hs4
Figure 5-9 shows LZT-Hs4 expression to be increased by oestradiol treatment (p<0.05) in 
MCF-7 cells and to be partially suppressed by faslodex (not significant) and X-media 
(p<0.012). Only the faslodex late stage resistance and X-cells showed increases in LZT-Hs4 
relative to the wild-type cells with only the former being ANOVA significance (p<0.05) 
(Figure 5-10).
5.2.6 LZT-Hs5
Unfortunately, Hs5 could not be detected in any of the RNA sets at 29 PCR cycles.
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5.2.7 LZT-Hs6
As mentioned in the previous Affymetrix section, expression of the LZT-Hs6 gene appeared 
suppressed by oestradiol treatment (Table 5-1), and this was confirmed by PCR (Figure 5- 
11). Similarly, the PCR performed on the resistant cells was supportive of the Affymetrix 
data with increased levels of LZT-Hs6 mRNA being seen in faslodex resistance (p<0.009). 
The remaining forms of anti-hormonal resistant cells show no effect of the treatments. Figure 
5-12 shows LZT-Hs6 expression is elevated in faslodex resistance (p<0.009), faslodex late 
stage resistant cells (p<0.011) and in X-cells (not significant) in comparison to the wildtype 
MCF-7 cells.
5.2.8 LZT-Hs7, LZT-Hs8 and LZT-Hs9
These genes were largely unaltered in all treatment groups (Figures 5-13 to 5-18) with very 
low levels of LZT-Hs9 being observed throughout.
Table 5-5 summarises the above data and illustrates the variability of expression of the 9 
LZT subfamily members in individual treatment groups.
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Table 5-4 : PCR with ANOVA post-hoc test analysis (p<0.05) for LZT family members 
in treated and resistant cells
Gene Oestrogen-
regulation
Anova significant 
responses to oestradiol 
and responsive cells
Anova significant 
responses to 
hormone and anti­
hormones
Comments
LZT-Hsl V V Elevated in 
oestradiol and every 
form of resistances
LZT-Hs2 X Suppressed in 
tamoxifen, faslodex 
, up regulate in FasR 
late
LIV-1 V Suppressed in 
faslodex
LZT-Hs4 V V V Elevated 
significantly in 
oestradiol
LZT-Hs5 - - - Not expressed
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LZT-Hs6 X V Suppressed in both 
tamoxifen and 
faslodex elevated in 
the stated resistances
LZT-Hs7 X Unaltered 
expression in all cell 
models
LZT-Hs8 X V Suppressed 
expression in all cell 
models
LZT-Hs9 X With very low 
expression in all of 
the RNA sets
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Figure 5-1 : Relative mRNA expression of pS2 in oestradiol and anti-hormone treated
cells
I
> <-
II *  <r III ->
M +E2 C Tam Fas X-m +E2 C Tam Fas X-m +E2 C Tam Fas X-m
Actin
X-Med
The gel image shows the PCR result of pS2 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-2 : Relative mRNA expression of pS2 in anti-hormone resistant cells
I II III
M C Tam Fas FasRX-mX-c C Tam Fas FasRX-mX-c C TamFasFasR X-m X-c 
R R Late R R Late R R Late
□
Tam R Fas R FasRlate X-m
pS2
Actin
The gel image shows the PCR result of pS2 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-3 : Relative mRNA expression of LZT-Hsl in oestradiol and anti-hormone
treated cells
Actin
1.5 i
1 -
OD
0.5 - A ■0
+E2 C TAM FAS X-M
The gel image shows the PCR result of LZT-Hsl gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
143
Figure 5-4 : Relative mRNA expression of LZT-Hsl in anti-hormone resistant cells
II III
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o.o — .  1  l 1 1  - 1
C TAM R FASR FASRLATE X-M X-C
_________________________________________________________________________
The gel image shows the PCR result of LZT-Hsl gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-5 : Relative mRNA expression of LZT-Hs2 in oestradiol and anti-hormone
treated cells
Actin
OD
0.5
+E2 TAM FAS X-M
The gel image shows the PCR result of LZT-Hs2 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-6 : Relative mRNA expression of LZT-Hs2 in anti-hormone resistant cells
^ I___________ ^ _________ II  III
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The gel image shows the PCR result of LZT-Hs2 gene expressions in breast cancer cells. The
results are a representative of three mRNA sets. The graph below the gel image is a
compilation of the densitometric values from the gel image.
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Figure 5-7 : Relative mRNA expression of LIV-1 in oestradiol and anti-hormone treated
cells
Actin
+E2 C TAM FAS X-M
The gel image shows the PCR result of LIV-1 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-8 : Relative mRNA expression of LIV-1 in anti-hormone resistant cells
M C Tam Fas FasRX-mX-c C Tam Fas FasRX-mX-c C TamFasFasR X-m X-c 
R R Late R R Late R R Late
Actin
■
T A M R  FA SR  FA SR L A T E  X-M
The gel image shows the PCR result of LIV-1 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-9 : Relative mRNA expression of LZT-Hs4 in oestradiol and anti-hormone
treated cells
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M +E2 C Tam Fas X-m +E2 C Tam Fas X-m +E2 C Tam Fas X-m
LZT-Hs4
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The gel image shows the PCR result of LZT-Hs4 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-10 : Relative mRNA expression of LZT-Hs4 in anti-hormone resistant cells
-► <4- II III
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The gel image shows the PCR result of LZT-FIs4 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-11 : Relative mRNA expression of LZT-Hs6 in oestradiol and anti-hormone
treated cells
Actin
+ E 2  C T A M  F A S  X -M
The gel image shows the PCR result of LZT-Hs6 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-12 : Relative mRNA expression of LZT-Hs6 in anti-hormone resistant cells
I _  II _  HI
M C Tam Fas FasRX-mX-c C Tam Fas FasRX-mX-c C TamFasFasR X-m X-c 
R R Late R R Late R R Late
Actin
C TAMR FASR FASRLATE X-M X-C
The gel image shows the PCR result of LZT-Hs6 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-13 : Relative mRNA expression of LZT-Hs7 in oestradiol and anti-hormone
treated cells
II III
M +E2 C Tam Fas X-m +E2 C Tam Fas X-m +E2 C Tam Fas X-m
LZT-Hs7
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1 A \  1
The gel image shows the PCR result o f LZT-Hs7 gene expressions in breast cancer cells. The
results are a representative o f three mRNA sets. The graph below the gel image is a
compilation of the densitometric values from the gel image.
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Figure 5-14 : Relative mRNA expression of LZT-Hs7 in anti-hormone resistant cells
M C Tam Fas FasRX-mX-c C Tam Fas FasRX-mX-c C TamFasFasR X-m X-c 
R R Late R R Late R R Late
Actin
C TAMR FASR FASRLATE X-M X-C
The gel image shows the PCR result of LZT-Hs7 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-15 : Relative mRNA expression of LZT-Hs8 in oestradiol and anti-hormone
treated cells
Actin
0.0 4----
+E2 C TAM FAS X-M
The gel image shows the PCR result o f LZT-Hs8 gene expressions in breast cancer cells. The
results are a representative o f three mRNA sets. The graph below the gel image is a
compilation o f the densitometric values from the gel image.
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Figure 5-16 : Relative mRNA expression of LZT-Hs8 in anti-hormone resistant cells
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The gel image shows the PCR result of LZT-Hs8 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-17 : Relative mRNA expression of LZT-Hs9 in oestradiol and anti-hormone
treated cells
Actin
+E2 C Tam Fas X-Medium
The gel image shows the PCR result of LZT-Hs9 gene expressions in breast cancer cells. The 
results are a representative of three mRNA sets. The graph below the gel image is a 
compilation of the densitometric values from the gel image.
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Figure 5-18 : Relative mRNA expression of LZT-Hs9 in anti-hormone resistant cells
^ ^  II________^ _________ HI _______^
M C Tam Fas FasRX-mX-c C Tam Fas FasRX-mX-c C TamFasFasR X-m X-c 
R R Late R R Late R R Late
Actin
C TAMR FASR FASRLATE X-M X-C
The gel image shows the PCR result of LZT-Hs9 gene expressions in breast cancer cells. The
results are a representative of three mRNA sets. The graph below the gel image is a
compilation of the densitometric values from the gel image.
158
Table 5-5 : Summary of the LIV-1 family of genes derived from the PCR data in 
response and resistance studies
Treatment Histogram
Oestradiol
treated
MCF-7
cells
Hsl Hs2 LIV-1 H s4 Hs5 Hs6 Hs7 Hs8 Hs9
Wildtype
MCF-7
cells
Tamoxifen
treated
MCF-7
cells
1.2
1.0
OD °oi 
0.4 
0.2 
0.0
,i.. ili
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
1.2
1.0
ooal
0.4
0.2
0.0 iii ili
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
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Tamoxifen
resistant
0.5
0.0MCF-7 cells
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
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Faslodex late 
resistant 
MCF-7 cells
1:2 ] |
■  T11 i - - 1■
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
X-medium 
MCF-7 cells ■i
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
X-cells
MCF-7
1.2
1.0
0.8
o d 0.6
0.4
0.2
0.0
lili
Hsl Hs2 LIV-1 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9
Legend:
Hsl:LZT-Hsl, Hs2:LZT-Hs2, LIV-1:LIV-1, Hs4:LZT-Hs4, Hs5:LZT-Hs5, Hs6:LZT-Hs6, 
Hs7:LZT-Hs7, Hs8:LZT-Hs8, Hs9:LZT-Hs9
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5.3 ERE Promoter search
5.3.1 Ensemble Data
Information for each of the LZT subfamily was performed using Ensemble software 
packages. In each instance, the accession numbers of the LZT subfamily members were used 
as an input to select their respective eukaryotic sequences. The sequence of each family 
member was then used to search for the oestrogen response elements (EREs) via a computer 
software package, Dragon ERE Finder version 2.1. This package searches the 5’ upstream 
region of the gene.
5.3.2 Estrogen Response Elements Data
Results from the RNA study suggested that several members of the LZT subfamily are 
oestrogen responsive, and therefore an attempt was made to relate this property to the 
presence or absence of EREs in the promoters of the LZT subfamily. Dragon ERE Finder 
version 2.1 uses a model system that contains the minimum palindromic sequence, which is 
GGTCAnnnTGACC, where ‘nnn’ is the typical 3 basepairs. This sequence is a consensus 
sequence that is only found in some oestrogen-regulated genes and therefore the analysis 
allows the detection of imperfect EREs patterns. These are referred as the ‘new patterns’, and 
are potentially functional. Tables 5-6 to 5-14, show the EREs search results for the LZT 
subfamily and identities of multiple imperfect EREs in each family member. Any nucleotide 
that changes from the consensus sequence are underlined as indicated in the tables. The 
tables also include information on the frequency of nucleotides that differ from the consensus 
palindromic sequence of the ERE. Interestingly, changes occur throughout the LZT family
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sequences either in the first half of the consensus sequence (GGTCA) or in the second half o f 
the sequence (TGACC). They were noticeable in both the forward and reverse strands of the 
DNA.
Observation from Table 5-6 shows imperfect EREs were identified in the LZT-Hsl 
promoter, 1 on the forward strand, and 3 on the reverse strand. In all but one instance, 2 
nucleotides were changed. Three alterations were seen in the reverse strand of ERE located at 
nucleotide position -709. Examination of the promoter of LZT-Hs2 produced a broadly 
similar pattern with 4 imperfect EREs being detected. However, the majority, 75%, contained 
3 nucleotide changes. LIV-1 contained 2 imperfect EREs, one with 2 changes and one with 3. 
Equivalent imperfect EREs were seen throughout the remaining LZT family members and no 
obvious association was seen between the experimental data any of the oestrogen response of 
the gene or their expression in resistant cells and their EREs number, location on the forward 
or reverse strand or the number of nucleotides altered with the EREs sequences.
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Table 5-6 : Compilation of ERE sites in LZT-Hsl both forward and reverse strands
Consensus G G T C A
/ J
T G A C C Frequency
Fl:+2039 G C C C A T G C C C 2
Rl: -2875 G G T C A / T G A 1 G 2
R2:-709 G G T C A / G G C C A 3
R3:-64 G G C C A
y
C C A C C 2
Altered nucleotides as compared to the consensus sequence are underlined
Table 5-7: Compilation of ERE sites in LZT-Hs2 both forward and reverse strands
Consensus G G T C A / T G A C C Frequency
F I:+2960 G C C C A / T G G C C 3
F2:+3370 G G G C A T A C C C 3
Rl :-2148 G G C C A
/
T G A G C 2
R2:-3986 G A C C A
/
T G G C C 3
Altered nucleotides as compared to the consensus sequence are underlined
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Table 5-8 : Compilation of ERE sites in LIV-1 both forward and reverse strands
Consensus G G T C A T G A C C Frequency
Fl:+3489 1 G T G A / T G A C C 2
RL-2623 G G A C A / A G G C C 3
/
Altered nucleotides as compared to the consensus sequence are underlined
Table 5-9: Compilation of ERE sites in LZT-Hs4 both forward and reverse strands
Consensus G G T C A / T G A C C Frequency
Fl:+373 G A A C A / T G A C C 2
F2:+1444 G G G C A / T G G C 1 3
R l>2043 G A C C A / T G G C C 3
R2:-l 381 A G C C A
/
T G C C C 3
Altered nucleotides as compared to the consensus sequence are underlined
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Table 5-10: Compilation of ERE sites in LZT-Hs5 both forward and reverse strands
Consensus G G T C A / T G A C C Frequency
Fl:+358 G G C C A / T G G 1 C 3
F2:+910 G G C C C / T G G C C 3
Rl:-1316 G A C C A / T G A C C 1
Altered nucleotides as compared to the consensus sequence are underlined
Table 5-11: Compilation of ERE sites in LZT-Hs6 both forward and reverse strands
Consensus G G T C A / T G A C C Frequency
Fl:+1712 G G G C A / T G G C 1 3
F2:+2334 G G C C A / T G C C C 2
F3:+5572 G G C C A / T G G 1 C 3
Rl:-6787 G A C C A / T G A 1 C 3
Altered nucleotides as compared to the consensus sequence are underlined
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Table 5-12: Compilation of ERE sites in LZT-Hs7 both forward and reverse strands
Consensus Frequency
Fl:+238
F2:+838
F3:+1390
F4:+1780
Rl :-l 796
R2:-254
Altered nucleotides as compared to the consensus sequence are underlined
Table 5-13: Compilation of ERE sites in LZT-Hs8 both forward and reverse strands
Consensus G G T C A T G A C C Frequency
F1H-2167 G G T G A / T A A C C 2
F2:+3567 A G T C A / T G A C C 1
R l>4056 G G G C A / T C A C C 2
R2:-4717 G G T C A / T G G 1 G 2
Altered nucleotides as compared to the consensus sequence are underlined
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Table 5-14: Compilation of ERE sites in LZT-Hs9 both forward and reverse strands
Consensus G G T C A
/
T G A C C Frequency
Fl:+744 G A G C A
/ j
T G G C C 2
F2:+2164 G G A C A
/
T G G C C 1
R 1.-3021 G G G C A
/
G G 1 C 1 2
R2:-2180 G G A C A
/
T G G C C 2
R3:-463 G A C C A
/
T G G C C 3
R4:-374 G G A C A / G G G C C 3
/
Altered nucleotides as compared to the consensus sequence are underlined
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5.4 siRNA LZT-Hsl
The characterization of LZT subfamily in the Affymetrix search and mRNA profiling 
revealed that one member of the family LZT-Hsl gene to be present in increased amounts in 
several forms of anti-hormone resistance, including tamoxifen resistance. Importantly, the 
resistant cells have gained an ability to grow in the presence of the anti-hormones, where 
previous studies have shown an involvement of EGFR and Src signalling. The current section 
explores the signalling consequences of LZT-Hsl knockdown with a siRNA technology.
5.4.1 LZT-Hsl knockdown in tamoxifen resistant cells
Initial experiments showed that the Lipofectamine2000 reagent exhibited some toxicity in the 
tamoxifen resistant cells (Figure 5-19) and was in itself, able to partially decrease the levels 
o f LZT-Hsl by approximately 70% at 24 hours post-transfection, and that this effect was also 
seen in the presence of a scrambled siRNA treated cells. Significantly, this also affected the 
expression/activation of the other signalling molecules. In light of the inhibitory effects of the 
Lipofectamine2000, only the actions of the siRNA to LZT-Hsl over and above the scrambled 
siRNA are presented.
As may be seen in Figure 5-20, siRNA to LZT-Hsl promotes an approximately 70% 
knockdown of LZT-Hsl mRNA versus the scrambled control cells which was not 
significantly different as evidenced by the large error bars. One replicate showed a clear 
knockdown of LZT-Hsl whereas the other 2 were not so pronounced. However, a successful 
knockdown of LZT-Hsl protein was shown in Figure 5-22. No comparable knockdown of
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LZT-Hs6 was seen (not significant with large error bars) with the siRNA to LZT-Hsl (Figure 
5-21) treated cells.
Examination of the effects of the siRNA to LZT-Hsl on LZT-Hsl protein levels revealed 
that although the scrambled siRNA treatment in the presence of Lipofectamine2000, 
considerably reduced LZT-Hsl protein levels, they were further decreased by the siRNA 
(Figure 5-22A).
Importantly, examination of EGFR phosphorylation at the tyrosine 1068 (Figure 5-22B) and 
tyrosine 1173 (Figure 5-22C), showed an syjpreciable reduction in the levels of 
phosphorylation at these sites in the presence of the siRNA to LZT-Hsl, together with a 
comparable reduction in the phosphorylation of c-Src 418 (Figure 5-22D). These data are 
suggestive of a regulating role o f LZT-Hsl in EGFR/Src signalling and potentially the 
growth of tamoxifen resistant cells.
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Figure 5-19 : Relative mRNA expression of LZT-Hsl in tamoxifen resistant and
siScramble treated cells
0.9 
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TamR Control siScramble treatment
The gel image shows the PCR result of LZT-Hsl gene expressions in tamoxifen resistant and 
siScramble treated cells. The results are representative of three mRNA sets. The graph below 
the gel image is a compilation of the densitometric values from the gel image.
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Figure 5-20 : Relative mRNA expression of LZT-Hsl in tamoxifen resistant and siRNA
LZT-Hsl treated cells
siScramble siRNA LZT-Hsl
LZT-Hsl
b-actin
siScramble treatment si treatment
The gel image shows the PCR result of LZT-Hsl gene expressions in tamoxifen resistant and 
siScramble treated cells. The results are representative of three mRNA sets. The graph below 
the gel image is a compilation of the densitometric values from the gel image.
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Figure 5-21 : Relative mRNA expression of LZT-Hsl in siScramble treated and LZT- 
Hs6 in siRNA LZT-Hsl cells
r
Tamoxifen Resistant siRNA to LZT-Hsl
^a r
LZT-Hs6
b-actin
siScramble treatment siRNA treatment
The gel image shows the PCR result of LZT-Hsl gene expressions in tamoxifen resistant and 
siScramble treated cells. The results are representative of three mRNA sets. The graph below 
the gel image is a compilation of the densitometric values from the gel image.
173
Figure 5-22: Relative protein expression in various cell groups of tamoxifen resistant,
siScramble and siRNA LZT-Hsl treated cells
A)
B)
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b-actin
c-Src
b-actin
A) LZT-Hsl(56kDalton) protein was reduced after siRNA treatment compared to TamR 
control and siScramble treatment B) EGFRY1068 (175kDalton) protein was reduced after 
siRNA treatment compared to TamR control and siScramble treatment C) EGFRY1173 
(175kDalton) protein was reduced after siRNA treatment compared to TamR control and 
siScramble treatment D) c-Src (60kDalton) protein was reduced after siRNA treatment 
compared to TamR control and siScramble treatment. In all samples p-Actin is 42kDalton.
174
5.5 Discussion
The current study is unique in that it represents the first time that the expression of the 9 LZT 
family members have been examined in breast cancer and anti-hormone resistance. Indeed, 
while previous studies have invariably looked at the role individual family members might 
play in normal or pathological condition (Manning et al. 1994; Schaner et al. 2003), we 
believe that there is considerable merit in trying to unravel the complexities of signaling 
within this newly identified family of proteins involved in zinc transport. In addition, 
hopefully in identifying which are most critical to the growth of breast cancer cells we will 
also determine which are potentially the most appropriate therapeutic targets (Duffy et al. 
2000). Excitingly, the initial Affymetrix study, although limited in that only 5 family 
members were represented on the Affymetrix gene chip, clearly identified that at least one 
family member showed some regulation by oestrogen at the mRNA level and that several 
appeared raised in one or more forms of anti-hormone resistance. These results provided the 
impetus to develop semi-quantitative PCR methods to detect all of the LZT family in our 
RNA preparations and in turn confirm the appropriateness of the Affymetrix approach as an 
initial screening procedure.
Initially, the RNA preparations were PCR screened for pS2, a known oestrogen regulated 
gene, whose levels fall in tamoxifen (Dardes et al. 2002) and faslodex resistance (Hutcheson 
et al. 2003). Reassuringly, similar patterns were seen using PCR with data indicating that the 
pS2 gene was elevated by oestradiol however the expression falls significantly in tamoxifen 
and both early and late stage faslodex resistances.
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Examination of the LZT family of genes by PCR identified several important features 
associated with the Affymetrix data and their differential expression in breast cancer cells. As 
compared to the Affymetrix data, the current study had shown that the PCR technique gave 
comparable results for the anti hormone resistance however not for hormone/anti-hormone 
response. Although the reasons for this are unclear, PCR is a technique where individual 
primers and assay conditions are designed to maximise the PCR product, whereas an 
Affymetrix analysis is based on multiple sets of probes some of which may lead to variable 
results, which are then averaged. This can lead to obscuring modest alterations in our gene 
expression profiles. In the results, some of the gene expression profiles have histograms with 
large error bars. As mentioned in Chapter 2 that the RNA samples maybe degraded due to the 
storage procedure or samples have been kept a long period before the respective RNA 
expression study started.
Interestingly, several papers have been shown that LZT-Hs5 tissue distribution is specific 
and restricted to intestinal tissues (Nakano et al. 2003). In contrast, LZT-Hs9 is suggested to 
be expressed in mammary tumours metastatized to lung tissue (Strausberg et al. 2002) and 
many other tissue (Figure 3-5) showed widespread distribution, therefore ubiquitously 
expressed..
In this study, LZT-Hsl and LZT-Hs4 were shown to be oestrogen regulated, while LIV-1 
showed a non-significant trend in this direction. Since the oestrogen regulation of the full
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LZT family has not been examined previously, no literature comparisons can be made. With 
respect to the LIV-1 gene, several studies have previously shown it to be increased in 
expression by oestradiol (El-Tanani and Green 1996) confirmed by Affymetrix and 
additionally, its expression in clinical breast cancer specimens has been linked to oestrogen 
receptors (El-Tanani and Green 1997).
In light of the limited literature in this area, an attempt was made to evaluate the effects of 
oestradiol on the expression of the LZT family and investigate the presence of oestrogen 
response elements (EREs) in their promoter. Using Dragon ERE Finder 2.0, imperfect EREs 
were located in the promoters of all of the family members, in both the forward and reverse 
strands. This analysis, however, did not detect any sequences corresponding to the consensus 
sequence GGTCA nnn TGACC, and it is unclear how many alterations are allowed before 
oestrogen receptor (ER)-ERE binding activity is lost. Certainly, it has been suggested that 
two alterations can lead to either gain or loss of ERE activity (Bajic et al. 2003), and in many 
instances through out the LZT family members, as many as 3 alterations were detected. 
Significantly, oestrogen receptor activity is not necessarily wholly directed through EREs 
and, as previously stated, can operate through interactions with other nuclear transcription 
factors (NTFs) for example Spl and AP-1, and through the oestradiol binding to plasma 
membrane associated oestrogen receptor with direct induction of signal transduction 
pathways.
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Interestingly, in the tamoxifen resistance model, increased activity of epidermal growth 
factor receptor (EGFR) has been directly linked to tumour cell growth with the EGFR 
selective tyrosine kinase inhibitor (TKI), gefitinib, promoting exclusive growth inhibition.
Subsequently, experiments by our group (Taylor et al. 2005), have shown tamoxifen resistant 
cells have increased levels of intracellular zinc, and that exposure of the cells to exogenous 
zinc is able to facilitate EGFR signalling via a Src dependent mechanism. Increases in zinc 
transporter levels might therefore promote the increased zinc levels in tamoxifen resistant 
cells and thus aid EGFR growth signaling.
Although 4 of the LZT family members were altered in expression across multiple forms of 
anti-hormone resistance, (LZT-Hsl, LZT-Hs4 and LZT-Hs6), only LZT-Hsl was elevated in 
the tamoxifen resistance model. Consequently, to further study the relevance of zinc 
transporter and their involvement in anti-hormone resistance, we specifically targeted the 
LZT-Hsl in the tamoxifen resistance model with an siRNA and investigated its effect on 
EGFR signalling. Encouragingly, even as only a preliminary study and set against a 
background of Lipofectamine2000 that induced cell toxicity, was able to demonstrate some 
knockdown of LZT-Hsl mRNA and protein which produced a reduction in the 
phosphorylation of the EGFR at two tyrosine sites (Y1068 and Y1173), and the levels of 
activated c-Src 418 and subsequent experiments in the Tenovus laboratories have confirmed 
this (Taylor, personal communication).
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All together, these data imply an important role for zinc transporters in the growth of breast 
cancer cells and specifically the acquisition of endocrine resistance.
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Chapter 6 
Discussion
6.1 General discussion
The work performed in this thesis is unique in that it represents the first occasion that an 
attempt has been made to assess the relevance of the LIV-1 family to a disease state. Thus, 
although individual family members are increasingly being examined in multiple species 
(Strausberg et al. 2002), tissues (Strausberg et al. 2002) and in various diseases states 
(Manning et al. 1994; Nakano et al. 2003), less is known about how they might collectively 
act in cells and influence the disease process.
As such, this thesis has examined a few different areas, firstly, the similarity or dissimilarity 
of predicted secondary protein structures within the 9 family members of the LZT family. 
Secondly, successfully characterized the properties of LZT-Hs7, LZT-Hs8 and LZT-Hs9, 
where 2 gene have not been previously examined in the literature. Thirdly, analysed the 
oestrogen regulation of the LZT family members and their expression in endocrine resistance 
and finally, observed the cellular affects of LZT-Hsl knockdown by siRNA as this gene 
shows clear up-regulation in several forms of anti-hormone resistance.
In this thesis, the expression of the different members of LZT subfamily has been examined
in endocrine responsive and anti-hormone resistant breast cancer cells. Of particular
significance is the absent or low expression of two family members in breast cancer cells,
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LZT-Hs5 and LZT-Hs9, respectively. It has previously been reported that the LZT-Hs5 gene 
expression in tissues is restricted to the developing and mature intestine and is centrally 
involved in the pathogenesis of acrodermatitis enteropathica thus proving its specific tissue 
distribution (Huang et al. 2005). In contrast, LZT-Hs9 has been suggested to be expressed 
widely in many tissues such as in glioblastoma multiforme, liposarcoma, squamous cell 
carcinoma, bone, lung tumour, pituitary, neuroblastoma, kidney tumour and cervix tumour 
tissue (Strausberg et al. 2002), although there is no data available for breast tissue. As a 
consequence of the low expression displayed in the current study and they are excluded from 
the model.
An attempt has been made to assign the remaining 7 members of the LZT family to a 
subcellular location, with computer predictions, immunolocalisation studies and reference to 
the literature. These are suggesting that LIV-1 (Taylor et al. 2003), LZT-Hs4 ((Taylor et al. 
2005) and LZT-Hs7 (Wang et al. 2004) are present on the cell’s plasma membrane, whilst 
LZT-Hsl is present in the endoplasmic reticulum (Taylor et al. 2004) and the Golgi body 
(Huang et al. 2005). For the first time, our current study showed that LZT-Hs8 and LZT-Hs9 
genes are present in the endoplasmic reticulum in permeabilised cells; however, LZT-Hs8 is 
also present on the plasma membrane in unpermeabilised cells, albeit with low abundance. 
Significantly, in the present study LZT-Hs7 showed no evidence of zinc handling capacity 
which is in direct contrast to previous results showing LZT-Hs7 capable of transporting zinc. 
In conclusion, LZT-Hs8 and LZT-Hs9 showed evidence of zinc activity with each of them 
are suggested to act differently, one as efflux and the other as influx, respectively.
Among the LZT subfamily genes that are up regulated in one or multiple forms of acquired 
anti-hormone resistance are LZT-Hsl, LZT-Hs4 and LZT-Hs6. Furthermore, only LZT-Hs2 
and LZT-Hs7 are unaltered in endocrine responsive and resistant breast cancer cells. LZT- 
Hs2 has been shown to have widespread tissue distribution and interestingly, it is involved in 
metastatis to the lymph nodes in breast cancer (Strausberg et al. 2002). However, LZT-Hs7 is 
commonly expressed in other tissues such as stomach tumour tissue or liver tumour tissue 
(Strausberg et al. 2002) and not commonly found in breast cancer tissue. This observed tissue 
distribution readily explains the reason for the unaltered expression across breast cancer cells 
Of LZT-Hs2 and LZT-Hs7. Figures 6-1 to 6-4 attempt to summarise what has been 
discovered about the remaining 5 members of the LZT subfamily in the endocrine responsive 
and anti-hormone resistant breast cancer cells.
Based on the model we can suggest a few interesting characters or properties of the LZT 
family in breast cancer. Firstly, each individual LZT family members are performing their 
respective cellular functions in differing compartments of the cell. In the cell, LZT-Hsl is 
located in the endoplasmic reticulum and Golgi body whilst LZT-Hs2, LIV-1 and LZT-Hs4 
and LZT-Hs7 are located on the plasma membrane, LZT-Hs8 located on plasma membrane 
however LZT-Hs9 in endoplasmic reticulum, and LZT-Hs6 on vesicle membranes. Although 
they appeared to be located in different sub-cellular compartment, their ability to transport 
zinc ions should be into the cytoplasm transporting zinc ions from either outside the cell or 
intracellular stores. Therefore, at any moment in time, the cytoplasmic zinc concentration 
will in part be a function of the levels of these zinc transporters.
In endocrine responsive and resistant breast cancer, zinc handling may be restricted primarily 
to 4 members of the LZT family, LZT-Hsl, LIV-1, LZT-Hs4 and LZT-Hs6. Some of the 
genes in this group appear to be oestrogen regulated while others are constitutively expressed 
in the cell. Those genes that are constitutively expressed may maintain the cell’s basal 
cellular functions such as normal growth activity and cell survival processes. Whereas those 
genes that are oestrogen regulated enable the oestrogen-mediated responses to occur, such as 
additional/abnormal growth of the cell (Figure 6-1).
Figure 6-1 illustrates a model showing which LIV-1 family members have evidence of 
oestrogen regulation in the endocrine responsive MCF-7 cells, specifically, LZT-Hsl located 
in the endoplasmic reticulum, LIV-1 and LZT-Hs4 that are located on the plasma membrane.
Of these 5 members of the LZT family that have been identified, only LZT-Hsl, LIV-1 and 
LZT-Hs4 show evidences of oestrogen regulation and might therefore contribute to the 
altered behaviour of hormone and anti-hormone treated breast cancer cells. In the latter 
instance, when the cells become resistant to anti-hormone treatment, LZT-Hs6 appeared to be 
up regulated, adding to the already 3 existing genes. It is postulated that since LZT-Hs2, 
LZT-Hs7, LZT-Hs8 and LZT-Hs9 are constitutively or poorly expressed, they may perform 
basal zinc handling, and not being reactive to external stimuli. Figure 6-3 shows genes that 
appeared to be increased in tamoxifen resistant cells are LZT-Hsl and LZT-Hs4, and 
interestingly, these two genes (alongside with LIV-1 and LZT-Hs6) also appeared up 
regulated in prolonged oestrogen deprived breast cancer cells (Figure 6-2). LZT-Hsl and
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LZT-Hs4 genes together with additional, LZT-Hs6, are increased in another resistant state, 
faslodex resistant cells (Figure 6-4). It is believed that this will provide a growth advantage to 
the resistant cells possibly through the activation of growth factor signalling. This principle 
was proven by our preliminary study of siRNA to LZT-Hsl in the tamoxifen resistant cells, 
which was able to reduce activation of the EGFR and Src pathways, as this is the dominant 
pathway of tamoxifen resistant cells.
6.2 Exciting things to do in the future
This study poses a series of questions about involvement of the LZT family in resistant 
tissues after endocrine treatment. The siRNA to LZT-Hsl study implied that LZT-Hsl was 
able to activate epidermal growth factor receptor. However, this should be further 
investigated for instance, to determine the affect on the EGFR Y845 site or if LZT-Hsl also 
affects the activation of other growth factors such as insulin growth factor receptor, as these 
two receptors often cross-talk in many forms of resistance. Additionally, it would be useful to 
determine is siRNA knockdown of LZT-Hsl would affect the growth and invasiveness of the 
resistant cells. Clear understanding of the mechanism of action of LZT-Hsl may provide 
evidence of its ability to be a therapeutic candidate for an inhibitory compound.
LZT-Hsl, LZT-Hs4 and LZT-Hs6 recombinant clones are available to study the over­
expression of the LZT family in responsive cells. These genes have been found to be elevated 
in resistant cells however if we could deliberately over-express them in responsive cells, this 
could determine if alone they are able to create a resistant phenotype. This individual
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phenotypic feature would therefore be a marker to differentiate which tumour cells have the 
capability to become resistant to anti-hormone therapies.
As we have already cloned most of the above genes, their expression may be manipulated by 
mutation technology within the sequences that are of interest. This study would determine 
which region on the sequence was important for transport of zinc ions. Some of the regions 
of interest are the CPALLY motif, HEXPHE region and transmembrane domain III and IV. 
If they were mutated, this study could help us understand the zinc transport system of the 
zinc influx transporters, LZT subfamily. The mutations may additionally affect the cell 
morphology and would show, which is the most appropriate region for the design of 
inhibitory compounds, could have a role in the treatment of anti-hormone resistant breast 
cancer.
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Figure 6-1: A cell diagram illuatrate the LZT subfamily involvement in oestrogen
regulation
Cell membrane
Rough ER _
Smooth ER-
Nucleus. 
Vacoule/Vesicle.
The MCF-7 cells under oestradiol stimulus appeared to up-regulate some members of the 
LZT subfamily; they are LIV-1 and LZT-Hs4, which are located on the plasma membrane 
and LZT-Hsl, located in the endoplasmic reticulum region. In the schematic diagram of LZT 
subfamily protein shows zinc located at the predicted binding site between transmembrane III 
and IV.
Ribosomes
Golgi body
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Figure 6-2 : A cell diagram illustrates the LZT subfamily involvement in prolonged
oestrogen deprivation cells
Cell membrane
Rough ER _
Smooth ER
Nucleus
Ribosomes 
Golgi bodyVacoule/Vesicle
The MCF-7 cells under prolonged oestrogen deprivation condition appeared to up-regulate 
some members of the LZT subfamily; they are LZT-Hsl and LZT-Hs4 significantly shown 
in our study data however, LIV-1 gene is expressed but not significant.
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Figure 6-3 : A cell diagram illustrates the LZT subfamily involvement in tamoxifen
resistant cells
pjjwSfoijjj Ribosomes
Golgi bodyVacoule/Vesicle
Cell
Rough ER 
Smooth ER 
Nucleus
The MCF-7 cells under tamoxifen resistant condition appeared to up-regulate some members 
of the LZT subfamily; they LZT-Hsl and LZT-Hs4 only. It is suggested that the LZT 
subfamily proteins involved are promoting abnormal growth via EGFR/Src pathway, shown 
by cell rough edges.
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Figure 6-4 : A cell diagram illustrates the LZT subfamily involvement in faslodex 
resistant cells
Cell membrane
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Smooth ER
Nucleus
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The MCF-7 cells under faslodex resistant condition appeared to up-regulate some members 
of the LZT subfamily; they are LZT-Hsl, LZT-Hs4 and LZT-Hs6. The cell is progressing 
aggressively under resistant condition showing aggressive phenotype cell with membranes 
pointing outward to invasion.
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Appendix A
Molecular Biology
Luria Bertani Broth, LB Broth
LB broth was prepared by adding 1% of bacto-tryptone, 0.5% of bacto-yeast extract and 
0.17M of NaCl in 950ml of deionised water. The pH was adjusted to 7.4 with IN NaOH and 
the final volume was made up to 1 litre. The broth was sterilised by autoclaving for 40 
minutes at 121°C temperature.
LB Broth with Ampicillin
LB broth was supplemented with lOOpg/ml ampicillin after the broth was sterilised and 
lukewarm, 55°C before antibiotic addition.
Luria Bertani Agar, LB Agar
LB Agar was prepared by adding 1.5% of bacto-agar in 1 litre of LB broth before 
sterilisation by autoclaving.
Antibiotic Ampicillin
Ampicillin was kept as 100X concentrated stock solutions in sterilised deionized water, and 
sterilised by filtration through 0.2pM filter. The antibiotics were aliquot and kept in -20°C to 
avoid degradation and frequent freeze-thawing process. For the purpose of selection media, 
lOOpg/ml of Ampicillin was added to the sterilised media prior to using the media.
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Tris/Acetate buffered EDTA, TAE Buffer
TAE buffer is used in the agarose gel electrophoresis procedure and the 50X concentration 
buffer was made of 242g of Trizma® base, 57.1ml of glacial acetic acid and 18.2g of EDTA 
into 1 Liter of deionised water.
DNA loading buffer
DNA loading buffer is used to load DNA samples into agarose gel and the 5X concentration 
buffer was made of 5ml glycerol, 200pl of 50X TAE buffer, 1ml of saturated bromophenol 
blue and 1 ml of 10% solution of xylene cyanol and the volume was adjusted to 10ml with 
deionized water. The buffer was aliquot and stored at -20°C.
PCR Buffer
The PCR buffer is used in PCR mixture and 10X concentration buffer was made of 4ml 0.5M 
Tris-HCl (pH 8.3), 10ml of 1M KC1, 300pl 1M MgCb, lOOpl of 2% gelatine and 5.6ml 
sterile nuclease free water and the volume was adjust to 20ml with deionized water. The 
buffer was aliquot and stored at -20°C.
0.5M Tris-HCl with pH 8.3
This Tris-HCl buffer was used in preparing the PCR buffer and the 0.5M Tris-HCl was made 
of 6.05g Trizma® base which was dissolved in 80ml of sterile nuclease free water. 
Concentrated HC1 acid was used to correct the pH to 8.3 and the volume was adjusted to 
100ml with nuclease free water. This solution was sterilised by autoclaving and stored at 
room temperature.
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Appendix B
Protein Biochemistry
10% Sodium dodecyl sulphate, SDS
10% of SDS solution was made by adding lOg SDS in 90ml of sterile nuclease free water 
and left overnight to dissolve without stirring or shaking. Then adjust the volume to 100ml 
and stored the solution at room temperature.
Phosphate Buffer Solution-Tween, PBS-T
IX PBS-T is used in the dilution of antibody for binding purpose and as washing buffer in 
the immunoblotting procedure. 10X concentrated PBS-T buffer was made up of 3.9g 
Na2HPC>4, 10.7g NaH2PC>4 and 85g NaCl dissolved in and adjust the volume to 1L with 
distilled water. 10ml of Tween 20 was added to have 0.01% final concentration of PBS-T 
and the solution was stored at room temperature. Further dilution to prepare IX PBS-T 
solution is using distilled water.
Protein sample buffer
Protein sample buffer is used to add to protein samples in the SDS-PAGE procedure. The 
protein sample buffer was made up of 0.02M Tris-HCl pH 8.0, 0.002M EDTA, 2% SDS 
(v/v), 10% 2-Mercaptoethanol (v/v), 20% glycerol, 2.5% bromophenol blue (v/v), 200pl of 
Tris-HCl with pH8.0, 4ml glycerol, 500pl of saturated bromophenol blue were added into a 
sterile universal and in a fume cupboard, add 2ml of 2-Mercaptoethanol was added into.
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Finally, the volume was adjusted to 20ml with nuclease free water. The buffer was aliquot 
and stored at -20°C.
2M Tris-HCl with pH 8.0
To prepare stock solution of 2M Tris-HCl, for preparing other Tris containing buffers, was 
made up of 242.2g Trizma® base dissolve in 850ml of deionized water. Concentrated HC1 
acid was used to correct the pH to 8.0 and the volume was adjusted to 1L with deionized 
water. The solution was sterilized by autoclaving and stored at room temperature.
0.5M Ethylenediamine tetra-acetic acid, EDTA
To prepare stock solution of 0.5M EDTA, for preparing other EDTA containing buffers, was 
made up of 93.05g EDTA-NA2 2 H2O dissolve in 300ml of deionized water and 10N NaOH 
solution was used to correct pH to 8.0 and the volume was adjusted to 500ml with deionized 
water. The solution was sterilized by autoclaving and stored at room temperature.
10N NaOH
To prepare stock solution of 10N NaOH, for preparing other NaOH containing buffers, was 
made up of 40g NaOH dissolve in 90ml of sterile nuclease free water. The volume was 
adjusted to 100ml with sterile nuclease free water and store at room temperature.
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5X SDS-PAGE Running Buffer (0.05M Tris, 0.384M glycine, 1% SDS)
IX SDS-PAGE running buffer is used as the electrophoresis buffer for running the gels in 
SDS-PAGE procedure. 5X concentrated SDS-PAGE running buffer was made up of 30.2g 
Trizma® base and 144g glycine dissolve in 600ml deionized water. Then 100ml of 10% SDS 
solution was added and adjust the volume to 1L using deionized water and the solution was 
stored at room temperature. Further dilution to prepare IX SDS-PAGE solution is using 
deionized water.
10X SDS-PAGE Transfer Buffer (25mM, 192mM, 0.1% SDS)
IX SDS-PAGE transfer buffer is used as the electrophoresis buffer for western transfer of 
protein to be immobilized on PVDF membranes. 10X concentrated SDS-PAGE transfer 
buffer was made up of 30g Trizma® base and 143.5g glycine dissolve in 500ml deionized 
water. Then 100ml of 10% SDS solution was added and adjust the volume to 800ml using 
deionized water and the solution was stored at room temperature. Further dilution to prepare 
IX SDS-PAGE transfer buffer, 100ml of the 10X SDS-PAGE as stock solution, was diluted 
into 700ml deionized water and was added with 200ml methanol.
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Appendix C 
DNA and Protein Marker
DNA Molecular Weight Marker
1 Kilobase (kb) DNA
In the 1 kb DNA has 13 DNA fragments in range of 250 kb, 253 kb, 500 kb, 750 kb, 1 kb, 
1.5 kb, 2 kb, 2.5 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb and 10 kb in sizes. 1 kb to 10 kb with exact 1 
kb increments. On an EtBr stained gel, only the 1 kb and 3 kb fragments have increased 
intensities relative to other fragments which each has approximately 25ng/pl of DNA. To 
load the ladder in a convenient volume is 5ul in a lane.
Hyperladder IV
Hyperladder IV has 9 DNA fragments in range of 100 bp and 200 bp which both fragments 
has 20ng amount of DNA, 300 bp and 400 bp with each both fragments has 40ng amount of 
DNA, 500 bp and 600 bp each has 60ng amount of DNA, 700 bp and 800 bp each has 80ng 
amount of DNA and 1 kb size fragment with lOOng amount of DNA. The DNA amount in 
the each fragments help to accurately quantify the sample on the stained EtBr gels. To load 
the ladder in a convenient volume is 5pi in a lane.
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Protein Molecular Weight Marker
Full range Rainbow™ coloured protein molecular weight marker
The full range Rainbow™ coloured protein molecular weight marker has 10 protein bands 
that are in these sequence; 10 kD, 15 kD, 30 kD, 35 kD, 50 kD, 75 kD, 105 kD, 160 kD and 
250 kD. To load the ladder in a convenient volume is 10 pi in a lane.
196
Appendix D 
Abbreviation
ANOVA analysis of variance 
ATP adenosine triphosphate
cDNA Complementary or copy DNA
DNA deoxyribonucleic acid
dNTP Deoxynucleotide triphosphate
EDTA ethylenediaminetetraacetic acid
kb kilo base
mRNA messenger RNA
RCF relative centrifugal field
r.p.m revolutions per minute
RNA ribonucleic acid
RT reverse transcriptase
RT-PCR reverse transcription polymerase chain reaction
siRNA small interfering RNA
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Appendix £  
Publication
‘The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer’
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The Emerging Role of the LIV-1 Subfamily of Zinc Transporters 
in Breast Cancer
Kathiyn M  Taylor,1 Helen E M organ1 Kathryn Sm art1 Normawati M  Zaltari1 Sara Pumford,1 Ian 0  Ellis,2 
John F R Robertson,3 and Robert I Nicholson
lTenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom;
Departments of :Histopathology and Surgery, University of Nottingham, City Hospital, Nottingham, Uni fed Kingdom
Zinc transporter UV-l (SLC39A6) is estrogen regulated and present in increased amounts in estrogen receptor-positive breast 
cancer as weil a s  in tumors that sprecd to the lymph nodes. Tne LiV-1 subfamily of ZIP zinc transporters consists of nine human se­
quences that share considerable homology across transmembrane domains. Many of these sequences have been  shown to 
transport zinc and /o r other ions across cell membranes. Increasingly, studies have implicated members of the LIV-1 transporter 
subfamily in a  variety of diseases. We review these studies and  report our own investigations of the role in breast cancer of the 
nine LfV-1 zinc transporters. We have docum ented the response of these transporters to  estrogen and antiestrogens, and also 
their presence in our models of resistance to antiestrogens. Resistance to antiestrogen drugs such as tamoxifen and  fulvestrant 
often occurs in ad v a n ce d  breast cancer, in these models we observed differential expression of individual LIV-1 famiiy members, 
which may b e  related to  their observed variabie tissue expression. We were unabie de tec t ZIP4, which is known to  be  expressed 
in the intestine, HKE4/3LC39A7 had elevated expression in both antiestrogervresistant ceil lines, and ZIPS had eievated  expression 
in fuivestrant-resistant cells. In addition, we investigated the expression of the nine LIV-i family members in a  ciinical breast can ­
cer series. Although a  number of different UV-l famiiy members showed seme association with growth factor receptors, LIV-1 was 
scieiy associated with estrogen receptor end a  variety of growth factors commcniy associated with ciinicai breast cancer. HKE4, 
however, did show an  association with the marker of cell proliferation Ki67 the spread of breast cancer to  ivmph nodes.
Online address; http://www.molmed.org 
dci: 10.2119/20Q7-00040.Taylor
INTRODUCTION TO THE UV-l FAMILY 
OF ZINC TRANSPORTERS
Zinc Transporter Families
Zinc is an essential ion in cells; with­
out it cells cannot sustain life. Zinc is 
a cofactor for more than 300 enzymes, 
representing more than 50 different en­
zyme classes, and is essential for cell 
growth (1). Zinc is involved in protein, 
nucleic acid, carbohydrate, and lipid 
metabolism, as w ell as in the control of 
gene transcription, differentiation, de­
velopment, and growth (2). Zinc defi­
ciency can be detrimental, causing 
stunted growth and serious metabolic 
disorders (3), while excess zinc can be
toxic to cells (4). Cellular levels of zinc 
are tightly regulated by specific zinc 
transporter proteins, of which there are 
two known families. These two fami­
lies have opposing action on zinc 
transport The ZnT family (SLC30A) 
(previously termed CDF for cation dif­
fusion facilitator) of zinc transporters 
(5) transport zinc out of cells or into 
intracellular compartments .from the 
cytoplasm, whereas the ZIP family (for 
Zrt-, Irt-like Proteins) (SLC39A) of zinc 
transporters (6) transport zinc into the 
cell cytoplasm from either outside the 
cell or from intracellular compart­
ments. Although these two families are 
termed zinc transporters, evidence
show's that some members are able to 
transport other divalent cations such 
as iron, cadmium, copper, and man­
ganese as well as zinc. The exact mo­
lecular mechanism for such transport 
is still unknown, however. The ZnT 
family contains nine human sequences, 
and the ZIP family contains 14 human 
sequences (7). Increasing evidence 
implicates various members of the 
SLC39A family of ZI.P transporters in 
disease states and suggests that aber­
rant expression of zinc transporters 
leads to uncontrolled growth such that 
occurring in cancer. Thus any mole­
cules controlling cellular zinc levels 
acre worthy of investigation.
The LIV-1 Family of ZIP Transporters
More than 100 SLC39A sequences have 
been identified, originating from more 
than 12 species (7,8). The 14 human 
members of the SLC39A family have
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Figure 1. Phylogenetic tree and aiignment of the human members cf the ZIP superfamily of zinc transporters. (A) This phylogenetic tree 
was drawn using ClustalW and treeview software. (B) This alignment demonstrating the highly conserved motif in TM V for the LIV-1 family 
was performed using ClustaiW and shaded using Boxshaae software. Black shading represents a t least 50% identity, gray shading repre­
sents a t least 50% complementary residues. (C) This aiignment demonstrating the CPALLY motif directly upstream of TM I was performed 
using CiustalW and  shaded using Boxshade software. Black shading represents a t least 50% identity, gray shading represents at least 50% 
complementary residues.
been divided into four separate groups 
(Figure 1 A), nine of which are in the LI\-1 
subfamily (7). Importantly, the LIV-1 sub­
family is a highly conserved group of 
eight transmembrane domain proteins 
that are mainly situated on the plasma 
membrane and transport zinc into cells. 
At least one SLC39A sequence, however, 
member HJKE4 (SLC39A7/ZIP7), exists 
on intracellular membranes and trans­
ports zinc into the cytosol (9). All of the 
SLC39A LIV-1 family members contain 
the consensus sequence present in other 
ZIP transporters, located in the region 
of transmembrane domains IV and V, 
and a histidine^rich motif (of the form 
HXHXH, where H is histidine and X is 
any amino add) thought to be important 
in zinc transport, located on the long in­
tracellular loop between TM III and IV, 
immediately preceding TM IV (10). The
LIV-1 family sequences also contain a 
highly conserved potential metallopro- 
tease motif, which closely resembles the 
active site motif of matrix metallopro- 
teases and is situated in transmembrane 
domain V (Figure IB), and considerably 
increased histidine residues on the N- 
terminus and extracellular loop between 
TM n and HI (7). For example, Z1P10 has 
49 histidines in the extracellular N-termi- 
nus, nine on the first extracellular loop 
between TM II and HI and 20 on the in­
tracellular loop between TM III and IV. 
Interestingly, two of the LIV-1 family se­
quences, ZIP14 and BIGM103 /ZIP8, 
have the initial H of the HEXXH motif 
in TM V replaced with an E, which may 
suggest an ability to transport ions other 
than zinc. Furthermore, ZIP8 has been 
demonstrated to transport cadmium in 
the testis (11), and ZIP14 mediates
non-transferrin-bound iron uptake into 
hepatocytes (12).
The Properties of the LIV-1 Family of 
ZIP Transporters
Current information about the various 
members of the LIV-1 subfamily, includ­
ing clarification of the names of each 
sequence, is documented in Table 1. 
Most sequences have widespread tissue 
distribution, as judged by the EST se­
quences in the GenBank, whereas ZIP4, 
ZIP5, and ZIP12 appear to be more tis­
sue specific. Most of the LIV-1 family 
proteins reside on the plasma mem­
brane of cells, a characteristic consistent 
with a role as a zinc influx transporter. 
This role has been demonstrated for 
ZIP4 (13), ZIP5 (14), LIV-1 (15), and 
ZIP14 (16,17), but not for HKE4, which 
has been observed on the endoplasmic
L I V - I  Z I N C  T R A N S P O R T E R S  I N  B R E A S T  C A N C E R
Table 1. Nomenclature and Known Function of LIV-1 Family Members.
Human
gen© Protein Other Cell Tissue Transport Disease Chrom­ Accession
nam e n am e names location distribution function link osome number
SLC39A4 2P4 LZT-Hs5 PM Smail intestine, 
stomach, 
colon, 
cecum , 
kidney
2nc uptake Acrodermatitis
enteropathica
(35-37)
8q24.3 NM_017767
SLC39A5 2P5 LZT-Hs7 Basoiateral
surface
of
polarized
cells
Kidney, liver, 
spieen, 
coion, 
stomach, 
pancreas
2nc removal 12ql3.13 NMJ 73596
SLC39A6 UV-1.
ZIP6
L2T-HS3 PM Widespread 2nc influx Breast cancer 
(21-22).
18a 12.1 • NM_012319
SLC39A7 HKE4,
2P7
LZT-Hsl ERand
Soigi
widespread Z!nc and
m anganese
bidirectional?
(20)
Tamoxifen 
resistance in 
breast cancer
6p21.3 NM_0u6979
SLC39A8 B1GM103,
2P8
LZT-HS6 Vesicles Widespread Cadmium influx 
<11 ),2nc influx
Fcslcdex resistance 
in breast 
cancer
4q22-q24 NM_022154
SLC39A10 2P10 LZT-Hs2 PM Widespread Zinc influx 2a33.1 NM_020342
SLC39A12 2P12 LZT-HsS Brain, lung, 
testis, retina
Asthma (32) 10pl2.33 NMJ 52725
SLC39A13 2P13 ■ LZT-Hs? Widespread 11 p i 1.12 NMJ 52264
SLC39A14 2P14 LZT-HS4 PM Widespread 2nc influx, non­
transferrin- 
bound iron 
uptake (12)
Asthma (22). 
inflammation 
mediated by 
' IL-6C31)
•8p21.2 NM_015359
PM, plasma membrane.
reticulum (9) and golgi (18) membranes, 
or BIGM103/ZIP8, which has been ob­
served on intracellular vesicles such as 
lvsosomes and endosomes (19).
Because of membrane topology, loca­
tion on intracellular membranes is pre­
sumed to enable ion transport from in­
tracellular compartments to the 
cytoplasm. However, the yeast equiva­
lent of HKE4, Yke4p, has recently been 
shown to balance the zinc level between 
the cytosol and the secretory pathway 
by transporting zinc in either direction 
across membranes, depending on the 
zinc status of the cells (20). This observa­
tion is interesting and may explain the 
presence in the LIV-1 family sequences 
of additional histidine-rich regions posi­
tioned on die side of the membrane op­
posing that of the other ZIP transporters.
We have previously observed a con­
served motif, which we termed 
CPALLY, immediately preceding the 
first TM domain (Figure 1C). This motif 
does not occur in HKE4, which is not 
present on the plasma membrane, or- 
Z1P13, which is grouped with ZIP7 in 
the phylogenetic tree and thus may also 
reside on intracellular membranes. This 
CPALLY motif contains three conserved 
cysteines, which usually form disulfide 
bonds with other cysteine residues. Fur­
thermore, all of the human LIV-1 family 
members, except HKE4 and ZIP13, have 
a conserved cysteine immediately pre­
ceding their HEXXH motif in TM V.
This motif may be involved in binding 
to this additional cysteine, thus closing 
the pore and regulating the movement 
of zinc across the membrane.
Normal Tissue Expression of UV-1 
Family Members
The normal tissue expression of the dif­
ferent members of the LIV-1 family 
shows considerable variation, which may 
indicate their diverse roles in different tis­
sues (Table 1). ZIP4 is present in the in­
testine and kidney (21), particularly the 
duodenum and jejunum, which are cru­
cial sites of zinc absorption. ZIP5 is ex­
pressed in kidney, liver, pancreas, and in­
testine, particularly the basoiateral 
membrane of die adult and developing 
mouse intestine (22). LIV-1 has wide­
spread distribution but is not appreciably 
present in heart and intestine and is pri­
marily increased in hormonally con­
trolled tissues (15). HKE4 (9), ZIP14 (17), 
and ZIP13 are ubiquitously expressed, 
appearing in many tissues. ZIP12 is ex­
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Figure 2. Celiuiar location of three human UV-1 family members in MCF-7 ceils. MCf-7 
ceils expressing recombinant HKE4, UV-1, or ZIP 14 were imaged using a  mouse anti-V5 
antibody (Invitrogen) conjugated to Aiexa Fiuor 488 (green) and assembled onto slides
using Vectorshieid with DAPi (Vector Laboratories). Ai! ceiis were incubated with Texas red 
phailoidin to stain F-Actin fiiaments red. Coverslips were viewed on a  Leica RPE auto­
matic microscope using a  63x oii immersion lens. The fluorescent superimposed images 
were acquired using a  muitiple bandpass filter set appropriate for DAPi, fluorescein, and 
Texas Red as well as bright field for differential interference contrast imaging.
pressed in brain, lung, testis, and retina, 
and ZIP10 is predominantly expressed in 
brain and spinal cord (data obtained from 
expression array in the HUGO database).
The LIV-1 Family of ZIP Transporters 
and  D isease S tates
The first member of the LIV-1 family 
to be linked to disease was LIV-1 itself, 
which was shown to be estrogen regu­
lated and present in increased amounts 
in estrogen-receptor-positive breast can­
cers that spread to the lymph nodes 
(23,24). More recently, this association of 
UV-1 with estrogen receptors has been 
substantiated by larger scale analysis of 
breast cancer specimens. These studies 
have shown (hat LIV-1 is such a reliable 
marker of estrogen-receptor-positive 
cancers (25,26) that it is one of the genes 
used routinely to distinguish the luminal 
A type of clinical breast cancer (27,28). 
Furthermore, in zebrafish embryos, LIV-1 
was shown to be the downstream target 
of the transcription factor STATS, which 
has a proven role in the development of 
cancer (29). This work also found that 
UV-1 was essential for the nuclear local­
ization of the transcription factor Snail, 
which plays a major role in the epithe- 
lial-to-mesenchymal switch because of its 
ability to down regulate the expression 
of genes associated with cell adhesion. 
This finding suggests that LIV-1 could 
form a link between cancer and normal 
development (30) and raises the question 
of whether any other UV-1 family mem­
bers have a similar role. Interestingly, the 
expression of two other LIV-1 family se­
quences, ZIP4 and ZIPS, has been ob­
served in the developing mouse intestine 
(22) and the Drosophila UV-1 family 
member called fear of intimacy (FOI) 
has been shown to be essential for gonad 
development (31). Another LIV-1 family 
member, ZIP14, is substantially increased 
during the zinc-dependant differentia­
tion of adipocytes (16) and is regulated 
by IL-6, a mechanism that requires 
STAT3 signaling (32).
Additionally, the LIV-1 family of zinc 
transporters has been implicated in 
other disease states. For example, in­
creases in expression of the zinc trans­
porters UV-1, ZIP12, and ZIP14 have 
been observed during acute inflamma­
tion in the airway and asthma and have 
been suggested to promote an increase 
in zinc uptake, which can reduce inflam­
mation (33). The zinc content in brajns of 
individuals with schizophrenia is lower 
than that of individuals with other cere­
bral diseases (34), and a role for the 
ZIP12 gene has been demonstrated by 
observation of mutations in ZIP12 in a 
small group of schizophrenic patients. 
Significantly, brain zinc content was 
maintained in rats fed a zinc-deficient 
diet by a compensatory rise in LIV-1 ex­
pression in the brain (35). The ZIP4 gene 
has been demonstrated to be mutated in 
the zinc deficiency disorder acrodermati­
tis enteropathiCa (21,36), and the ob­
served mutations were shown to disrupt 
the molecule in areas thought important 
for zinc transport (37).
INVESTIGATION OF THE UV-1 FAMILY 
OF ZIP TRANSPORTERS IN BREAST 
CANCER.
The increase of scientific literature Im­
plicating ZIP transporters in a variety of 
diseases has led to our recent investigation 
of the relevance of the expression of the 
nine family members of the UV-1 family 
of ZIP transporters in breast cancer. Be­
cause LIV-1 itself is known to be regulated 
by estrogen, we initially investigated the 
response of these nine LIV-1 family mem­
bers to short-term treatment with estrogen 
and antiestrogens. We then followed up 
with investigation of these nine LIV-1 fam­
ily members in our cell-line models of 
longer-term treatment, which have devel­
oped resistance to antiestrogens, as well 
as expression in breast cancer samples. 
These results are detailed below.
In addition, we transiently trans­
fected MCF-7 cells w ith constructs 
for three LIV-1 family members with a
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Figure 3. Comparison of the effect of antihormones on the RNA expression of the nine 
human UV-1 family members. MCF-7 cells were trea ted  with 4-hydroxytamoxifen (TAM), 
fulvestrant (FAS), Gr oestradiol (E2) for seven days in serum growth factor-free DCCM 
medium before total RNA was extracted, reverse transcribed to  cDNA, and PCR per­
formed for individual ZIPs. Ail d a ta  were normalized to  individual p-actin levels. The 
upper pane! shows representative agarose gels of pS2, UV- i , HKE4, and  ZIP8 in MCF-7 
treated  with oestradiol (iane 1), untreated (iane 2), trea ted  with Tamoxifen (lane 3). or 
treated  with Fulvestrant (lane 4). M represents size markers. Lower pane! shows mean ± 
SEM densitometrlc values of 8 genes, comparing their expression levels in MCF-7 ceils 
untreated (CON), or treated with oestradiol (E2). Tamoxifen (TAM), or Fulvestrant (FAS). 
Statistically significant results are indicated with asterisks, an d  the relevant P  value is 
given. Z1P4 was undetectable.
C-terminal V5 tag to confirm the same 
cellular location as previously observed 
in Chinese hamster ovary cells (9,15,16). 
Figure 2 shows plasma membrane 
staining for both UV-1 and ZIP14 
(green) in unpermeabilized MCF-7 cells 
as determined by colocalization with 
F-actin filaments (red) and association 
with the outside of the cell, observed by
DIC imaging. In contrast, HKE4 stains 
intracellular compartments in perme- 
abilized MCF-7 cells, such as the endo­
plasmic reticulum (green), as evidenced 
by perinuclear staining and an equal 
meshlike appearance throughout the 
cell interior, yet dearly does not reach 
the cell extremities, which were stained 
by F-actin (red).
pS2
Actin —**
LIV-1 — . 
Actin —-
The Response of the  LfV-l Family of 
ZIP Transporters to Antiestrogens
Because of the similarity between the 
sequences of the nine LIV-1 family mem­
bers, we investigated whether any of the 
other UV-1 family members were also 
estrogen-regulated and/or expressed in 
breast cancer cells. To achieve this we 
compared the RNA expression of all 
nine members of the LIV-1 family of ZIP 
transporters in the estrogen-receptor- 
positive MCF-7 breast cancer cell line 
that had been exposed to estrogen, the 
partial antiestrogen tamoxifen ,or the 
pure antiestrogen fulvestrant for 10 days. 
Cells were harvested, RNA was pre­
pared, RT-PCR was performed, and 
DNA for individual genes was amplified 
by PCR in the presence of actin, to allow 
normalization of the results (Figure 3). To 
verify the profile of the samples, we first 
investigated the expression of the estro­
gen-regulated gene pS2, whidi was char­
acterized by elevation in response to es­
trogen, little response to tamoxifen, and 
reduced expression in response to fulves­
trant (see Figure 3 A). We observed differ­
ential expression of all nine LIV-1 family7 
members, both in the amount of RNA 
present and in the response to different 
treatments (see Figure 3B). We show rep­
resentative gels of the three LIV-1 family 
members with the largest response (see 
Figure 3A). ZIP4 was undetectable in all 
samples, a finding that may reflect its 
known expression in the intestine and 
kidney (21). The levels of ZIPS, 10,12, 
and 13 did not change across the treat­
ments, and all were expressed at rela­
tively low7 levels, at which ZIPS, ZIP10, 
and ZIP12 required an increased number 
of PCR cycles compared with the other 
LIV-1 family members. LIV-1 and ZIP14 
appeared to be estrogen regulated, show­
ing an increased response to estrogen 
and reduced response to tamoxifen or 
fulvestrant, which was statistically sig­
nificant (see Figure 3>. Although HKE4 
was also significantly increased in re­
sponse to estrogen treatment, it was also 
increased, to a lesser ^extent, in response 
to both tamoxifen and fulvestrant. ZIP8 
showed a slight decrease in response to
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Figure 4. Comparison of RNA expression of the nine human UV-1 family members in anti­
hormone-resistant MCF-7 ceils. The expression of different ZIPs in tamoxifen (TamR> and ful­
vestrant (FasR)-resistant MCF-7 cells was com pared with wild-type MCF-7 cells. RNA was 
extracted and reverse transcribed to cDNA. The upper pane! shows representative gels of 
pS2. UV-1, HKE4, and ZIPS In MCF-7 (lane 1). TamR (lane 2) and FasR (lane 3) cell lines. M 
represents size markers. Lower panel shows m ean ± SEM densitometric values of 8 genes 
comparing their expression levels in MCF-7, TamR, and FasR cells. Statistically significant re­
sults are indicated with asterisks, and the relevant P  value is given. ZIP4 was unaetectabie.
estrogen, which was not significant pre­
sumably due to the large error bars.
The observed changes in the SLC39A- 
family mRNA levels reported here are an­
ticipated to be reflected in the production 
of the individual proteins, but this possi­
bility has not been examined across the 
SLC39A family because of the absence of 
available antibodies. However, recent re­
sults in our laboratory with two new anti­
bodies to endogenous LIV-1 and HKE4 
suggest that this relationship exists, be­
cause both LIV-1 and HKE4 proteins were 
increased by estrogen treatment, and LIV-1 
was decreased with both tamoxifen and 
faslodex treatments whereas HKE4 was 
unchanged, mirroring the results that we 
observed at the mRNA leveL
The UV-1 Family of ZIP Transporters in 
A ntiestrogen Resistance
Although estrogen-receptor-positive 
breast cancers are routinely treated clini­
cally with antihormones such as tamox­
ifen or fulvestrant, with time the tumors 
develop resistance to these agents, lead­
ing to subsequent regrowth, usually 
with an altered and more aggressive 
phenotype (38). To better understand 
the mechanisms underlying the occur­
rence of resistance, w e have developed a 
unique panel of anti estrogen responsive 
and resistant cell lines derived from the 
estrogen-receptor-positive human breast 
cancer cell line MCF-7 (39,40). We have 
investigated the expression of all nine 
human LIV-1 family members in both 
our tamoxifen (TamR)- and fulvestrant 
(FasR)-resistant cell lines and compared 
them to the wild-type MCF-7 cells 
(Figure 4) in an effort to examine any 
potential role that individual LIV-1 fam­
ily members may play in the develop­
ment of antihormone-resistant breast 
cancer. These antihormone-resisfcant cell 
lines are able to grow in the presence of 
antiestrogens by efficiently utilizing 
signaling pathways such as epidermal 
growth factor receptor (EGFR) (39,40),
Src (41), Insulin-like .growth factor recep­
tor 1 (1GFI-R) (42), and c-Met (43), 
which allows them to exhibit a more 
aggressive phenotype (44). Cells were 
harvested, RNA prepared, RT-PCR per­
formed, and DNA for individual genes 
was amplified by PCR in the presence of 
actin, to allow' normalization of the re­
sults. The cell samples were first charac­
terized for pS2 levels, and showed the 
expected decrease in the FasR cells (45). 
Representative gels are given for the 
three LIV-1 family members that ap­
peared most altered, LIV-1, HKE4, and 
ZIP8. ZIP4 levels were again undetect­
able, and the levels o f  ZIP5, Z1P10, 
ZIP12, and ZIP13 were relatively low, 
with ZIP5, ZIP10, and ZIP12 again re­
quiring an increased number of PCR cy­
cles. Levels of ZIP5, 2JP12, and ZIP13 
did not change, and the levels of LIV-1, 
Z1P12, and ZIP13 w ere either unchanged 
or reduced in the resistant cell lines. 
ZIP14, although present in low amounts, 
was increased in the resistant cells, and 
ZIP10 was decreased in TamR cells.
Only HKE4 and ZIP 8 produced statisti­
cally significant changes, with HKJE4
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Table 2. Summary of UV-1 Family Expression Response to Treatments or Antihormone 
Resistance >
Cells Z1P4 ZIP5 UV-1 HKE4 Z1PB ZIP 10 Z1P12 ZIP! 3 ZIP14
MCF-7 + E2 ND — Up Up Down — — —  Up
MCF-7 + TAM ND — — — —  — — —  Down
MCF-7 + FAS ND — Down
Tamoxifen-resistant cells ND — — Up —  — — —  —
Fulvestrant-resistant cells ND — -T- Up Up — — —  —
ND, not determined; — , no change.
elevated in both resistant states, whereas 
ZIP8 was considerably elevated in FasR 
cells. These results suggest that a number 
of LIV-1 family members (ZIP4, ZIP5, 
UV-1, ZIP10, ZIP12, and ZIP13) appear 
unaltered or decreased by the acquisi­
tion of endocrine resistance. However, 
both HKE4 and ZIP8 were elevated in 
one or both antihormone-resistant cell 
lines, suggesting a possible role in the 
development of resistance. These results 
are summarized in Table 2.
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Figure 5. Comparison of the expression of LIV-1 family members in a  series of samples 
from breast cancer patients. (A) representative results from 10 patient tumor samples am­
plified with gene specific primers for ZIP5, HKE4, ZIP10, UV-L ZIP8, Z1P14, and p-actln. (B) 
distribution of the densitometric values for ZIP5, HKE4,2IP10, LIV-1, ZIPS, and Z1P14 in the 
patient samples, with no correction for the number of PCR cycles.
We have previously demonstrated that 
our TamR cells have increased intracellu­
lar zinc levels (46; Taylor et al, unpub­
lished results), increased EGFR (39), Src 
(41), and IGF1-R (42) signaling as well as 
increased growth and invasion (41). In­
terestingly, treatment of these cells with 
20 |aM zinc can activate EGFR, Src, and 
IGF1-R signaling as well as growth and 
invasion (46; Taylor et al, unpublished 
results). Furthermore, we have demon­
strated a role for HKE4 in the develop­
ment of the aggressive phenotype in 
TamR cells by using siRNA for HKE4 
which prevented the observed zinc-in­
duced activation of signaling pathways 
(Taylor et al, unpublished results). 
Whether ZIPS has a similar role in the 
FasR cells needs to be investigated. We 
have, however, not examined whether 
these transporters have the ability to 
transport metals other than zinc or 
whether these pathways can be stimu­
lated by other metals.
LIV-1 FAMILY OF ZIP TRANSPORTERS IN 
BREAST CANCER SAMPLES
UV-1 is an estrogen-regulated gene 
that has been implicated in estrogen-re­
ceptor-positive breast cancer and the sub­
sequent spread to die regional lymph 
nodes (23-26), and more recently it has 
been used as a reliable marker of luminal 
A type clinical breast cancer (27,28). We 
therefore investigated whether any other 
LIV-1 family members also had a positive 
association with breast cancer. For this 
analysis we used a series of tumor sam­
ples from 74 patients presenting with pri­
mary breast cancer to the Breast Cancer 
Unit, City Hospital, Nottingham, between 
1987 and 1989. For sample analysis we 
used the same PCR conditions described 
in Figure 3. The expression of three LJV-1 
family members, ZIP4, ZIP12, and ZIP13, 
was undetectable in these samples, and 
examples of the expression levels of the 
remaining six LIV-1 family members are 
documented in Figure 5 for 10 patients. 
The graph depicting the variation of each 
LIV-1 family member with increasing pa­
tient number (see Figure 5) demonstrates 
that UV-1 and Z3P5 show the most heter-
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Table 3. Statistical Analysis of LIV-1 Family Members with Indicators of Breast Cancer 
Progression ______
Z!P5 UV-1 HKE4 ZIP8 ZIP 10 ZIP14
ER 0.009 (+) < 0.001 (+) NS 0.04 (-) 0.033 (+) NS
EGFR NS < 0.001 (-) NS . NS NS NS
ErbB2° NS NS NS 0.027 <-) NS NS
ErbB3° NS < 0.001 (+) 0.001 (+) NS < 0.001 (+) NS
ErbB4 NS 0.028 (+) NS NS NS NS
IGF1-R NS 0.02 (+) NS NS NS NS
STAT3a NS 0.007(+) 0.031 (+) NS <0.001(+) 0.004 (+)
Ki 67 NS NS 0.026 (+) NS NS NS
G ra d e NS 0.007 (-) NS NS NS NS
C om parative analysis of densitometric da ta  assumed statistical significance was assumed 
if P<  0.05. NS, not significant. aSpearman's correlation test.
ogeneity, with samples varying from low 
to medium and high values. However, it 
is noteworthy that ZIP5 required an in­
creased number of PCR cycles, suggesting 
low  levels in the breast cancer samples.
In contrast, the distribution of HKE4, 
ZIPS, ZIP10, and ZIP14 across the sam­
ples showed little variation.
Comparative analysis of densitometric 
data was performed using the SPSS (ver­
sion 10} statistical analysis package using 
either a two-sided Mann-Whitney U test 
with the previously described cut oft’ val­
ues or a Speannan rank correlation test 
where indicated (Table 3). Statistical sig­
nificance was assumed if P < 0.05 and is 
shown for a number of common indica­
tors of breast cancer progression and 
grade. LIV-1 has previously been identi­
fied as an estrogen-regulated gene and a 
prognostic marker of endocrine response 
(23,24). Here we confirm this association 
(P < 0.001, Figure 6 A) as well as an in­
verse relationship to EGFR (P < 0.001, 
Figure 6B) and a positive association 
with two other erbB receptor tyrosine ki­
nase members, erbBS (P = .001, r = 0.414) 
and erbB4 (P = .028), and another growth 
factor receptor, IGF1-R (P = .02). No 
other LTV-1 family member exhibits the 
same profile as LIV-1; however, ZIP5 
(P = .009, see Figure 6A) and ZIP10 
(P = .033) both show a positive associa­
tion with estrogen receptor (ER), although 
the distribution of ZEP10 in Figure 5B 
suggests that ZIP10 may be of less clini­
cal relevance. No other LIV-1 family
member has an association with EGFR or 
F.rbB4; however, HKE4 (P = .001) and 
ZIP10 (P < 0.001) both show a positive 
association with ErbBS. ZIP8 behaves 
differently from other LIV-1 family mem­
bers and shows a negative association 
with both F.R (P = .04) and ErbB2 (P = 
.027). This negative association with ER 
was also suggested in response of MCF-7 
ceils to estrogen treatment (see Figure 3) 
but was not statistically significant These 
results together suggest that the different 
LIV-1 family members may transport 
zinc, but their activation may be regu­
lated differently, allowing them variation 
of function in different cell types.
Recently, LIV-1 has been shown to be 
the downstream target of STATS in ze- 
brafish embryos (29), and Z1P14 is regu­
lated by IL-6 (32), a mechanism that uses 
STATS signaling. We have observed a 
positive correlation in these breast can­
cer samples between STATS and LIV-l 
(P = .007), ZIP14 (P = .004), HKE4 (P = 
.031), and ZIP10 (P = .001). This observa­
tion is interesting, especially because the 
level of STATS has been well docu­
mented to be associated with breast 
cancer progression (47).
We next investigated the association of 
LIV-1 family members with histological 
grade. LIV-1 was the only family mem­
ber associated with grade and was 
highly expressed in low histological 
grade tumors (P = .007, see Figure 6C). 
The only other observed relationship be­
tween any other LIV-1 family members
was a positive association of FIKE4 with 
the well-known proliferation marker 
Ki67 (P = .026) and those cancers with 
increased lymph node involvement (P = 
.036). Although this patient group was 
small, this latter result was an interesting 
observation which had previously been 
documented for LIV-1 (23) and may sup­
port a role of HKE4 in proliferating and 
metastatic tumors.
It appears from this small patient series 
that LIV-1 is the LTV-1 family member 
most associated with endocrine response 
in breast cancer, although HKE4 does have 
some association with factors suggestive 
of aggressive behavior such as increased 
proliferation and lymph node involve­
ment However, ZIP5 and ZIP10 also ap­
pear to be regulated by estrogen within 
the breast cancer samples, but due to their 
apparent low levels of expression may not 
have any useful clinical relevance Some 
UV-1. family members show an associa­
tion with members of the erbB growth 
factor family as well as STAT3, an associa­
tion that may be suggestive of their mech­
anism of action. Clearly, ZIPS and ZIPS 
are not regulated in the same way. The ob­
served diversity of expression within this 
LIV-1 family may be indicative of the dif­
ferent role that each molecule has in a va­
riety of different tissues. Zinc has a vital 
role in cellular processes, and deregulated 
expression of zinc transporters could have 
dramatic consequences in tire regulation of 
zinc, which in its turn could be pivotal in 
the initiation or progression of breast can­
cer. Investigations to decipher such actions 
and assess zinc transporters as novel ther­
apeutic targets are currently underway.
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APPENDIX
Materials qnd M ethods
Cell culture. MCF-7 cells were grown 
in the presence of 4-hydroxytamoxifen 
(10‘7 M), fulvestrant (10‘7 M), or estradiol 
(Kl’M} for seven days in serum growth-
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Figure 6. Comparison of the expression of LIV-1 and/or ZIPS with ER, EGFR and grade in a  
series of breast cancer samples. (A) shows the positive correlation of both UV-1 and ZIPS 
with estrogen receptor (ER). (B) shows the reverse relationship of UV-1 with EGFR. (C) 
shows the decreasing levels of UV-1 with worsening grade.
factor-free DCCM medium [Biosynergy 
(Europe), Cambridge, UK]. The produc­
tion of TamR- and FasR-resistant MCF-7 
cells has been described previously (40). 
The two antiestrogen-resistant cell lines 
were grown for four days before being 
transferred into phenol-red/steroid-free, 
serum growth-factor-free DCCM me­
dium for 24 h prior to harvest.
RNA extraction and RT-PCR. Total 
RNA was extracted and reverse tran­
scribed to cDNA using random hexamers 
as previously described (48). The follow­
ing PCR primers (MWG Biotech) were 
used to detect the ZIP genes: ZIP4 5 -  
CCCATCACCA TGGCGTCCCTGG-3' 
5'-GGTGCC CTCG GGGTTGCTGA GG-3' 
330 bp, ZIPS S'- GGGTGACCTG GAA 
GAGTCAA -3' 5'- CAGCAA GGGC 
CGTAGTA GAC-3' 388 bp, UV-15'-GTC
TAACAG C TCTAGGAGGC-3' 5'- 
CACCAATTGC TAGGCCATCG-3' 576bp, 
HKE4 5’-ATC GCTCTCT ACTTCAG ATC 
-3' S’-CTCTTCTGAA CCCCTC TTG-3' 
392 bp, ZIP8 S'-CCCATCACCA 
TGGCCCCGGG TCGCGCG-3' 5'- 
GGGTGAAAGT TCAATT GCTG TAA-3' 
335 bp, ZIP10 S'-TTGGCAGTTC AA- 
GAGG GAAAG-3' S'-CGA TTATGCT 
CATACTGT-3' 451 bp, ZIP12 5'- 
AAACTTGCCT TCCCCAGACT-3'
S'- TGAGTGAGAG GCCCTTCTGT-3' 
297 bp, ZIP 13 5'-CCCATCA CCA TGG 
CGGGCCC AAG-3' 5'-GGGAATGACA 
AGCAACGGGA A-3' 242 bp, ZIP14 
5'-TGCTTGGCTT ATGGAGAACC-3' 
S'-GAGATGACGG TCA CACAGAGG-3’ 
425 bp, (3-Actin (NMjOOllOl) 5'- 
GG AGCAATGA TCTTG ATC TT-3' 5'- 
CCTTCC TGGG CATGGAGTCCT-3'.
PCR parameters were optimized accord­
ingly from the previously described pro­
tocol (48) using 29 cycles for ZIP4, LIV-1, 
HKE4, ZIP8, ZIP13, and ZIP14; 31 cycles 
for ZfPlO and ZIP12; and 33 cycles for 
ZIP5. All data were normalized with re­
spect to individual {3-actin levels and sta­
tistical analysis (one-way ANOVA with 
post hoc Dunnett test) was performed.
Fluorescent microscopy. Recombinant 
proteins for LIV-1 (15), HKE4 (9), and 
ZIP14 (17) were engineered in vector 
pcDNA3.1 /V5-His-TOPO to provide a 
C-terminal VS tag as previously de­
scribed. MCF-7 cells were seeded on 
coverslips for 24 h before transfection 
with lipofectamine 2000 as described 
previously (15), and after 16-24 h were 
prepared for fluorescence microscopy by 
fixing with 4% formaldehyde, permeabi- 
lizing with 0.4% saponin if required, and 
blocking with 10% normal goat serum 
before incubating with a mouse and-V5 
antibody (1/2000, Invitrogen) conjugated 
to Alexa Fluor (1/2000) 594 (red) or 488 
(green), and then assembled onto slides 
using Vectorshield with DAPI (Vector 
Laboratories). All coverslips were viewed 
on a Leica RPE automatic microscope 
using a 63x oil immersion lens. The 
fluorescent superimposed images were 
acquired using a multiple bandpass fil­
ter set appropriate for DAPI, fluorescein, 
and Texas Red as well as bright field for 
differential interference contrast (DIC) 
imaging.
Tumor samples. Tumor samples were 
from 74 patients presenting with primary 
breast cancer to foe Breast Cancer Unit, 
City Hospital, Nottingham, between 1987 
and 1989. The samples were snap frozen 
in liquid nitrogen and stored at -70°C. 
Clinical and pathological data was pro­
vided, and that which was used in the 
study is presented in Table 2. Total RNA 
was extracted from each breast tumor 
sample as previously described (48).
RNA was extracted and reverse tran­
scribed to cDNA as described above.
Statistical analysis. Comparative anal­
ysis of densitometric data from the breast 
cancer samples was performed using the 
SPSS (version 10) statistical analysis
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package using either a two-sided. Mann- 
Whitney U test or a Spearman rank cor­
relation test with the previously de­
scribed cutoff values- Statistical 
significance was assumed if P < 0.05. 
Immunocytochemica.1 assays for ER, 
EGFR, and Ki67 were performed as pre­
viously reported and the positivity cut­
off points used for statistical analysis 
(49-51). The levels o£ other growth fac­
tors were determined by RT-FCR and 
quantified as described previously (52).
REFERENCES
1. Vailee BL, An Id DS. (1990) Zinc coordination, 
function, and structure of zinc enzymes and 
other proteins. Biochemistry 29:5647-59.
2. Vailee BL, Falchuk KH. (1993) The biochemical 
basis of zinc physiology. Pin/siclogicai Rev. 
73:79-118.
3. Truong-Tran AQ, Carter}, Ruffin RE, Zalewski PD.
(2001) The role of zinc in Caspase activation and 
apoptotic cell death. Biometab 14:315-30.
4. Koh JY, Suh SW, Gwag B], He YY, Hsu CY, Choi 
DW. (1996) The role o f zinc in selective neuronal 
death after transient global cerebral ischemia. 
Science 272:1013-6
5. Palmiter RD, Huang L. (2004) Efflux and com- 
partmentalization of zm c by members of die 
SLC30 family of solute carriers. Pf.ugers Arch. 
447:744-51.
, 6. Eide DJ. (2004) The SL.C39 family of metal ion 
transporters. Pfhtgers Arch. 447:796-800.
7. Taylor KM, Nicholson RI (2003) The LZT pro­
teins; the new LIV-1 subfamily of ZIP zinc trans­
porters. BBA Biomembranes 1611:16-30.
8. Gaither LA, Eide DJ. (2001) Eukaryotic zinc 
transporters and their regulation. Biometab 14: 
251-70.
9. Taylor KM,Morgan HE, Johnson A, Nichoison RI. 
(2003) Struciure-funetion analysis of HKE4, a 
member of the new LIV-1 subfamily of zinc 
transporters. Bioehem. f. 377:131-9.
10. Guerinot ML. (2000) The ZIP family of metal 
transporters. Biocldm. Bicphys. Acta. 1465:190-8.
t l .  Dalton TP, He L, Wang B, et al. (2005) Identifi­
cation of mouse SLC39A8 as the transporter 
responsible for cadmium-induced toxicity- in 
the testis. Proc. Natl. Acad. Sci. U S A  102: 
3401-6.
12. Liuzzi JP, Aydemir F, Nam H, Knutson MD, 
Cousins RJ. (2006) Z ip l4  (Slc39al4) mediates 
non-transferrin-bound iron uptake into ceils. 
Proc. Natl. Acad. Sci. U S A .  103:13612-7.
13. Kirn BE, Wang F, Dufner-Beattie J, Andrews GK, 
Eide DJ, Petris MJ. (2004) Zn2+-stimulated endo- 
cytosis of the mZIP4 zinc transporter regulates 
its location at the plasma membrane, J. Biol. 
Client. 279:4523-30.
14. Wang F, Kim BE, Petris MJ, Eide DJ. (2004) The 
mammalian Zip5 protein is a zinc transporter
that localizes to the basoiateral surface of polar­
ized ceils. /. Biol. Chem. 279-51433—41.
15. Taylor KM, Morgan HE, Johnson A, Nicholson 
RL (2003) Structure-function analysis of UV-1, 
the breast cancer associated protein that belongs 
to a new subfamily of zinc transporters. Bioehem. 
f. 37551-9.
16. Tominaga K, Kagata T) Johmura Y, Hishiaa T, 
Nishizuka M, Imagawa M. (2005) SLC39A14, a 
LZT protein, is induced in adipogenesis and 
transports zinc. PEBS J. 272:1590-9.
17. Taylor KM, Morgan HE, Johnson A , Nicholson RL 
(2005) Structure-function analysis of a novel 
member of the UV-1 subfamily of zinc trans­
porters, ZIP14. PEBS Letters 579:427-32.
18. Huang L, Kixschke CP, Zhang Y, Yu YY. (2005)
The ZEP7 gene (SIc39a7) encodes a zinc trans­
porter involved in zinc homeostasis of die Golgi 
apparatus. J. Biol. Chem. 280:15456-63.
19. Begum NA, Kobayasfci M, Moriwaki Y, Matsumoto 
M, Toyoshima K, Seya T. (2002) Mycobacterium 
bovis BCG cell.wall and iipcpolysacchnride induce 
a novel gene, BIGM103, encoding a 7-TM protein: 
identification of a new protein family having Zn- 
transporter and Zn-metalloprotease signatures. 
Genomics. Sfh630—4o.
20. Kumanfasrov ics A, Poruk KE, Osbom KA, Ward 
DM, Kaplan J. (2006) YKE4 (YIL023C) encodes a 
bidirectional zinc transporter in the endoplasmic 
reticulum of Saccharomycss cerevisiae. J Bio! 
Qwm. 281 ■22566-74.
21. Kury S, Drer.o B, Bezieau S. Giraudet S. Kharfi M, 
Kamoun R, MoisanJP. (2002) Identification of 
SLC39A4, a gene involved in acrodermatitis en- 
teropathica. Nal. Genet. 31:23e-40.
22. Huang ZL. Dufner-Beattie J, Andrews GK. (2006) 
Expression and regulation of SLC39A family zinc 
transporters in the developing mouse intestine. 
Dev. Biol 295:571-9.
23. Manning DL, Robertson JFR, Ellis IO, et al. (1994) 
Estrogen-regula ted genes in breast-cancer: associ­
ation of p liv l with lymph-node involvement Eur. 
/. Cancer 3(lA,-675.
24. Manning DL, McClelland RA, Knowlden JM, et 
al. (19.95) Differential expression of estrogen- 
regulated g a tes  in breast-cancer. Acta Oncoiogica 
34:641-6.
25. Tozlu S, Girauit I, Vacher S, et al. (2006) Identifi­
cation of novel genes that co-cluster with estro­
gen receptor alpha in breast tumor biopsy speci­
mens, using a large-scale real-time reverse 
transcription-PCR approach. Endocr. Relat. Cancer 
13:1109-20.
26. Schneider J, Ruschhaupt M, Buness A. et al. (2006) 
Identification and meta-analysis of a small gene 
expression signahue for the diagnosis of estro­
gen receptor status in invasive ductal breast can­
cer. Int. J. Cancer 1192974-9.
27. Chung CH, Bernard PS, Perou CM (2002) Molec­
ular portraits and the family tree of cancer Nat. 
Genet. 32533-40.
28. Pemu CM, Sorlie X, Eisen MB, et al. (2000) Mole­
cular portraits of human breast tumours. Nature 
406:747-52.
29. Yamashita S, Miyagi C, Fukada T, Kagara N,
Che YS, Hirano T. (2004) Zinc transporter LIVI 
controls epithelial-mesenchymal transition in ze- 
brafish gastrula organizer. Nature 429298 -302.
30. Taylor KM; Hiscox S, Nicholson RL (2004) Zinc 
transporter LIV-1: a link between cellular devel­
opment and cancer progression. Trends Endocrinol. 
Metab. 15:461-3.
31. Mathews WR, Ong D, Milutinovich AB, Van 
Doren M. (2006) Zinc transport activity of Fear of 
Intimacy is essential for proper gonad morpho­
genesis and DE-cadherin expression, Develop mcnl 
133:1143-53.
32. Liuzzi JP, Lichten LA, Rivera S, et. al. (2005) In- 
terlsukin-6 regulates die zinc transporter Zip 14 
in liver and contributes to the hypozincemia of 
the acute-phase response. Proc. Nall. Acad. Sci.
U S A 102:6843-8.
33. Lang CJ, Murgia C, Leong M, et al. (2006) Anti­
inflammatory effects of zinc arid alterations in 
zinc transporter mRNA in  mouse models of al­
lergic inflammation. Am. }. Physiol. Lung Cell.
Mol. Physiol. In press.
34. Biy M. (2006) Examination of the zinc transporter 
gene, SLC39A12. Schizopfv. Res. 81-321-2.
35. Chowanadisai W, Kelleher 3L, Lor.nerdai B.
(2005) Zinc deficiency is associated with in­
creased brain zinc import and LIV-1 expression 
and decreased ZnT-1 expression in neonatal rais. 
/. Nutr. 135:1002-7.
36. Wang K, Zhou B, Kuo Y3VI, Zemansky J, Gitschier J.
(2002) A novel member c>f a zinc transporter fam­
ily is defective in acrodermatitis enteropathies. 
Am. [. Hum. Genet. 71:66—73.
37. Wang F. Kim BE, Dufner-Beattie J, Petris MJ, 
Andrews G, Eide DJ. (2004) Acrodermatitis en- 
teropathlca mutations affect transport activity, 
localization and zinc-responsive trafficking of tire 
mouse ZIP4 zinc transporter. Hum. Mol. Cenet. 
13:563-71.
38. Nicholson RI, Johnston SR. (2005) Endocrine 
therapy: current benefits and limitations. Breast 
Cancer Res. Treat 93(Suppl 1):S3—10.
39. Knowlden JM, Hutcheson IR, Jones HE, at al.
(2003) Eievated levels o f EGFR/c-erbB2 het- 
erodimers mediate an autocrine grov.-th regula­
tory pathway in Tamoxi fen-resistant MCF-7 cells. 
Endocrinology 144:1032—44.
40. McClelland RA, Barrow D, Madden TA, etal. 
(2001) Enhanced epidermal growth factor recep­
tor signaling in MCF7 bieast cancer cells after 
long-term culture in die presence of the pure 
antiestrogen ICI 182,780 (Faslodex) Endocrinology 
142:2776-88.
41. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, 
Nicholson RL (2006) Elev ated Src activity pro­
motes cellular invasion and motility in tamoxifen 
resistant breast cancer cells. Breast Cancer Res. 
Treat. 97:263-74.
42. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, 
Nicholson RI. (2005) Insulin-like growth factor-I 
receptor signaling in tamoxifen-resistant breast 
cancer: a supporting role to the epidermal 
growth factor receptor. Endocrinology 6:4609-18.
MOL  MED 1 3 ( 7 - 8 ) 3 9 6 - 4 0 6 ,  J U L Y - A U G U S T  2 0 0 7  I T AYL OR ET AL.  I 4 0 5
L I V - }  Z I N C  T R A N S P O R T E R S  I N  B R E A S T  C A N C E R
43. Hiscox S, Jordan N7, Jiang W, Harper M, 
McClelland R, Smith C, Nicholson RL (2006) 
Chronic exposure to fulvestrant promotes over­
expression of the c-Met receptor in breast cancer 
cells: implications for tumor-stroma interactions. 
Endocr. Relai. Cancer 13; 1085-99.
44. Hiscox S, Morgan L, Barrow D, Dutkowski C, 
Wakeling A, Nicholson, RL (2004) Tamoxifen 
resistance in breast cancer cells is accompanied 
by an enhanced motile and invasive phenotype: 
inhibition by gefitiiub ('Lressa', ZD1S39). Clin.
Exp. Metastasis 21:201-12
45. Kuske B, Naughtan C, Moore K, et. al. (2006) 
Endocrine therapy resistance can be associated 
with high estrogen receptor (alpha! (ERjalpha!) 
expression and reduced. ERIalphaJ phosphoryla­
tion in breast cancer models. Endocr. Relai. Cancer 
13:1121-33.
46. Tayior KM, Vichova P. Hiscox S, Nicholson RL 
(2005) Zinc-dependant stimulation of Src, EGFR 
and IGFR signaling pathways in tamoxifen- 
resistant breast cancer and the roie of zinc trans­
porters. Breast Cancer Res. Treat. 94:5162
47. Gamero AM, Young H A , Wiltrout RH. (2004) 
Inactivation of Stat3 in  tumor cells: releasing a 
brake on immune responses against cancer? 
Cancer Ceil 5:111-2.
48. Knowlden JM, Gee TM, Bryant S, et. al. (1997)
Use of reverse danscripiion-polymerase chain 
reaction methodology to detect estrogen-regulated 
gene expression in small breast cancer speci­
mens. Clin. Cancer Res. 3:2165-72.
49. Nicholson RI, McClelland RA, Gee JM, et al. 
(1994) Epidermal growth factor receptor expres­
sion in breast cancer: association with response 
to endocrine therapy. Breast Cancer Res. Treat. 29: 
117-25.
50. Snead DR. Bell JA, Dixon AR, Nicholson RL 
Elston CW, Blarney RW, Elis ID. (1993) Method­
ology of immunohistological detection of oestro­
gen receptor in human breast carcinoma in 
formalin-fixed, paraffin-embedded tissue: a 
comparison with frozen section methodology. 
Histomthology 231233—8.
51. van Dierendonck JH, Keijzer R, van de Velde CT, 
Comelisse CJ. (1989) Nuclear distribution of the 
Ki-67 antigen during die cell cycle: comparison 
with growth fraction in human breast cancer 
cells. Cancer Res. 49-2999-3006.
5 2  Knowlden JM, Gee JM. Seery LT, Farrow L, 
Gullick WJ, E lis TO, Blarney RW, Robertson JF, 
Nicholson RI. (1998) c-erbB3 and c-erbB4 expres­
sion is a feature of ihe endocrine responsive phe­
notype in dinical breast cancer. Oncogene 
17:1949-57.
4 0 6  I T AYL OR  ET AL.  I M O L  M E D  1 3 < 7 - 8 ) 3 9 6 - 4 0 6  , J U L Y - A U G U S T  2 0 0 7
Appendix F
Poster Presentation and Certificate of Attendance
20th EORTC-NCI-AACR Symposium on ‘Molecular targets and Cancer Therapeutics’ 
Geneva, Switzerland, 21-24 October 2008
199
THEIR ROLE IN BREAST CANCER.
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INTRODUCTION
Zinc participates in reactions of cellular metabolism attributed to 
body physiologic. Zinc-dependant enzyme and protein reactions 
needed zinc for catalyst or structural functions, directing desired 
growth.
Exclusively, zinc and enzymes are essential for synthesis of DNA 
and RNA, whilst zinc induces monocytes to produce IL-1 and IL-6 
Zinc absorption in cells by diffusion mechanism and protein- 
mediated processes. The latter involves proteins from two family 
of genes namely the solute-linked carrier (SLC), SLC30/ZnT and 
SLC39/ZIP. IV-1 family of protein is a new subfamily of IP, zinc 
Transporters family hence the term T is created.
Each of LIV-1 family of protein are called LZT-Hs1(SLC39A7),
LZT-Hs2(SLC39A10), LIV-1 (SLC39A6), LZT-Hs4(SLC39A14), 
LZT-Hs5(SLC39A4), LZT-Hs6(SLC39A8), LZT-Hs7(SLC39A5), 
LZT-Hs8(SLC39A12) and LZT-Hs9(SLC39A13). In brackets are 
equivalents names of their human gene, Hs for Homo sapiens.
It was reported that pLIV-1 predominantly expressed in the 
estrogen receptor tumours and lymph mode-positive patients.
This is the first occasion showed relevance of LIV-1 family 
members to a disease state using breast cancer cell lines (shown)] 
and clinical isolates (not shown). Uniquely, LZT-Hs7, LZT-Hs8 
and LZT-Hs9 positives clones were tested for their zinc capacity.
MATERIALS AND METHODS
RNA EXPERIMENT
1. RNA extractions of breast cancer cell lines and clinical isolates 
were available from the RNA/DNA bank in TCCR.
2. Primers pairs were designed and PCR programs optimization to 
the LIV-1 family members, respectively.
3. Electrophoresis gels were analysed converted into statistical data 
and graphs representation as shown.
DNA EXPERIMENT
1. LZT-Hs7, LZT-Hs8 and LZT-Hs9 were cloned into 
pcDNA5/FRTA/5-His-TOPO® TA vector. Earlier, the genes were
unsuccessful to be cloned into neither pcDNA3.1 Directional TOPO® 
and pEF5/FRTA/5 Directional TOPO®.
2. Stringent analysis were done for positive clones before these 
procedures: Western blot, immunohistochemistry (fluorescence 
microscope and fluorescent antibodies) and zinc detection using 
50pM Newport Green™ Diacetate, discharged directly on cells for 
30 minutes incubation at 37°C
RESULTS
RNA EXPERIMENT
LZT-Hs1 has increased expression in Tamoxifen resistant cells. LIV-1 
shows a reduction in signal intensities in both Tamoxifen and Faslodex 
resistant cells. LZT-Hs6 showed increased expression in Faslodex Late 
resistant cells. LZT-Hs5 gene expression was undetected in all cell lines.
DNA EXPERIMENT^
LZT-Hs7 recombinant with 
Alexa Fluor 594 (red 
stain) and localised with 
green fluoresce of 
Newport Green™ 
Diacetate.
LZT-Hs8 recombinant with 
Alexa Fluor 594 (red 
stain) and localised with 
green fluoresce of 
Newport Green™ 
Diacetate but almost 
undetected.
LZT-Hs9 recombinant with 
Alexa Fluor 594 (red 
stain) and localised with 
green fluoresce of 
Newport Green™ 
Diacetate, seem s to be 
in enclosed structure.
CONCLUSION
1. LZT-Hs1 is up-regulated in Tamoxifen resistant breast cancer cells.
2. LZT-Hs6 is up-regulated in Faslodex Late resistant breast cancer 
cells.
3. All LIV-1 family members expressed differentially in both the breast 
cancer cell lines and clinical isolates except LZT-Hs5 is undetected 
in neither models.
4. LZT-Hs7 protein size is 63 kDalton, LZT-Hs8 is 73 kDalton and 
LZT-Hs9 is 43 kDalton.
5. Recombinant protein of LZT-Hs7 localizes on the plasma 
membrane whilst LZT-Hs8 and LZT-Hs9 are located in the 
endoplasmic reticulum, interestingly, LZT-Hs8 is also found on the 
plasma membrane with minimal expression.
6. Preliminary work in zinc capacity, all recombinants have green 
fluoresce of Newport Green Diacetate™ dye in their respective 
protein locations and Tamoxifen resistant cells, with attention to 
LZT-Hs8 expression, is not easily seen as others, comparatively.
7. It is intriguing to study the LIV-1 family of proteins, individually and 
collectively, their functions and involvement in signalling pathways 
or growth hormone of a disease, i.e breast cancer; or as a 
supplement treatment for zinc deficiency and homeostasis.
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